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Abbreviations:
AA, arachidonic acid
2-AG, 2-arachidonoylglycerol
ADC, apparent diffusion constant
AEA, anandamide (arachidonoylethanolamide)
BSA, bovine serum albumine,
cAMP, cyclic adenosinemonophosphate
CB receptor, cannabinoid receptor
CBD, cannabidiol
CCCP, carbonyl cyanide m-chlorophenylhydrazone
CD, circular dichroism
CNS, central nervous system
(CR)EAE, chronic relapsing experimental allergic encephalomyelitis
DSE, depolarization-induced suppression of excitation
DSI, depolarizition-induced suppression of inhibition
DW, diffusion weighted,
ELISA, enzyme-linked immunosorbent assay
EPSC, excitatory postsynaptic currents
FAAH, fatty acid amide hydrolase
GABA, γ-aminobutyric acid
GAR-AP, goat anti-rabbit alkaline phosphatase conjugate
GC/MS, gas chromatography / mass spectrometry
GFAP, glial fibrillary acidic protein
IEF, isoelectric focusing;
IP3, inositoltriphosphate
IPSC, inhibitory postsynaptic currents
LC-MS, liquid chromatography mass spectrometry
LSC, liquid scintillation cocktail
LTXy, leukotriene Xy
MD, molecular dynamics,
MEM, (Eagle’s) minimal essential medium (plus Earle’s salts)
MRI, magnetic resonance imaging
mRNA, messenger RNA
NAE, N-acylethanolamine
NAPE, N-acylphosphatidylethanolamine
NMDA, N-methyl-D-Aspartate
NMR, nuclear magnetic resonance,
NO, nitric oxide
NOESY, nuclear overhauser effect spectroscopy
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NONOate, (Z-1-{N-[3-aminopropyl]-N-[4-(3-aminopropyl-ammonio)butyl]-amino}-
diazen-1-ium-1,2-diolate);
PBS, phosphate buffered saline
PGXy, prostaglandin Xy
pI, isoelectric point
PLD, phospholipase D
PMSF, phenylmethylsulfonyl fluoride
PND, post natal day
QSAR, quantitative structure activity relation
RP/CP-HPLC, reversed phase / chiral phase high performance liquid chromatography
RT-PCR, reverse transcriptase polymerase chain reaction
SD, standard deviation
SEM, standard  error of the mean
SNAP, S-nitroso-N-acetylpenicillamine
SNP, sodium nitroprusside
SPE, solid phase extraction
SPER-NO, spermine 
TE, time of echo
THC, tetrahydrocannabinol
TMS, trimethylsilyl
TNF, tumor necrosis factor
TOCSY, total correlation spectroscopy
TR, time of repetition
VR1, vanilloid receptor
x-H(P)AEA, x-hydro(pero)xy anandamide
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Chapter1
Anandamide, a lipid with cannabinoid activity
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1.1 Historical background
Marijuana is the most widely used illegal drug throughout the world and has aroused
great controversies. In the Netherlands, public debate centres upon the possible
legalization of marijuana for recreational and therapeutic uses. Nowadays, marijuana is
used by multiple sclerosis patients to alleviate tremors and by aids patients as well as cancer
patients with chemotherapy to stimulate appetite and to relieve nausea. However, in 1996,
the Health Council of the Netherlands came to the conclusion, based on a literature
survey, that the scientific evidence to justify the medical use of marijuana was insufficient1.
The Council concluded that physicians cannot accept responsibility for a product of
unknown composition that has not been subjected to a quality control. The Committee
was unable to comment on the use of any other preparation of the hemp plant, and its
active ingredient ∆9-tetrahydrocannabinol (THC, Fig. 1 and 2), or other components,
since there were no published reports1. Despite this advice the Dutch government has
recently approved the use of marijuana for medicinal purposes. In this introduction we
will give an overview of the latest developments in cannabinoid research, which may give
rise to a new assessment of this issue.
Marijuana (cannabis, bangh, hashish) is an extract from the plant cannabis sativa and
contains at least 400 chemical components of which 60 belong to the cannabinoid class2.
Marijuana and its main psychoactive compound THC, have been used for centuries.A first
description of its use came from the Chinese nearly 5000 years ago. Cannabis was
cultivated for its fibre and oil of the seeds. It was never widely used as a psychoactive
substance in China, because it disturbed the equilibrium of the brain and made one ”see
devils”3.Ancient Hindus hailed the medicinal properties of the plant, which was credited
with curing all major ills and creating “vital energy”3.
It took until 1964 before THC was isolated and characterized4. The structure
elucidation of THC led to the design of a series of analogs. More than 300 cannabinoid
derivatives were synthesized and used to study the structure activity relationships for
psychotropic activity by 19865. In addition, a completely different class of molecules,
termed aminoalkylindoles, was discovered which could elicit strong cannabimimetic
effects (Fig. 2).The main representative of this class is WIN55.212-2 .
The mechanism of action of THC has also been a subject of discussion.At first it was
thought that cannabinoids due to their lipophilic nature perturbed the membrane, thereby
producing cellular effects. However, the requirement of a specific enantiomer and
stringent structural features of THC to produce pharmacological responses raised the
question whether cannabinoids could act via membrane receptors. The development of
the potent bicyclic cannabinoid CP55.940 (Fig. 2), which could be radio-labelled, allowed
Devane et al. to demonstrate selective and specific binding sites in the brain for the first
time in 19886. The identification and cloning of a receptor responsible for this binding
followed within two years7.This receptor, which is highly expressed in the central nervous
10
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system (CNS), was termed cannabinoid (CB1) receptor.The existence of another subtype
cannabinoid receptor(CB2) was demonstrated in 1993
8. The CB2 receptor is primarily
found in cells of the immune system8,9.
The presence of cannabinoid receptors in mammalians suggested the existence of
endogenous ligands for these receptors. In 1992, the first endogenous ligand for these
receptors was isolated.The chemical structure of this component proved to be an amide
of ethanolamine and arachidonate, and named anandamide (ananda is Sanskrit for internal
11
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The endocannabinoid system. Figure 1
The endocannabinoid system, including the cannabinoid (CB1) receptor, transporter
protein (T) and fatty acid amide hydrolase (FAAH), which inactivates the endogenous
cannabinoids 2-arachidonolglycerol (2-AG) and anandamide (AEA). (Adapted from 12)
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bliss, Fig. 1 and 2)10.Anandamide (AEA; 5Z,8Z,11Z,14Z-eicosatetraenoyl-N-(2-hydroxy-
ethyl)-amine was able to inhibit the vas deferens twitch-response, a typical cannabinoid
action. Furthermore, AEA could be synthesized by neurons upon stimulation and it
mimicked many biochemical, pharmacological and behavioural properties of classical
cannabinoids (Fig. 1 and 2)11,12.
Three years after the discovery of AEA, 2-arachidonoylglycerol (2-AG) was found as
a second endogenous ligand for the cannabinoid receptors13,14.AEA and 2-AG are termed
endocannabinoids.Very recently a third endogenous compound, 2-arachidonoyl glyceryl
ether, was isolated from porcine brain, which could activate CB1 receptors
15.
In order to function as a neuromodulator or as a neurotransmitter the concentrations
of endocannabinoids have to be regulated in a strict manner.A reuptake process into cells
and a rapid enzymatic inactivation have been reported (Fig. 3). In 1996 the enzyme
responsible for the degradation of AEA by hydrolysis of the amide bond was purified,
cloned and termed fatty acid amide hydrolase (FAAH)16. The CB receptors,
endocannabinoids and the proteins of the inactivation process constitute the endogenous
cannabinoid system.To date, the proteins responsible for the biosynthesis of AEA and its
facilitated diffusion into cells have not been purified or cloned. The discovery of the
cannabinoid system together with the development of the selective antagonists SR141716
and SR144528 for CB1 and CB2 receptors, respectively, have led to an explosion of
knowledge on the molecular mode of action of cannabinoids17,18. Its (patho)physiological
role is beginning to be unravelled. It is thought that the endocannabinoid system is
involved amongst others in physiological processes, such as the regulation of pain, motor
activity, blood pressure, appetite and tumour cell growth19-22.
This introduction will focus on the biosynthesis, metabolism and function of
endocannabinoids, in particularly AEA, and CB receptors in relation to neuronal cell
injury and the current knowledge of (endo)cannabinoids in neuroprotection.
1.2 Biosynthesis of anandamide
In contrast to most other neurotransmitters, AEA is not stored in vesicles, but is
released from cells upon demand by stimulus-dependent cleavage of membrane
phospholipid precursors11. The biosynthesis of AEA has been demonstrated to occur in
several cell-types, e.g. N18 neuroblastoma cells, J774 mouse macrophages, RBL-2H3
basophiles and in mesenteric arteries23. Astrocytes do not seem to be able to synthesize
AEA. Stimulation of striatal neurons and J774 macrophages with the calcium ionophore
ionomycin increased AEA content. Importantly,AEA, but not 2-AG, has been shown to
be released in the striatum of freely moving rats upon stimulation of dopamine D2-like
receptors21. However, stimulation of glutamate-releasing fibers in the Schaffer collaterals
in the hippocampus did not increase AEA concentrations, while 2-AG content was
12
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increased 24.
Already in the early 80’s Schmid et al. had characterized a biosynthetic pathway for N-
acylethanolamines. According to this scheme acylethanolamides, including AEA and
linoleoylethanolamide (18:2), are formed through sequential N-acylation and
phosphodiesterase activities (Fig. 3).A membrane-bound calcium-dependent transacylase
catalyses the transfer of fatty acids from the sn-1 position of various 1,2-diacyl
glycerophospolipids and 1-acyl-lysophospholipids to yield N-acyl(lyso)phosphatidyl-
ethanolamines (NAPEs).As yet, the N-acyltransferase is not purified or cloned, but several
properties of this enzyme are known. The N-acyl transferase activity is membrane-
associated and energy-independent; neither free fatty acids nor acyl-CoA derivatives serve
as the acyl donor. The N-acyltransferase activity in brain is calcium-dependent at
concentrations between 0.5 and 2 mM CaCl2.This suggests that the N-acyltransferase is
quiescent at resting concentrations of calcium in the cell and is only activated when
cellular concentrations rise to very high values. NAPE synthesis is inhibited by the
calcium chelator EGTA, but not by inhibitors of calcium/calmodulin-dependent protein
kinases or protein kinase C.Activators of adenylyl cyclase, such as forskolin, have no effect
alone, but enhance ionomycin-induced NAPE synthesis in intact cells. The activity of N-
acyltransferase changes considerably during development of rat brain being high in infant
rats and several fold lower in adult rats (reviews25,26).
The formation of NAPEs seems to be rate limiting. Enzymatic hydrolysis of the
corresponding NAPEs by a phosphodiesterase of the phospholipase D-type, which seems
to be an unregulated enzyme, generates the corresponding acylethanolamide (Fig.3). In rat
brain NAPE phospholipase D activity increases with development being very low at birth
and increasing to a 15-fold higher level in the adult rat. It is important to consider that so
far no fatty acid selectivity for either the enzymes involved in the biosynthesis or
hydrolysis of N-acyl-PE could be demonstrated. Furthermore, very low amounts of
arachidonic acid are found at the sn-1 position of phospholipids. It is almost exclusively
in the sn-2 position of brain phospholipids. (reviewed by Schmid et al.25,26). Any
selectivity in AEA generation must therefore rely on other mechanisms. For example,
physiological stimuli might increase arachidonic acid content at the sn-1 position.
Recently, it has been shown that the simultaneous application of glutamate and carbachol
(an acetylcholine receptor agonist), but not of either agent alone, caused a marked increase
in AEA biosynthesis in cortical neurons27.Thus, membrane depolarization was necessary
for the biosynthesis, but was insufficient per se to initiate AEA biosynthesis. Interestingly,
AEA-formation was stimulated by coactivation of α7-muscarinic receptors, while
palmitoylethanolamide and oleoylethanolamide levels were increased by coactivation of
muscarinic receptors27. However, it remains unclear where this selectivity was generated,
because the distribution of fatty acids in NAPEs and at the sn-1 position of donor-
phospholipids was not studied.
AEA concentrations are very low in brain homogenates and have been shown to vary
14
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in different brain regions. Highest AEA concentrations were found in human (2h
postmortem)  hippocampus (110 pmol/g) and thalamus (75 pmol/g) and somewhat lesser
amounts in striatum (55 pmol/g) and cerebellum (30 pmol/g)28. The levels of AEA
measured in human brain were at least 10-fold lower than those reported for GABA and
glutamate. In rat brain AEA concentrations varied from 0-87 pmol/g, being highest in the
striatum and lowest in cerebellum and cortex. AEA accounts for a smaller part of the total
NAE, usually between 1-10%. (reviewed by Hansen et al.29)
1.3 Formation of endocannabinoids in models of neuronal injury
It should be noted that the variations of AEA levels in brain do not necessarily reflect
differences in AEA content of “anandamergic” neurons. It is possible that differences in
the analytical methods and tissue preparation caused the observed variations. It is known
that when the time between death of animal and the lipid extraction procedure increased,
AEA content increased.While postmortem increase in brain AEA levels may be an artifact
of tissue damage, it is also possible that similar mechanisms may regulate AEA
concentrations in living tissue that has been subjected to ischemic or hypoxic stress.
Various studies indicate that in vivo and in vitro levels of NAPEs and NAE increased after
toxic stimuli, e.g. in ischemic canine hearts and in inflamed testes25,30,31. In primary
neocortical neurons in culture treated with N-methyl-D-aspartate (NMDA) or glutamate
AEA levels were also increased32. Hansen et al. have demonstrated that the increase in
NAPEs and NAEs varied in different in vivo models of neuronal damage and is dependent
on the type of cell death33. High levels of NAPEs were found in neonatal rats 24 h after
receiving a striatal injection of NMDA (25 nmol). In the same model, total NAE levels
were increased 46-fold in cerebral cortex34.While AEA concentrations were elevated by
a factor 13, no increase in 2-AG levels was found. Mild closed head injury or NMDA
receptor blockade, which is a model for apoptotic cell death, produced a less pronounced
NAE accumulation and had no effect on 2-AG levels34. In contrast, a large increase in 2-
AG was found in a closed head injury model in mice35 and in rats treated with
picrotoxinin36. Differences in species, brain areas analyzed and type of injury may explain
the varying results.
1.4 Metabolism of anandamide
1.4.1 Transport into cells and enzymatic degradation
After release,AEA and 2-AG may be eliminated by a two-step mechanism consisting
of carrier-mediated transport into cells followed by enzymatic hydrolysis (Fig. 4).
Neuronal and non-neuronal cells rapidly take up extracellular AEA through a mechanism
15
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that meets four key criteria of carrier-mediated transport: fast rate, temperature
dependent, saturability, and substrate selectivity37,38. Importantly and in contrast with
transport systems for classical neurotransmitters, [3H]AEA reuptake is neither dependent
on external Na+ nor affected by metabolic inhibitors, suggesting that a process of carrier-
facilitated diffusion may mediate it. This suggests that AEA movement across cellular
membranes should be bi-directional. [3H]AEA uptake was not affected by fatty acids,
neutral lipids, neurotransmitters, biogenic amines, prostaglandins, leukotriens and was
insensitive to substrates or inhibitors of fatty acid transport, organic anion transport, P-
glycoproteins (reviewed by Hillard39).To date, the protein responsible for [3H]AEA uptake
has not been purified or cloned, but its activity has been demonstrated in human umbilical
vein endothelial cells, RBL-2H3, cells, porcine leukocytes, a human astrocytoma cell line,
primary cultures of rat cortical neurons or astrocytes and rat brain slices38-42.To date, no
data are available about [3H]AEA uptake in human neuronal and immune cells.
Once inside the cell AEA is rapidly inactivated by hydrolysis of its amide bond to
arachidonic acid and ethanolamine. An amidohydrolase activity was already identified by
Schmid et al. in rat liver in 1984. After the discovery of AEA, biochemical evidence
suggested that the same enzyme activity could degrade AEA11,43.This activity has been
characterized in rat neuronal and RBL-2H3 cells and in rat, porcine and dog brain
homogenates.The gene responsible for the enzyme activity has recently been cloned from
rat, mouse and human liver cDNAs allowing molecular mass determination and substrate
specificity analysis of the enzyme44. The enzyme is termed fatty acid amide hydrolase
(FAAH) and has been shown to degrade a broad spectrum of fatty acid amides and esters
among them were oleamide (a novel sleep inducing factor), palmitoylethanolamide and 2-
arachidonoylglycerol16,45. FAAH is an intracellular membrane-bound  64 kDA protein
with a conserved amidase sequence. A consensus class II SH3 domain binding sequence
was also identified suggesting that other proteins may interact with FAAH to regulate its
activity and/or subcellular localization. The rank order in activity in homogenates of
different rat brain areas was: globus pallidus > hippocampus > sustantia nigra > striatum
> thalamus > cerebellum > cortex > brain stem > medulla46,47. CB1 receptors are
present in various brain regions that also express FAAH, but there appears to be no direct
correlation between the concentrations for these two proteins47. Recently, FAAH knock-
out mice have been bred48.These mice were severely impaired in their ability to degrade
AEA and when treated with AEA exhibited an array of intense CB1-dependent
behavioural responses, including hypomotility, analgesia, catalepsy and hypothermia.
FAAH-/- mice possessed 15-fold augmented endogenous brain levels of AEA and
displayed reduced pain sensation, which was reversed via SR14171648. In contrast, to date
no information is available on the inactivation process of AEA in human brain tissue and
cells.
17
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1.4.2 Oxidative metabolism
In mice AEA has been shown to be metabolized within a few minutes to arachidonic
acid and to more polar derivatives, but the pharmacological effects lasted for a longer time
period49-52. It is thought that some of the metabolites of AEA may produce some of the
pharmacological effects. The identity of these metabolites was never investigated. It is
known that AEA with its unmodified arachidonic acid backbone is a substrate for
cytochrome P450s, cyclooxygenases and mammalian lipoxygenases, which produce more
polar metabolites.To date very little information is available about the oxygenated AEA-
derivatives.
AEA was shown to be oxidized by cytochrome P450 to yield at least 20 different
metabolites, however, most of their structures were not identified.The P450-metabolism
was partly inhibited by the addition of the non-psychoactive cannabinoid CBD53-55.
Arachidonic acid can be converted into a large array of bioactive eicosanoids such as
prostaglandins, prostacyclins and thromboxanes. It is unknown whether AEA is converted
into all these types of metabolites, but selective cyclooxygenase inhibitors, like ibuprofen,
have been shown to inhibit the metabolism of AEA56. Furthermore, cyclooxygenase-2,
which normally catalyzes the formation of the prostaglandin PGE2, converted AEA into
PGE2-ethanolamide, whereas cyclooxygenase-1 was inactive
57. The chemically
synthesized putative cyclooxygenase products of AEA, i.e. ethanolamides of PGE2, PGA2,
PGB1 and PGB2, failed to bind to the CB1 receptor
58.
AEA has been shown to be a substrate in vitro for porcine leukocyte 12-lipoxygenase
59 and rat pineal gland 12-lipoxygenase60. Human platelets converted AEA into 12-
hydroxyanandamide (12-HAEA) and human polymorphonuclear leukocytes oxygenated
AEA to 12-HAEA and 15-hydroxyanandamide (15-HAEA)61. Furthermore, the affinities
of 12-HAEA and 15-HAEA for rat CB1 and human CB2 receptor were reported
60,61.The
18
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presence of endogenous lipoxygenase metabolites of AEA has never been detected, but
recent data raise the possibility that the contractile action of AEA in guinea-pig bronchus
may be due, at least in part, to some oxygenated metabolites of AEA62.
1.5 CB1 and CB2 receptor expression
Many of the actions of AEA are mediated via either the CB1 or CB2 receptor. The
cannabinoid receptors belong to the class of G-protein coupled receptors. CB1 and CB2
are the only two cannabinoid receptors so far identified, but recent pharmacological and
electrophysiological data in CB1 knock-out mice suggest that a novel CB-type receptor(s)
may exist63-65.A splice variant of CB1 cDNA CB1a has also been isolated. CB1a mRNA
exists only as a minor transcript and there is no evidence for any notable differences
between the pharmacology of CB1 and CB1a receptors
66. CB1 receptor has been detected
both in the central nervous system and in certain peripheral tissues. The central
distribution pattern of CB1 receptor is heterogeneous and was found in high levels in
brain regions thought to mediate typical cannabinoid agonist effects, i.e., impairment of
motor behaviour, memory and cognition (Fig. 5). In many brain areas specific cannabinoid
binding sites density greatly exceeded that of neuropeptide receptors and is similar to the
densities of cortical benzodiazepine, striatal dopamine and whole brain glutamate
receptors.The CB1 receptor is found at high or moderate levels in the cerebral cortex,
hippocampus, lateral caudate putamen, substantia nigra pars reticulata, globus pallidus,
entopeduncular nucleus and the molecular layer of the cerebellum67-69. CB1 transcripts
are also found in peripheral tissues such as, pituitary gland, adrenal gland, heart, lung,
prostate, uterus, ovary, testis, bone marrow, thymus and tonsils70.
In situ hybridisation using labelled oligonucleotides to CB2 have suggested that CB2
transcripts are not present in brain tissue. CB2 receptor mRNA has primarily been found
in immune tissues, with an expression level 10-100x higher than that of CB1 in these
tissues9. In spleen and tonsils, the CB2-transcript content reaches levels equivalent to that
of CB1-mRNA in the central nervous tissue. Among the human blood cell populations
CB2 receptor was found in B-cells > natural killer cells > monocytes >
polymorphonuclear neutrophils > T8 cells > T4 cells9.
19
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1.6 Signal transduction via CB receptors
The cannabinoid receptors have the structural characteristics of G-protein coupled
receptors. Ki values for AEA to displace [
3H]CP55940, a potent synthetic cannabinoid,
from the CB1 receptor range from 27-543 nM in the presence of the FAAH inhibitor
PMSF and 1-10 µM in its absence70. Ki values for AEA varied from 30-2000 nM for the
CB2 receptor
70.The ligand selectivities of the CB1 and CB2 receptor do not differ to a
large extent.The rank order of binding affinities for both receptors is HU210 > CP55940
> THC >AEA > CBD71.
AEA has been shown via [35S] GTPγS-autoradiography to induce binding of Gi/o-
proteins to the cannabinoid receptors and to stimulate low Km GTPase activities. The
efficacy of cannabinoid agonists on mouse brain membranes was: CP55940 > HU 210 >
AEA > THC72.
20
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Figure 5 Transversal view of human brain.
Dots indicate expression of CB1 receptors, which is found amongst other areas in the cerebral cortex,
cerebellum, hippocampus and in the basal ganglia, which  consist of four nuclei (caudate nucleus, putamen
(which form together the striatum), substantia nigra and globus pallidus). (Adapted from NIDA)
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Both CB1 and CB2 receptors inhibit cAMP formation via Gi-proteins and activate
mitogen-activated-protein (MAP) kinases (Fig 6.)70. In addition, CB1 receptors activate
ion channels such as A-type and inwardly rectifying potassium channels and inhibit
voltage sensitive N-type and P/Q-type calcium channels and D-type potassium
channels12,73,74. The coupling to A and D-type potassium channels is thought to be
regulated via cAMP. Activation of  CB1 receptors may also lead to arachidonic acid release
and closing of 5-HT3 receptor ion channels. Under certain conditions the CB1 receptor
may couple to Gs-proteins, which activate adenylate cyclase and reduce outward
potassium K+ current, possibly via arachidonic acid stimulation of protein kinase C75. CB1
and CB2 receptor activation by AEA and 2-AG in N18TG2 neuroblastoma and NG108-
15 neuroblastoma-glioma hybrid cells have been shown to induce a rapid transient
increase in intracellular free calcium via its release from IP3-sensitive calcium stores
76,77.
It should be noted that CHO-cells transfected with either CB1 or CB2 receptors failed to
exhibit changes in IP3 or phosphatidic acid in response to AEA or WIN55212-2 under
conditions in which other exogenously expressed receptors coupled to phospholipases C
could evoke such responses70,71,78. Hampson et al. demonstrated that AEA reduced
NMDA receptor mediated calcium responses in rat cortical and cerebellar slices, which
could be blocked by pertussis toxin and agatoxin (P/Q-type calcium channel blockers)79.
It was suggested that voltage sensitive calcium channels were activated in response to the
depolarization associated with NMDA-induced calcium influx, so that their inhibition by
cannabinoid receptor activation reduced the overall calcium current79. Noteworthy,AEA
potentiated NMDA-induced calcium currents in cortical, cerebellar and hippocampal
slices in the presence of SR141716A.This capacity of AEA to increase calcium currents
was also observed in Xenopus oocytes expressing NMDA receptors, which suggested that
AEA could directly interact with NMDA receptors79. In the same expression system AEA
was shown to directly inhibit AMPA receptor currents in a CB1 receptor independent
manner80. Furthermore, it was recently shown that CB1 receptors on cultured cerebellar
granule neurons could operate through a phospholipase C-sensitive mechanism to
enhance NMDA-elicited calcium release from inositol-1,4,5-triphosphate-gated
intracellular stores81.
CB receptors have also been shown to couple to the generation of the lipid second
messenger ceramide via two different pathways: sphingomyelin hydrolysis and ceramide
synthesis de novo82,83. Ceramide in turn has been shown to control cell fate and to
mediate cannabinoid-induced apoptosis.
1.7 Signal transduction via other proteins
Recent data demonstrate that AEA is capable of interacting with other molecular
targets than CB receptors, such as 5-hydroxytryptamine receptors, L-type calcium
channels, Shaker related K+-channels, TASK-1 channels, a non-CB1 G-protein coupled
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Figure 6 Molecular bases of some neuromodulatory actions of AEA.
At the presynaptic and postsynaptic nerve terminal AEA and THC can activate G-protein coupled CB1
receptors, modulating neuronal membrane permeability to Ca2+ and K+ ions and the activity of adenylate
cyclase (AC), thereby affecting neurotransmitter release or action, or both. (Figure adapted from 12) 
BOC van der Stelt1  05-02-2002  16:38  Pagina 22
AEA receptor in astrocytes and a non-CB1 non-CB2 G-protein coupled receptor for AEA
and WIN55.212-2 in mouse brain64,84. Furthermore, AEA seems to be a full agonist at
vanilloid type 1 receptors (VR1), the sites of action of the pungent component of ‘hot’
red peppers, capsaicin. Yet, in heterologous expression systems the potency of AEA to
induce typical VR1-mediated effects (e.g. cation currents, Ca
2+-influx and cell
depolarization) is 5-20 fold lower than its average potency at CB1 receptors
85. However,
recent data seems to indicate that some in vitro and ex vivo pharmacological actions of AEA
are due to activation of native vanilloid receptors. It is suggested that AEA might act as an
“endovanilloid” 86.
1.8 (Endo)cannabinoids modulate neurotransmission 
The relation of the cannabinoid system to various neurotransmitter systems is of
importance to understand its action on the central and peripheral nervous system. The
cannabinergic system is involved via presynaptic and postsynaptic CB1 receptors in
regulation of the release, uptake and actions of excitatory and inhibitory transmitters such
as acetylcholine, noradrenaline, dopamine, 5-hydroxytryptamine, γ-aminoburyric acid
(GABA), glutamate and aspartate (Fig. 6)12.
1.8.1 GABA-ergic transmission
According to the location and morphology, many CB1-like neurons appeared to be
GABAergic in an immunohistochemical distribution study87. Cannabinoids facilitate
GABAergic transmission in some brain areas as reviewed by88,89. It is suggested that the
cannabinoid-induced increase in GABAergic transmission in the globus pallidus is mainly
caused by an inhibited uptake of GABA, rather than an increased release of GABA90-92.
By contrast, cannabinoids have also been shown to suppress the release of GABA from
presynaptic terminals in nucleus accumbens, hippocampus, substantia nigra and rostral
ventromedial medulla neurons22,93-97.
1.8.2 Dopaminergic transmission
Dopamine levels in the nucleus accumbens and in the vental tegmental area were
increased by application of cannabinoids. It was shown that the mesolimbic system was
activated by cannabinoids in a similar manner to heroin98,99. Furthermore, increased levels
of dopamine upon application of exogenous cannabinoids excited dopaminergic neurons
in the substantia nigra. However, other studies indicate that cannabinoids potentiate the
behavioural effects of dopamine antagonists (neuroleptics) and reduce electrically evoked
dopamine release from rat striatal slices. Injection of CB1 receptor agonist in rat basal
ganglia counteracted the motor responses of locally administered D2 receptor agonists.
Activation of dopamine D2 receptors led to an increase in AEA-concentrations in the
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striatum of freely moving rats, thereby it was demonstrated for the first time that
endogenous AEA was acting as a neuromodulator in vivo21.
1.8.3 Glutamatergic transmission 
In the brain, glutamate is the predominant excitatory neurotransmitter and it has an
important role in many brain pathologies. In rat hippocampal cultures glutamatergic
transmission could be blocked by cannabinoids at subnanomolar concentrations in a
receptor-mediated manner100.The inhibition was stereoselective with the following rank
order CP55.939> CP55.940> WIN55.212-2> AEA and could be blocked by pertussis
toxin. WIN55.212-2 blocked stereo selectively AMPA receptor-mediated excitatory
postsynaptic currents (EPSCs) elicited by presynaptic stimulation with an extracellular
electrode, but did not affect the presynaptic action potential or currents elicited by direct
application of kainate100. It was suggested that this CB1-mediated inhibition of excitatory
synaptic transmission was developmentally regulated in rat hippocampus, being most
prominent in neonatal rats101. Furthermore, other studies have indicated that CB1
receptors are involved in the regulation of long term potentation in the hippocampus24.
By contrast, histological studies could not detect CB1 receptors on glutamatergic
terminals in the hippocampus. A possible explanation was recently put forward by Hajos
et al.65. Electrophysiological measurements in hippocampal slices of CB1 knock-out mice
suggested that a novel cannabinoid-sensitive receptor could be responsible for the
inhibition of glutamatergic neurotransmission65. Nevertheless, definite proof of a new
CB-type receptor in the hippocampus awaits cloning.
Recently, it was shown that WIN55.212, HU210 and AEA inhibited excitatory
synaptic transmission in rat striatal neurons102,103. HU210 reduced the amplitude of
evoked EPSCs in a dose-dependent matter. WIN55.212-2 significantly increased the
paired-pulse facilitation of synaptically evoked EPSCs, while having no effect on the
sensitivity of postsynaptic neurons to AMPA102. Superfusion of WIN55.212-2 elicited a
membrane hyperpolarization accompanied by a decrease in input resistance. The
WIN55.212-2-mediated synaptic inhibition was blocked by the Gi/o-protein inhibitor
pertussis toxin and reversed by SR141716, but not by GABAA receptor antagonist
bicuculline or GABAB receptor antagonist SCH50911.
102 Pretreatment with the N-type
Ca2+ channel antagonist ω-conotoxin (GVIZ) selectively abolished the WIN-55.212-2
mediated synaptic inhibition.These results suggest that cannabinoids depress corticostriatal
glutamatergic synaptic transmission through the activation of presynaptic CB1 receptors
to inhibit N-type Ca2+ channels activity, which in turn reduces glutamate release.When
Ca2+ was replaced by Sr2+ in the extracellular solution, application of HU-210
significantly reduced the frequency, but not amplitude, of evoked, asynchronous quantal
release events103. Spontaneous synaptic release events occurring between stimuli were
similarly decreased in frequency but not in amplitude. Thus while CB1-activation may
lead to reduced glutamate release via reduced Ca2+ influx, a more direct and Ca2+-
24
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independent inhibition of the release process is also implicated by the results of Gerdeman
and Lovinger103.
CB1-mediated inhibition of glutamatergic transmission has also been found in rat
cerebellar slices104, substantia nigra pars reticulata105, in rat substantia gelatinosa neurons
of the spinal cord106, mouse nucleus accumbens107 and in slices of the periaqueductal
gray108 as well as in rat prefrontal cortex pyrimidal neurons109. In the latter study it was
shown that SR141617A acutely increased glutamatergic transmission and favoured Long
Term Potentiation at the expense of Long Term Depression109. In contrast, in vivo
microdialysis in rat prefrontal cortex revealed that i.p. injection of WIN55.212-2 led to a
release of glutamate, which was counteracted by SR141716A110.
1.8.4 Endocannabinoids as retrograde messengers
Importantly, the findings, as described above, were taken a step further by the results
of a number recent studies in which endogenously released endocannabinoids were shown
to mediate retrograde signals from depolarized postsynaptic neurons to presynaptic
terminals (Fig. 7;22,111-116). It is thought that endocannabinoids are responsible for
depolarization-induced suppression of inhibition and excitation (DSI and DSE). In
hippocampal neurons, depolarization of postsynaptic neurons and resultant elevation of
intracellular Ca2+ led to transient suppression of inhibitory transmitter release, while in
cerebellar purkinje cells post-synaptic elevation of intracellular Ca2+ concentrations
caused transient suppression of excitatory transmitter release. These effects could be
mimicked by cannabinoid receptor agonist WIN55.212-2 and were completely blocked
by application of the CB1 antagonists SR141716A and AM281
22,111-116. DSI was not
present in CB1 knock-out mice, and pharmacological and kinetic data suggested that CB1
activation inhibited presynaptic Ca2+ channels through direct G-protein inhibition111.
Metabotropic glutamate receptor antagonists, a GABAB receptor antagonist and
postsynaptically applied botulinum toxin, which inhibits vesicular glutamate release from
the postsynaptic cell, were ineffective. Interestingly, flash photolysis of caged Ca2+ was
sufficient to induce DSI. However, stimulation of metabotropic glutamate receptors,
without elevation of calcium levels, could also induce cannabinoid-dependent DSE in
cerebellar purkinje cells112. At the moment it is unclear, which endocannabinoid is
responsible for DSI and DSE and what the mechanism is of its synthesis and release.
1.9 Physiological functions
The involvement of the endocannabinoid system in the regulation of three widespread
cellular signalling mechanisms (calcium, cAMP, and ceramide) combined with its broad
distribution pattern in both the central nervous system and in peripheral tissues may
explain its implication in many physiological actions. The general idea is that the
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Figure 7 Hypothetical model of retrograde AEA-action.
(1) Presynaptic depolarization leads to calcium influx, which in turn activates glutamate exocytosis (2).
Glutamate diffuses through synaptic cleft and activates post-synaptic glutamate receptors (3). Activation of
NMDA, AMPA and other glutamate-subtype receptors lead to post-synaptic depolarization and calcium
influx (4). Elevated post-synaptic calcium levels activate a transacylase (TA), which converts
phosphatidylethanolamine (PE) into N-arachidonoylphosphatidylethanolamine (NAPE) (5). NAPE is
hydrolysed by a phospholipase D (PLD), which yields AEA. AEA is released from the post-synaptic cell and
diffuses back to presynaptic CB1 receptors (6). Upon activation of CB1 receptors by AEA, Gi/o-proteins are
released, which inhibit N-, and P/Q-type voltage sensitive calcium channels (7). Closing of voltage sensitive
calcium channels results in a reduced release of neurotransmitters such as glutamate or GABA (8). Adapted
from 12
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endogenous cannabinoid system may be a widespread tuning system of various different
physiological responses. It should be noted that the physiological effects of the
cannabinoid system are usually studied with the use of exogenously applied
(endo)cannabinoids. Little is known of the involvement of the endogenously formed
ligands of the cannabinoid system.The endocannabinoid system seems to be involved in
regulation of blood pressure, secretion of pituitary and steroid hormones, embryo
implantation, tumour growth and immunomodulation.The latter may depend at least in
part on CB2 receptor mediated suppression of proinflammatory cytokine release and
enhancement of anti-inflammatory cytokine release from immune cells. CB1 receptors
may regulate different physiological functions by modulating neurotransmission in
different parts of the brain, such as body temperature (thalamus), perception
(sensorimotorcortex, olfactory bulb), cognitive functions such as sleep and memory
(hippocampus, cortex), appetite (hypothalamus), pain processing (thalamus, periaqueductal
grey, amygdala) and (psycho)motor functions (basal ganglia, cerebellum).12,20,21,70,83,117-126
Recently, two different strains of CB1 knock-out mice have been bred
127,128.
Differences between the strains have been observed. The CB1
-/- mice generated by
Ledent128 were fertile and appeared healthy.The mice exhibited mild increased locomotor
activity and the spontaneous nociceptive threshold of wild-type and mutant and naive
mice was similar. Interestingly, in these CB1
-/- mice the reinforcing properties of
morphine and the severity of the withdrawal syndrome were strongly reduced. These
observations suggest that the CB1 receptor is involved in motivational properties of opiates
and in the development of physical dependence.
The mice generated by Zimmer et al. appeared also healthy and fertile127, however, in
contrast to the Ledent mice, the Zimmer mice displayed reduced locomotor activity,
increased ring catalepsy, and hypoalgesia in hotplate and formalin tests. Remarkably, the
mice had a significantly increased mortality rate. The mice died suddenly without any
obvious signs of disease, such as weight loss, dehydration, or abnormal posture.The reason
for this increased mortality is currently unknown. Since cannabinoids induce pronounced
hypotension and bradycardia, it is speculated that the mice succumb to latent
cardiovascular problems. Alternatively, CB1-/- mice have an increased risk of developing
neurological problems such as seizures127.
1.10 Pathophysiological implications
1.10.1  Huntington’s disease
The cannabinoid system has been implicated in a variety of neurological and
neurodegenerative diseases, such as glioma growth, Parkinson’s and Huntington’s disease
and Multiple Sclerosis19,129. In postmortem brains of patients with Huntington’s disease a
relative loss of CB1 and dopamine receptors was observed through several grades of
pathology in the globus pallidus and substantia nigra130. It is speculated that the early
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down regulation of cannabinoid receptors is a compensatory mechanism in Huntington’s
disease. In a recent study it has been shown that CB1 mRNA was down regulated in the
lateral striatum and cortical regions of transgenetic Huntington’s disease mice, prior to the
development of either Huntington’s disease phenotype or neuronal degeneration131.
Furthermore, in another rat model of Huntington’s disease CB1 binding sites were lost,
and the CB1-mediated activation of GTP-binding proteins were reduced in the basal
ganglia132. These changes were paralleled by a decrease of AEA and 2-AG levels in the
striatum, whereas in the non-lesioned cerebral cortex normal endocannabinoid levels
were found.At the moment it is unclear to what extent these observations contribute to
the symptomology of Huntington’s disease, or whether they are a side effect of toxin-
induced destruction of striatal GABAergic neurons132.
1.10.2 Parkinson’s disease
It was shown that intrapallidal administration of cannabinoids reduced the uptake of
GABA from striatopallidal terminals and voluntary movement, thereby reproducing
Parkinson’s disease-like symptoms90,91. Stimulation of CB receptors increased catalepsy
produced by dopamine receptor antagonists133, and it reduced the anti-parkinson-like
actions of D2 dopamine receptor agonists
134. Furthermore, increased 2-AG levels were
found in the globus pallidus of rats treated with reserpine, a rodent model of Parkinson’s
disease.This substantiates the hypothesis that an increased cannabinoid tone in the globus
pallidus contributes to the symptoms of Parkinsons’ disease135. Indeed, SR141716A
increased the efficacy of anti-parkinson-like effects of dopamine receptor agonists in this
model135. Moreover, SR141716A was therapeutically useful, by reducing L-dopa-induced
dyskinesia in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-treated primates136.
However, in another recent study with non-human primates SR141716A failed to
alleviate the parkinson-like symptoms137,138. Differences in dose-regimen, methods to
deplete dopamine, and species differences in endogenous cannabinoids levels might
explain the differences between rodent and primate models137.
1.10.3 Multiple Sclerosis
Cannabis use has been reported to reduce the muscle spasticity associated with
multiple sclerosis or spinal cord injury (reviewed:129). THC has been shown to reduce
spasticity and pain in a few small clinical trials129. The efficacy of THC in MS has also
been tested in animal models.THC was able to inhibit the progression of experimental
autoimmune encephalomyelititis (EAE), the most commonly used animal model of MS,
in rodents. The presumed mode of protection was its immunosuppressive actions rather
than a direct effect on paralysis itself139,140 However, recent studies indicate that THC as
well as synthetic cannabinoids can ameliorate both tremor and spasticity via CB1 and/or
CB2 receptors in mice with chronic relapsing experimental allergic encephalomyelitis
(CREAE)141. Also AEA, 2-AG and palmitoylethanolamide were demonstrated to
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ameliorate the spasticity in the same model142. Interestingly, in brain areas associated with
brain damage, increased levels of AEA, 2-AG and palmitoylethanolamide were found,
whereas comparable levels of these compounds were found in normal and non-spastic
mice142. Hydrolysis and uptake inhibitors of endocannabinoids were shown to ameliorate
spasticity to an extent comparable with that observed with synthetic potent cannabinoid
agonists. According to the authors the results opened new horizons to the therapy of
multiple sclerosis and other neuromuscular diseases, based on agents modulating
endocannabinoid levels and actions, which exhibit little psychotropic activity142.
1.10.4 Ischemia and excitotoxicity
The central nervous system is highly vulnerable to ischemia induced by a stroke or
traumatic brain injury. Neuronal death caused by ischemia is executed via a complex array
of processes in which excitotoxicity plays a major role. Several lines of evidence reveal a
connection between cannabinoids and excitotoxicity. In excitotoxicity, cell death is
triggered by the overstimulation of excitatory amino acid receptors by glutamate. This
leads to cytotoxic levels of calcium and subsequent activation of destructive pathways,
involving among others caspases, calpains and the generation of reactive oxygen
species143,144. The excitotoxicity hypothesis is also used to explain the common
biochemical basis behind many chronic neurodegenerative disorders such as amyotrophic
lateral sclerosis, Parkinson’s, Huntington’s and Alzheimer’s diseases143-145.
Several in vitro studies have reported neuroprotection with classical and synthetic
cannabinoids (see also chapter 6). Depending on the model used, cannabinoids were
shown to protect neurons via CB1-mediated inhibition of glutamate exocytosis
146, CB1-
mediated closing of voltage sensitive calcium channels147,148, anti-oxidant activity149, and
suppression of the formation of tumour necrosis factor alpha150.AEA and 2-AG have been
shown to rescue cerebral neurons from in vitro hypoxia and glucose deprivation via a CB1
and CB2-independent pathway
151. By contrast, some in vitro studies do not support a
neuroprotective action of cannabinoids. AEA was shown to be ineffective to protect
neurons against prolonged exposure to toxic levels of glutamate152,153. Hampson and
Grimaldi have suggested that the varying and uncontrolled levels of cAMP in in vitro
models of neurotoxicity may explain the lack of neuroprotection by cannabinoids154.
The therapeutic effects of cannabinoids in in vivo models of cerebral ischemia are
described in a few studies, but are also not consistent. Chronic ∆9-THC administration
has been shown to reduce the impact of an ischemic insult evoked by a reduced blood
pressure and 12 min bilateral carotid artery occlusion. The involvement of the CB1
receptor was not studied155. No protective effect could be found for WIN55.212, a
synthetic CB receptor agonist, in rats when the middle cerebral artery was occluded for 2
h. Surprisingly, the CB1 receptor antagonist was protective
1. By contrast, the CB receptor
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agonist WIN 55.212-2 afforded protection to hippocampal and cortical neurons in CB1-
dependent manner in rats with a permanent middle cerebral artery occlusion or global
ischemia156. In gerbils subjected to transient global ischemia pretreatment with CP55940
reduced ischemia-induced hyperlocomotion and improved electroencephalographic
(EEG) spectral power after 24h, which lasted for at least 7 days157. Currently, there is no
explanation for the contradictory in vivo studies. It should be noted that in each of these
stroke models different perturbations in cerebral blood pressure and flow were induced. It
might be possible that cannabinoid-induced vasorelaxation158 is affecting the extent and
pathway of neuronal demise in a different manner in each of these stroke models.
In summary, exogenously applied cannabinoids can protect neurons against neuronal
damage in various ways depending on dose, time of application and type of injury.
However, to date most studies have been conducted in vitro with classical and synthetic
cannabinoids. Only one in vitro study has demonstrated a neuroprotective effect of AEA
and there are no data available from in vivo studies. To date it is unknown whether
endogenously released AEA can protect the brain against acute neuronal injury.The role
of endocannabinoids in neurodegenerative diseases may be clarified by studying the effects
of both exogenous and endogenous cannabinoids in an in vivo model of (secondary)
excitotoxicity, without directly affecting blood pressure and flow to the brain.
1.11 Aim
The developments as described above indicate that the endocannabinoid system is a
potentially valuable field for drug discovery. CB1 and CB2 receptors, FAAH and the
transporter protein may play a role as important drug targets. This will circumvent the
need of a marijuana extract as a medicine, thereby avoiding marijuana’s complex unknown
and varying composition and possibly its psychotropic side effects. For example, the
development of CB2 receptor selective ligands may lead to therapeutic agents without
activation of the central CB1 receptor, which is responsible for the psychotropic effects.
The same accounts for CB1 receptor ligands, which cannot pass the blood brain barrier,
but which can still activate the peripheral CB1 receptors. The development of selective
FAAH inhibitors or AEA-uptake inhibitors might also yield useful therapeutics. FAAH
inhibitors may act as indirect agonists. It is unlikely that they will affect all parts of the
endocannabinoid system at one time, like direct agonists. They will only increase the
concentrations of endocannabinoids at sites where ongoing biosynthesis is already
occurring, thereby preventing the sustained activation of CB receptors at other sites.Yet,
if pharmaceutical agents targeted towards the cannabinoid system are going to play a role
in medicine, if any, some important questions have to be answered. i) Is it possible to
develop selective and potent molecular probes to each of the proteins of the
endocannabinoid system? ii) Is the endocannabinoid system involved in specific
pathophysiological states? If inhibitors of endocannabinoid inactivation are going to play
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a role, then iii) does the inactivation system also limit the actions of the endocannabinoid
system in humans? iv) What is the influence of the oxidative metabolism of
endocannabinoids on their function?
The aim of this thesis is therefore to study a) the metabolism of AEA in human cells and brain
tissue, b) the interaction of its oxygenated metabolites with the proteins of the endocannabinoid
system, and c) the role of the endocannabinoid system in in vivo neurodegeneration.
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Abstract
Anandamide (arachidonoylethanolamide, AEA) has important
neuromodulatory and immunomodulatory activities.This lipid is rapidly taken
up and hydrolyzed to arachidonate and ethanolamine in many organisms. As
yet, AEA inactivation has not been studied in humans. Here, a human brain
fatty acid amide hydrolase (FAAH) has been characterized as a single protein
of 67 kDa and pI of 7.6, showing apparent Km and Vmax for AEA of 2.0 ± 0.2
µM and 800 ± 75 pmol.min-1.mg protein-1, respectively.The optimum pH and
temperature for AEA hydrolysis were 9.0 and 37°C, respectively, and the
activation energy of the reaction was 43.5 ± 4.5 kJ.mol-1. Hydro(pero)xides
derived from AEA or its linoleoyl analogues by lipoxygenase action were
competitive inhibitors of human brain FAAH, with apparent Ki values in the
low micromolar range.A FAAH activity sharing several biochemical properties
with the human brain enzyme was demonstrated in human neuroblastoma
CHP100 and lymphoma U937 cells. Both cell lines have a high affinity
transporter for AEA, which had apparent Km and Vmax for AEA of 0.20 ± 0.02
µM, 30 ± 3 pmol.min-1.mg protein-1 (CHP100 cells), and 0.13 ± 0.01 µM, and
140 ± 15 pmol.min-1.mg protein-1 (U937 cells), respectively. The AEA carrier
of both cell lines was activated up to 170% of the control by nitric oxide.
Introduction
Anandamide (arachidonoylethanolamide, AEA) is an endogenous lipid that binds to
cannabinoid CB1 and CB2 receptors, which are mainly found in the central nervous
system and in peripheral immune cells. It mimics the pharmacological effects of ∆9-
tetrahydrocannabinol, the active principle of hashish and marijuana1,2. AEA formation
occurs mainly through phosphodiesterase-mediated cleavage of N-arachidonoyl-
phosphatidylethanolamine3,4, though a direct synthesis from arachidonic acid and
ethanolamine has also been described5,6.AEA can be released from depolarized neurons3.
Upon binding to CB1 receptors, AEA induces inhibition of forskolin-induced cAMP
accumulation, inhibition of N-type Ca2+ channels, activation of mitogen-activated-
protein (MAP) kinase signal transduction pathway7, and increases protein tyrosine
phosphorylation8.Activation of the CB2 receptor leads to inhibition of adenylate cyclase
and activation of the MAP-kinase signaling9. Interestingly, AEA binding to cannabinoid
receptors is coupled to nitric oxide (NO) release in the central nervous system of
invertebrates and in peripheral immune cells of both invertebrates and humans10.
The pharmacological effects of AEA on CB1 and CB2 receptors depend on the life
span of the lipid in the extracellular space, which is limited by a rapid and selective process
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of cellular uptake, followed by intracellular degradation of AEA to ethanolamine and
arachidonic acid by the enzyme fatty acid amide hydrolase (FAAH). Both components of
the inactivation process of AEA are the subject of active investigation. AEA uptake has
been characterized in rat neuronal cells3,11,12 and rat basophilic leukemia (RBL-2H3)
cells13. FAAH has been demonstrated and partially characterized in rat, porcine and dog
brains14-16. Furthermore, FAAH activity has been shown in one “neuronal” cell line,
namely mouse neuroblastoma N18TG2
17, and in one “non-neuronal” cell line, namely
RBL-2H313.The FAAH gene has recently been cloned from rat, mouse and human liver
cDNAs, allowing molecular mass determination and substrate specificity analysis of the
enzyme18,19. As yet, no information is available on the activity of human FAAH, or on
AEA uptake by human cells.This prompted us to investigate some biochemical properties
of FAAH from human brain and human neuronal and immune cells, i.e. neuroblastoma
CHP100 and lymphoma U937 cells.AEA uptake was characterized in these two cell types
to gain information on the AEA inactivation process in humans.The cell lines chosen are
widely used as experimental models for neuronal and immune tissues20,21. In these two
cell types AEA uptake was demonstrated and characterized.
Taken together, the results reported here represent the first biochemical
characterization of human brain FAAH. Most properties of this enzyme are shared by
FAAH found in human neuronal and immune cells in culture. Remarkably, both cell lines
seem to inactivate AEA in the same way, which strengthens the concept of a
neuroimmune axis in humans, which is evident, for instance, in the “axon-reflex” model
for neurogenic inflammation13. Possible implications of FAAH activity and expression in
brain pathology are also discussed.
Materials and Methods
Materials 
Chemicals were of the purest analytical grade. Anandamide (arachidonoylethanolamide; AEA),
arachidonic acid, ethanolamine, phenylmethylsulfonyl fluoride (PMSF), iodoacetic acid, N-
ethylmaleimide, carbonyl cyanide m-chlorophenylhydrazone (CCCP) and sodium nitroprusside
(SNP) were purchased from Sigma. S-Nitroso-N-acetylpenicillamine (SNAP) was from Research
Biochemicals International, and spermine NONOate (SPER/NO, (Z)-1-{N-[3-aminopropyl]-N-
[4-(3-aminopropylammonio)butyl]-amino}-diazen-1-ium-1,2-diolate) was from Alexis
Corporation (Switzerland). Leukotriene B4 (LTB4) and prostaglandin E2 (PGE2) were from Cayman
Chemical Co. Inc. [1-14C]AEA was synthesized from ethanolamine and [1-14C]arachidonic acid
(NEN DuPont de Nemours, Germany, 52 mCi/mmol) as described22. Linoleoylethanolamide
(9Z,12Z-octadecadienoylethanolamide, LEA), linoleoylamide (9Z,12Z-octadecadienoylamide, LA),
linoleoylmethylamide (9Z,12Z-octadecadienoylmethylamide, LMA), and their 13-hydroxy
derivatives 13-HLEA, 13-HLA and 13-HLMA, were synthesized and characterized (purity > 96%
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by gas-liquid chromatography) as described22 15-Hydro(pero)xyanandamide (15-hydro-
(pero)xyeicosa-5Z,8Z,11Z,13E-tetraenoyl-ethanolamide, 15-H(P)AEA, purity > 96%) and 11-
hydro(pero)xyanandamide (11-H(P)AEA, a mixture of 45% 11-H(P)AEA, 24% 5-H(P)AEA, 18%
15-H(P)AEA, 9% 8-/9-H(P)AEA and 4% 12-H(P)AEA by reversed phase high performance liquid
chromatography) were synthesized as described in23.
Biological material 
Human brain specimens were obtained from five different male patients (aged 73-77),
undergoing surgical operation to remove meningioma tumors. Brain tissues were removed and
donated by Prof. R. Giuffrè and Dr. G. De Caro (Neurosurgery Division, University of Rome Tor
Vergata, Sant’Eugenio Hospital, Rome, Italy). In four cases the perilesional white matter
surrounding the tumor area was removed (1 g of fresh tissue in total) and used for fatty acid amide
hydrolase (FAAH) characterization. In one case, both meningioma and perilesional white matter
(0.1 g of each fresh tissue) were removed and used to compare FAAH activity and expression in
meningioma and healthy brain.
Human neuroblastoma CHP100 cells were cultured as reported20, in a 1:1 mixture of Eagle’s
minimal essential medium plus Earle’s salts and Ham’s F-12 medium (Flow Laboratories Ltd.,
United Kingdom), supplemented with 15% heat-inactivated fetal bovine serum, sodium bicarbonate
(1.2 g/l), 15 mM Hepes, 2 mM L-glutamine and 1% non essential amino acids. Human lymphoma
U937 cells, a gift by Dr. E. Faggioli (Department of Public Health and Cell Biology, University of
Rome Tor Vergata), were cultured in RPMI 1640 medium (Gibco, United Kingdom), supplemented
with 25 mM Hepes, 2.5 mM sodium pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin and
10% heat-inactivated fetal calf serum21. Both CHP100 and U937 cells were maintained at 37°C in
humidified 5% CO2 atmosphere.
Assay of fatty acid amide hydrolase (FAAH) 
Immediately after surgical removal, human brain specimens were washed in phosphate-buffered
saline and homogenized with an UltraTurrax T25 in 50 mM Tris-HCl and 1 mM EDTA, pH 7.4
(buffer A), at a 1:10 homogenization ratio (fresh weight/volume). Membranes from these tissue
homogenates were then prepared as described22.The final pellet, containing most FAAH activity,
was resuspended in ice-cold buffer A at a protein concentration of 1 mg/ml and stored at -80°C
until use. Both CHP100 and U937 cells (3x108/sample) were collected in phosphate-buffered saline
and centrifuged at 1000 xg for 10 min.The dry pellet was resuspended in 30 ml ice-cold buffer A
and sonicated on ice three times for 10 s, with 10 s intervals, using a Vibracell sonifier (Sonics &
Materials Inc.) with a microtip at maximum power. The homogenate was then centrifuged
sequentially as described above for the human brain, and the final pellet was stored at -80°C in
buffer A at a protein concentration of 1 mg ml-1 until use.
The assay of FAAH (E.C. 3.5.1.4, arachidonoylethanolamide amidohydrolase) activity was
performed by reversed-phase high performance liquid chromatography (HPLC) as described22.
Thermal stability and pH dependency of FAAH activity were studied as described17. Activation
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energy values were calculated as reported24. Kinetic and inhibition studies were performed using
different concentrations of [1-14C]AEA (in the range 0-21 µM) and two different concentrations
(10 µM and 20 µM) of each inhibitor to calculate the kinetic parameters. Fitting of the experimental
points to a Lineweaver-Burk plot by a linear regression programme (Kaleidagraph 3.0) yielded
straight lines with r-values > 0.95.
The assay of the FAAH synthase activity was performed by measuring the formation of
[1-14C]AEA from [1-14C]arachidonic acid and ethanolamine as reported5. Tissue or cell
homogenates (20 µg proteins/test) were incubated for 15 min at 37°C in 200 µl 50 mM Tris-HCl,
pH 9.0, containing 10 µM [1-14C]arachidonic acid (52 mCi/mmol) and 2 mM ethanolamine.The
reaction was stopped, and the products were extracted and analyzed by reversed-phase HPLC,
following the same procedure as described above for the hydrolase activity. FAAH synthase activity
is expressed as pmol AEA  min-1mg protein-1.The effect of various compounds on the hydrolase or
synthase activity of FAAH was determined by adding each substance directly to the assay buffer at
the indicated concentrations.
Immunochemical analysis 
SDS-polyacrylamide gel electrophoresis (12%) was performed under reducing conditions in a
Mini Protean II apparatus (Bio-Rad) with 0.75-mm spacer arms. Rainbow molecular mass markers
(Amersham International, United Kingdom) were phosphorylase b (97.4 kDa), bovine serum
albumin (66.0 kDa) and ovalbumin (46.0 kDa). Native isoelectric focusing (IEF) was performed in
the Mini Protean II apparatus using a 5% polyacrylamide gel containing ampholytes in the pH range
5.0-9.0 (Sigma) as described25. IEF was calibrated by running the following isoelectric point (pI)
markers (Sigma): lentil (Lens culinaris) lectin (pI 8.8, 8.6 and 8.2), myoglobin from horse heart (pI
7.2 and 6.8), carbonic anhydrase I from human erythrocytes (pI 6.6) and carbonic anhydrase II from
bovine erythrocytes (pI 5.9). Human brain homogenates (20 µg/lane), prepared as described above
for FAAH assay, were subjected to either SDS-polyacrylamide gel electrophoresis or IEF and then
slab gels were electroblotted onto 0.45 µm nitrocellulose filters (Bio-Rad), using a Mini Trans Blot
apparatus (Bio-Rad) as reported26. Immunodetection of FAAH on nitrocellulose filters was
performed with specific anti-FAAH polyclonal antibodies (diluted 1:200), raised in rabbits against
the conserved FAAH sequence VGYYETDNYTMPSPAMR19, conjugated to ovalbumin. This
peptide antigen and the anti-FAAH polyclonal antibodies were prepared by Primm S.r.l. (Milan,
Italy). Goat anti-rabbit alkaline phosphatase conjugate (GAR-AP, Bio-Rad) (diluted 1:2000) was
used as secondary antibody, and immunoreactive bands were stained with the alkaline phosphatase
staining solution according to the manufacturer’s instructions (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA) was performed by coating the plate with human
brain homogenate (20 µg/well), prepared as described above for FAAH assay.Anti-FAAH polyclonal
antibodies were used as primary antibody (diluted 1:300) and GAR-AP as secondary antibody
(diluted 1:2000). Color development of the alkaline phosphatase reaction was measured at 405 nm,
using p-nitrophenylphosphate as substrate. For peptide competition experiments, the peptide
antigen was preincubated with a 1000-fold molar excess of anti-FAAH polyclonal antibodies for 30
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min at room temperature before adding the antibodies to the wells18. Controls were carried out
using non-immune rabbit serum and included wells coated with different amounts of bovine serum
albumin.
Reverse transcriptase polymerase chain reaction (RT-PCR) and sequencing 
2-5x106 cells or 20 mg tissue were used to isolate total RNA by means of the S.N.A.P.™ Total
RNA Isolation Kit (Invitrogen). Control reactions were carried out to ensure complete removal of
genomic DNA. RT-PCRs were performed using the EZ rTth RNA PCR kit (Perkin Elmer)
following the manufacturer’s instructions.The reaction conditions were carefully examined to stop
the reaction during the exponential phase of amplification of each gene. Briefly, 100 ng (for the
amplification of FAAH), or 0.4 ng (for 18S rRNA) of total RNA, were reversibly transcribed and
amplified in the same tube in a total reaction volume of 10 µl, in the presence of 3 mCi of α-32P-
dCTP (Amersham International, United Kingdom, 3000 Ci/mmol).The amplification parameters
were as follows: 2 min at 95°C, 45 s at 95°C, 30 s at 55°C and 30 s at 60°C. Linear amplification
was observed after 20 cycles.The primers were as follows:
(+)5’-TGGAAGTCCTCCAAAAGCCCAG,(-) 5’-TGTCCATAGACACAGCCCTTCAG,
for FAAH;(+)5’-AGTTGCTGCAGTTAAAAAGC, (-)5’-CCTCAGTTCCGAAAAC-CAAC, for
18S rRNA.
Five µl of the reaction mixture were electrophoresed on a 6% polyacrylamide gel, which was
then dried and subjected to autoradiography. Products were validated by size determination and
sequencing. For quantitation of the RT-PCR products, bands were excised from the gel and
counted in a LKB1214 Rackbeta scintillation counter (Sweden). Linear amplification sequencing
was performed by using Cyclist™ DNA Sequencing Kit (Stratagene), according to the
manufacturer’s instructions. RT-PCR products for sequencing were prepared without the α-32P-
dCTP and sequenced with the same primers used for amplification after labeling them with γ-32P-
dATP (Amersham International, United Kingdom, 3000 Ci/mmol).
Determination of anandamide uptake
The uptake of [1-14C]AEA (52 mCi/mmol) by intact CHP100 or U937 cells was studied
essentially as described13. CHP100 and U937 cells were resuspended in their serum-free culture
media at a density of 1x106 cells/ml. Cell suspensions (2 ml/test) were incubated for different time
intervals at 37°C with 100 nM [1-14C]AEA, then they were washed three times in 2 ml culture
medium containing 1% bovine serum albumin and were finally resuspended in 200 µl phosphate-
buffered saline. Membrane lipids were then extracted27, resuspended in 0.5 ml methanol and mixed
with 3.5 ml Sigma-Fluor liquid scintillation cocktail for non-aqueous samples (Sigma), and
radioactivity was measured in a LKB1214 Rackbeta scintillation counter (Sweden).To discern non-
protein-mediated from protein-mediated transport of AEA into cell membranes, control
experiments were carried out at 4°C13. Incubations (15 min) were also carried out with different
concentrations of [1-14C]AEA (in the range 0-750 nM) in order to determine apparent Km and
Vmax of the uptake by Lineweaver-Burk analysis (in this case, the uptake at 4°C was subtracted from
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that at 37°C).The Q10 value was calculated as the ratio of AEA uptake at 30°C and 20°C
11. AEA
uptake is expressed as pmol AEA taken up per min mg protein-1.The effect of different compounds
on AEA uptake was determined by adding each substance directly to the incubation medium at the
indicated concentrations. In the case of CCCP, cells were preincubated with 50 µM CCCP for 15
min at 37°C before addition of [1-14C]AEA to abolish mitochondrial transmembrane potential28.
Cell viability after each treatment was checked with Trypan blue and found to be higher than 90%
in all cases. It is noteworthy that no specific binding of [3H]CP55940, a potent cannabinoid, was
obtained with plasma membranes of CHP100 cells, and U937 cells express hardly detectable CB1
mRNA and very low levels of CB2 mRNA
21, thus [1-14C]AEA binding to CB receptors is not
likely to interfere in the uptake experiments11,13.
Data  analysis 
Data reported in this paper are the mean (± S.D.) of at least three independent determinations,
each performed in duplicate. Statistical analysis was performed by the Student’s t-test, elaborating
experimental data by means of the InStat programme (GraphPad Software).
Results
Characterization of FAAH in human brain and human CHP100 and U937 cells 
Pilot experiments indicated that human brain FAAH activity was linearly dependent
on the amount of tissue homogenate (in the range 0-30 µg protein) and the incubation
time of the reaction (in the range 0-30 min), whereas it depended on AEA concentration
according to Michaelis-Menten kinetics (Fig. 1A) (data not shown), yielding an apparent
Km of 2.0 ± 0.2 µM and a Vmax of 800 ± 75 pmol.min
-1.mg protein-1. The activity of
FAAH was assayed in the pH range 5.0-11.0 and in the temperature range 20-65°C,
showing an optimum pH and temperature at 9.0 and 37°C, respectively. Arrhenius
diagrams of AEA hydrolysis by FAAH in the temperature range 20-45°C allowed us to
calculate an activation energy of 43.5 ± 4.5 kJ.mol-1.
Western blotting showed that anti-FAAH polyclonal antibodies specifically recognized
a single immunoreactive band in brain homogenates, corresponding to a molecular mass
of ~ 67 kDa and an isoelectric point of ~ 7.6 (Fig. 2).
Hydroxylated AEA derivatives and its linoleoyl analogues were competitive inhibitors
of human brain FAAH, with apparent Ki values ranging from 3.2 to 24.5 µM (Table I).
The substrate specificity of FAAH from human brain resembled that of the enzyme from
mouse or rat brain18,19.
Human neuronal (CHP100) and immune (U937) cells in culture also showed FAAH
activity, with pH and temperature profiles superimposable to those observed with the
human brain enzyme (data not shown). Both cell lines showed a FAAH activity (Fig. 1A
and B) characterized by apparent Km and Vmax values of 6.5 ± 0.6 µM,32 ± 3 pmol.min
-1.mg
47
Anandamide Hydrolysis by Human Cells in Culture and Brain
BOC van der Stelt2  06-02-2002  11:04  Pagina 47
protein-1 (CHP100) and 6.5 ± 0.6 µM, 520 ± 50 pmol.min-1.mg protein-1 (U937), for
AEA. The activation energy of AEA hydrolysis by FAAH from CHP100 or U937 cells
(45.0 ± 4.5 kJ.mol-1 in either case) was the same as the human brain enzyme. Moreover,
15-HAEA, LEA and 13-HLEA competitively inhibited FAAH activity from both cell
lines, with apparant Ki 4.5 ± 0.4, 11.1 ± 0.9, and 6.1 ± 0.5 µM (CHP100) and 3.8 ± 0.4,
10.5 ± 1.0, and 4.5 ± 0.4 µM (U937), respectively.
Excess (100 µM) arachidonic acid, but not ethanolamine, strongly inhibited FAAH
activity in all human sources tested, in line with previous findings on mouse FAAH17.
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In A, FAAH activity was assayed at various anandamide concentrations in human brain (J) and human
lymphoma U937 cells (H) in culture. In B, FAAH activity was assayed in human neuroblastoma CHP100 cells
(B) in culture. In both panels, FAAH activity was measured at pH 9.0 and 37°C.
Figure 1 Dependence of fatty acid amide hydrolase (FAAH) activity on anandamide concentration.
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Electrophoretic properties of human brain FAAH. Figure 2
Human brain extracts (20 µg/lane) were subjected to either SDS-polyacrylamide gel electrophoresis (left
panel) or isoelectric focusing (right panel). Slab gels were then electroblotted onto nitrocellulose filters and
FAAH was detected as immunoreactive band with specific anti-FAAH polyclonal antibodies. Molecular mass
markers and pI markers are shown.
Apparent inhibition constant (Ki) values were calculated by Lineweaver-Burk profiles of AEA
hydrolysis by FAAH.All compounds were reversible, competitive inhibitors of FAAH activity.
Compound (Ki, µM)
AEA None
15-HPAEA 4.8 ± 0.5  
15-HAEA 3.2 ± 0.3  
11-HPAEAa 5.2 ± 0.5  
11-HAEAb 4.0 ± 0.4  
LEA 9.0 ± 0.9  
LA 14.1 ± 1.3  
LMA 24.5 ± 2.1  
3-HLEA 3.0 ± 0.3  
13-HLA 5.3 ± 0.5  
13-HLMA 9.3 ± 0.9  
a 11-HPAEA was a mixture of 11-HPAEA (45%), 5-HPAEA (24%), 15-HPAEA (18%), 8-/9-HPAEA (9%)
and 12-HPAEA (4%);
b 11-HAEA was the same mixture as 11-HPAEA, reduced with NaBH4.
Inhibition of human brain FAAH activity by different anandamide products and analogues Table 1 
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FAAH activity was determined using 10 µM AEA as substrate. For uptake experiments, cells (2x106)
were incubated for 15 min at 37°C with 100 nM [1-14C]AEA  in the presence of each compound.
Activity and uptake values are expressed as percentage of the untreated controls, arbitrarily set to
100 (see below for absolute values). Results on FAAH activity in CHP100 and U937 cells were
superimposable, thus FAAH activity in CHP100 cells was omitted for the sake of clarity.
Compound FAAH activity Anandamide uptake
Brain U937 CHP100 U937
(%) (%)
None 100a 100b 100c 100d
Arachidonic acid (100 µM) 18 ± 2          16 ± 2 100 ± 10        100 ± 10  
Ethanolamine (100 µM) 83 ± 8          80 ± 8 95 ± 10        88 ± 9  
15-HAEA (10 µM) 33 ± 3         50 ± 5 90 ± 9        87 ± 9  
LEA (10 µM) 56 ± 6         62 ± 6 89 ± 9        85 ± 9  
13-HLEA (10 µM) 26 ± 3         43 ± 4 80 ± 8        82 ± 8  
Leukotriene B4 (1 µM) ND ND 105 ± 10        100 ± 10  
Prostaglandin E2 (10 µM) ND ND 105 ± 10        105 ± 10  
PMSF (100 µM) 6 ± 1          8 ± 1 50 ± 5        52 ± 5  
Iodoacetic acid (100 µM) 10 ± 1          12 ± 1 50 ± 5        48 ± 5  
N-Ethylmaleimide (100 µM) 15 ± 2          18 ± 2 55 ± 5        50 ± 5  
CCCP (50 µM) ND ND 85 ± 9        86 ± 9  
SNP (5 mM) 87 ± 9          85 ± 9 170 ± 17        see Fig. 5B  
SNAP (5 mM) 85 ± 9          87 ± 9 175 ± 18        see Fig. 5B  
SPER-NO (5 mM) 88 ± 9          84 ± 9 172 ± 17        see Fig. 5B  
a100% = 750 ± 70 pmol.min-1.mg protein-1;
b100% = 390 ± 40 pmol.min-1.mg protein-1;
c100% = 7.0 ± 0.7 pmol.min-1.mg protein-1;
d100% = 53.0 ± 5.5 pmol.min-1.mg protein-1.
ND, not determined.
Table 2 Inhibition of FAAH activity and [1-14C]anandamide uptake in human brain and human CHP100 and  U937 
cells
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Alkylating agents such as PMSF, iodoacetic acid and N-ethylmaleimide (at 100 µM)
almost abolished FAAH activity in all sources (Table 2).The NO-donors SNP, SNAP and
SPER-NO (at millimolar concentrations that release nanomolar concentrations of NO in
solution29,30)  hardly affected the hydrolase activity (Table 2).
An anandamide synthase activity31 was also present in the materials from human
sources. The following maximum reaction rates were found: 70 ± 7 (human brain),
24.5 ± 2.5 (CHP100) and 40 ± 4 (U937) pmol.min-1.mg protein-1.These values were ~
5-fold (CHP100 cells) to 10-fold (human brain and U937 cells) lower than the hydrolase
activity under the same assay conditions (i.e., 10 µM arachidonic acid and 20 µg proteins),
as shown in Fig. 1. Nevertheless, the synthase was affected by 15-HAEA, LEA, 13-HLEA
PMSF and SNP in the same way as the hydrolase activity (Table 2), both in human brain
and human cell lines (data not shown).
Expression of FAAH in human brain and human CHP100 and U937 cells
The analysis of FAAH expression in human brain and human cells was performed at
the protein (by ELISA) and mRNA (by RT-PCR) levels.The amount of FAAH protein
in human brain was ~2- or 10-fold higher than that observed in U937 or CHP100 cells,
respectively (Fig. 3A). This quantitation was validated by antigen competition
experiments18, showing that immunoreaction of the anti-FAAH polyclonal antibodies
with the enzyme protein in human homogenates was specific (Fig. 3A). RT-PCR analysis
showed similar differences in the mRNA levels (Fig. 3A and B). Sequencing of the FAAH
mRNA, amplified by RT-PCR from human brain, human CHP100 or U937 cells,
showed that human FAAH possessed a completely conserved sequence between
aminoacids 208-272, which contains a typical amidase consensus sequence (Fig. 3C).
FAAH activity and expression were measured also in human meningioma and were
compared to those found in the perilesional white matter (healthy brain).AEA hydrolysis
by meningioma FAAH followed Michaelis-Menten kinetics, with apparent Km and Vmax
values of 4.0 ± 0.4 µM and 370 ± 40 pmol.min-1.mg protein-1. Interestingly, the specific
activity of FAAH in human meningioma was 50% compared with that in healthy brain,
a value that was paralleled by the amount of FAAH protein in the same tissues (Fig. 4).
Characterization of AEA uptake in human CHP100 and U937 cells 
Neuroblastoma CHP100 and lymphoma U937 cells were able to accumulate
[1-14C]AEA, a process that was temperature-dependent (Q10 = 1.5 for both cell lines),
time-dependent (t1/2= 5 min for both cell lines), and concentration-dependent (Fig. 5A)
(data not shown). [1-14C]AEA uptake in CHP100 and U937 cells was saturable (Km =
0.20 ± 0.02 and 0.13 ± 0.01 µM,Vmax = 30 ± 3 and 140 ± 15 pmol.min
-1.mg protein-
1, respectively) was enhanced when incubations were carried out in the presence of NO-
donors SNP, SNAP or SPER-NO (Table 2 and Fig. 5B)and was reduced in the presence
of PMSF, iodoacetic acid or N-ethylmaleimide, each used at a 100 µM final concentration
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A) tissue or cell homogenates (20 µg/well) were subjected to ELISA using specific anti-FAAH polyclonal
antibodies (white bars).Antigen competition ELISA (black bars) are performed by preincubating anti-FAAH
polyclonals with a 1000-fold molar excess of peptide antigen. Absorbance values are expressed as percentage
of the maximum, arbitrarily set to 100 (100% corresponds to 0.760 ± 0.080 absorbance units at 405 nm).
FAAH mRNA levels (grey bars) were quantitated by liquid scintillation counting and were expressed as
percentage of the maximum, arbitrarily set to 100 (100% = 20000 ± 2000 cpm).The radioactivity of the bands
corresponding to 18S rRNA (see panel B), was identical in all samples (5000 ± 500 cpm). B) FAAH mRNA
(50 ng/lane) and 18S rRNA (0.2 ng/lane) were amplified by RT-PCR and electrophoresed on 6%
polyacrylamide gels. C) Shown is the conserved amino acid sequence deduced from FAAH mRNA isolated
from human brain, CHP100 or U937 cells. The sequence contains the amidase consensus sequence
(aminoacids 215-246) typical of all FAAH as yet known.
Figure 3 Quantitation of FAAH in human brain and human CHP100 and U937 cells.
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Comparison of FAAH activity and expression in human healthy brain and meningioma. Figure 4
FAAH activity (white bars) was measured using 10 µM AEA as substrate. FAAH protein content (grey bars)
was determined by ELISA using 20 µg proteins/well.Antigen competition ELISA (black bars) was performed
by preincubating anti-FAAH polyclonals with a 1000-fold molar excess of peptide antigen. FAAH activity and
content are expressed as percentage of the control (healthy brain), arbitrarily set to 100  (100% = 750 ± 70
pmol.min-1.mg protein-1 for the activity; 100% = 0.760 ± 0.080 absorbance units at 405 nm for the protein
content).
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(Table 2). Enhancement of [1-14C]AEA uptake by 5 mM SNP was prevented by co-
incubation with either 20 µM hemoglobin, a typical NO scavenger20, or 100 µM PMSF
(data not shown). SNP and PMSF affected the uptake kinetics by changing the Vmax value
but not the Km, thus changing the catalytic efficiency (i.e., the Vmax/Km ratio) of the
transporter (Table 3). On the other hand, 100 µM arachidonic acid or ethanolamine, and
10 µM 15-HAEA, LEA or 13-HLEA, did not significantly influence AEA uptake in either
cell type, nor did 1 µM leukotriene B4, 10 µM prostaglandin E2 or 50 µM CCCP (Table
2).
Discussion
Meningioma is a histologically benign tumor that is brain invasive only in 4% of cases 32.
Thus, perilesional white matter surrounding the meningioma can be considered an
essentially healthy brain area and was chosen in this study to characterize FAAH. Human
brain showed a remarkable FAAH activity, and anti-FAAH antibodies recognized a single
protein of 67 kDa with an isoelectric point of 7.6, characterized here for the first time
(Fig. 2).These values were in good agreement with the size of the full-length human liver
FAAH cDNA19 and the isoelectric point predicted from FAAH sequence by the
Wisconsin Sequence Analysis Package. Moreover, human brain FAAH cDNA had the
same amidase consensus sequence (Fig. 3C) as FAAH cloned from human, mouse and rat
livers18,19. It is noteworthy that the activation energy of the AEA hydrolysis catalyzed by
FAAH from all three sources was identical. Furthermore, the FAAH activity in human
54
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Table 3 Kinetic parameters of anandamide uptake in human CHP100 and U937 cells
Uptake of [1-14C]AEA was investigated in cell suspensions (2x106 cells/test), either untreated or
treated with NO-donor SNP or alkylating agent PMSF.Apparent Km and Vmax values are expressed
as µM and pmol.min-1.mg protein-1, respectively.
Human cell line Km Vmax Vmax/Km
Neuroblastoma CHP100 cells 0.20 ± 0.02 30 ± 3 150
+5 mM SNP 0.20 ± 0.02 50 ± 5* 250
+100 µM PMSF 0.20 ± 0.02 15 ± 2* 75
Lymphoma U937 cells 0.13 ± 0.01 140 ± 15 1077
+5 mM SNP 0.13 ± 0.01 230 ± 22* 1769
+ 100 µM PMSF 0.13 ± 0.01 75 ± 8* 577
* P < 0.01 compared with the control.
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CHP100 and U937 cells shared several other biochemical properties, such as pH and
temperature dependence and inhibition profile, with the enzyme from human brain. In
addition, the enzymes contained an identical amidase sequence.This might indicate that
the same enzyme was present in all human samples, although the participation of other
enzymes cannot be ruled out.
Human brain FAAH was further characterized with respect to its interaction with
inhibitors. Here, linoleoyl analogues of AEA and hydro(pero)xides generated thereof,
which might be produced in vivo by brain lipoxygenases14,33, were shown to be
competitive inhibitors of FAAH activity, with apparent Ki values in the low micromolar
range (Table 1). Interestingly, linoleoylethanolamide is a physiological constituent of rat
neurons3 and has recently been reported to be inactive at the CB1-receptor
22 (See also
chapter 3)
It is noteworthy that the apparent Vmax of human brain FAAH was approximately 2-
fold or 25-fold higher than that of U937 or CHP100 cells, respectively.The presence of
different amounts of FAAH in the cells could explain this observation. Indeed, FAAH
protein was 2- to 10-fold higher in human brain than in U937 or CHP100 cells,
respectively (Fig. 3A), and similar differences were observed in the level of FAAH mRNA
(Fig. 3B). Therefore, it can be suggested that a different expression (both at the
transcriptional and translational level) of the same enzyme might be responsible for the
different apparent Vmax values of FAAH from the different human sources. A differential
expression of FAAH might also be involved in human brain pathology, as suggested by
comparison of meningioma and the surrounding (healthy) white matter (Fig. 4). This
seems of interest, if one recalls that a neurotrophic effect of AEA has been proposed8 and
that AEA might act as growth factor for hematopoietic cell lines34,35.Therefore, a lower
expression of the AEA-hydrolyzing enzyme FAAH might be instrumental in prolonging
AEA-associated growth stimulus, ultimately leading to cell immortalization.
To be inactivated by FAAH, AEA has to be transported into the cell. Recent
experiments performed on rat neuronal cells3,11,12, rat basophilic leukemia (RBL-2H3)
cells and mouse J774 macrophages13 clearly showed the presence of a high-affinity AEA
transporter in the outer cell membranes. A similar methodology was used here to
characterize, for the first time, the AEA uptake in human neuronal (CHP100) and
immune (U937) cells. Both cell types rapidly took up AEA (t1/2= 5 min), in a
temperature-dependent (Q10= 1.5) and saturable way (Fig. 5A and data not shown).
[1-14C]AEA was taken up by CHP100 and U937 cells with similar high affinity, but
remarkably different velocity (Table 3). Interestingly, U937 cells, which possessed higher
FAAH activity than CHP100 cells, showed also a more efficient AEA uptake.The affinity
of the AEA transporter in human cells was comparable to that of rat astrocytes (Km = 0.32
µM)12, and was almost one order of magnitude higher than the affinity reported for
dopamine (Km = 1 µM) or glutamate (Km =1-5 µM) carriers in rat brain
36,37.
Furthermore, the uptake of AEA in human cells was affected by AEA hydrolysis products,
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leukotriene B4, prostaglandin E2 and alkylating agents (Table 2) in much the same way as
reported for rat neuronal and non-neuronal cells11-13. This suggests that AEA
accumulation is selective and mediated by a transporter other than the long chain fatty
acid transport protein38 or the prostaglandin transporter39, in keeping with recent data on
the AEA carrier of rat neurons and astrocytes12. AEA uptake in human CHP100 and
U937 cells was independent of mitochondrial energy metabolism, because the uncoupling
agent CCCP28 hardly affected AEA accumulation (Table 2). These results indicate that
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Binding of extracellular anandamide (AEA) to cannabinoid receptors (CBR) can lead to intracellular nitric
oxide production, which in turn may activate transporter (T)-mediated uptake of AEA. Once uptaken, AEA
can be rapidly cleaved by membrane-bound fatty acid amide hydrolase (FAAH), releasing arachidonic acid and
ethanolamine.Alternatively, hydro(pero)xides of AEA can be generated by lipoxygenase (LOX) activity, leading
to inhibition of FAAH.This alternate pathway is prevented by nitric oxide, short pulses of which are able to
inhibit LOX activity. It should be stressed that other signaling pathways, uncoupled to AEA binding to CBR,
can also enhance intracellular production of nitric oxide, thus may activate the sequestration process of this
lipid mediator.
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Scheme I Interaction between anandamide uptake and degradation.
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AEA is accumulated by a carrier-mediated, facilitated diffusion, as recently reported for
rat cells11.The enhancement of AEA uptake by the NO-donor SNP (Table 2) was due to
increased apparent Vmax (up to 170% of the control value), without changes in apparent
Km values. Conversely, alkylating agent PMSF reduced apparent Vmax to 50% of the
control, without changing apparent Km (Table 3). It is tempting to suggest that the active
site of the transporter may contain a cysteine residue, which could be the target of both
NO-donors and alkylating agents.The effect of co-incubation with PMSF strengthens this
hypothesis.
Altogether, the results reported here form the first characterization of human brain
FAAH. In addition, the observations highlight the possible role of linoleoyl analogues of
AEA, and hydro(pero)xides generated thereof and from AEA itself by lipoxygenase
activity, as inhibitors of human brain FAAH. The AEA transporter has also been
characterized for the first time in human cells, showing that it was not affected by the AEA
derivatives/analogues that inhibited FAAH, but was sensitive to NO-donors.
These findings give rise to a general picture of the inactivation process of AEA in
human neuronal and immune cells (Scheme I). AEA is brought into the cell by a
transporter protein and is rapidly cleaved by intracellular FAAH. Lipoxygenase-generated
products of AEA can competitively inhibit FAAH, which affords an elevated intracellular
AEA concentration.The resulting dissipation of the AEA gradient renders the transporter
inactive and leads to an enlarged extracellular AEA concentration. Enhanced CB-receptor
stimulation results in prolonged pharmacological activity. On the other hand, the
enhanced CB-receptor-induced NO formation potentiates the transporter protein, which
clears AEA from the extracellular space.The NO-stimulated accumulation of AEA might
be further enhanced by the fact that short pulses of NO are able to inhibit lipoxygenase
activity30, thus preventing inhibition of FAAH by lipoxygenase-generated hydroperoxides
of AEA and congeners. Interestingly, any signaling pathway leading to NO release, either
coupled or not coupled to cannabinoid receptors, might affect AEA metabolism by
activating AEA (re)uptake. In this perspective, CB1 and/or CB2 receptors might reside on
the same cell bearing the sequestration machinery or on different cells.The autacoid local
inflammation antagonism40 and glutamate excitotoxicity on neurons41, where AEA exerts
a(nta)gonistic effects on cannabinoid receptors and nitric oxide is released10,42, might be
two relevant processes in which the proposed sequestration scheme is operational. It is
noteworthy that lipoxygenase activity is found in processes such as lymphocyte activation
and neuronal cell death, where lipoxygenase activation43,44 might prolong the effects of
AEA13.
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Abstract
This study was aimed at finding structural requirements for the interaction
of the acyl chain of endocannabinoids with cannabinoid receptors, membrane
transporter protein and fatty acid amide hydrolase (FAAH). To this end, the
flexibility of the acyl chain was restricted by introduction of an 1-hydroxy-
2Z,4E-pentadiene system in anandamide (N-arachidonoylethanolamide, AEA)
and 2-arachidonoylglycerol (2-AG) at various positions using different
lipoxygenases. This brought about selectivity and attenuated the binding
potency of AEA and 2-AG. 15S-Hydroxyanandamide was found to bind
selectively to the CB1 receptor, whereas its 1-L-arachidonoylglycerol analog
and 13S-hydroxylinoleoylethanolamide could selectively bind to the CB2
receptor. 11S-Hydroxyanandamide did not bind to either receptor, whereas
12S-hydroxyanandamide did bind to both CB receptors with an affinity similar
to that of AEA. All hydroxyanandamide derivatives were good inhibitors of
FAAH (low µM Ki), but were ineffective on the AEA transporter.
Analysis of 1H-NMR spectra revealed that chloroform did not induce
notably different conformations in the acyl chain of 15S-hydroxyarachidonic
acid compared with water. Molecular dynamic (MD) simulations of AEA and
its analogs in the presence of explicit water molecules revealed that a tightly
folded conformation of the acyl chain is not the only requirement for CB1
binding. Structural details of the C2-C15 loop, such as a sp
2-carbon at position
11, are necessary for receptor binding. The MD simulations may suggest that
the average orientations of the pentyl tail of AEA and 12S-hydroxyanandamide
are different from that of the low-affinity, inactive ligands.
Introduction
Anandamide (AEA; 5Z,8Z,11Z,14Z-eicosatetrateonoyl-N-(2-hydroxyethyl)-amine;
arachidonoylethanolamide) is an endogenous lipid with neuro- and immunomodulatory
activities. Many of the physiological activities of AEA are mediated via its interaction with
cannabinoid CB1 and CB2 receptors, thereby mimicking some of the effects of ∆
9-
tetrahydrocannabinol (THC), the psychoactive compound in marijuana (Fig.1)1,2. AEA
and 2-arachidonoylglycerol (2-AG) are the main endocannabinoids, i.e. endogenous
ligands of the CB receptors3-5.The effects of the endocannabinoids at the CB1 and CB2
receptors depend on the life span of these molecules in the extracellular space. AEA and
2-AG are inactivated by a rapid and selective process of transporter-mediated cellular
uptake6, followed by intracellular degradation to arachidonic acid and ethanolamine or
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Chemical structures of classical, synthetic and endogenous cannabinoids and their derivatives. Figure 1
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glycerol by the enzyme fatty acid amide hydrolase (FAAH)7,8. The endocannabinoid
system, which constitutes the endocannabinoids, CB receptors, transporter protein and
FAAH, seems to be involved in the regulation of several physiological functions such as
embryo implantation, pain, appetite and blood pressure9-12. Selective molecular probes
targeted to one of the proteins of the endocannabinoid system are believed to yield useful
therapeutics for a variety of disorders such as  liver cirrhosis, multiple sclerosis and obesity,
as well as for several neurodegenerative diseases including stroke13-18. In order to develop
selective therapeutic agents, research is aimed at identifying essential structural properties
of the endocannabinoids, which are needed for specific interactions with the CB
receptors,AEA membrane transporter and FAAH15,19-21.
Crystal or NMR structures of any of the proteins of the endocannabinoid system
might help to elucidate the nature of the ligand-protein interaction, but they are not
available yet. Therefore, a structural comparison of active and inactive classical and
synthetic cannabinoids has been used to derive pharmacophore models22-24.These models
might also be used to predict and facilitate the design of novel compounds with greater
potency or selectivity at the molecular target of interest22-24. A prerequisite for the
building of such a pharmacophore model is to characterize an ensemble of active
conformations of a molecule. AEA can assume many different conformations, which
originate primarily in its acyl chain. It has been suggested that a tightly folded
conformation is responsible for the interaction of AEA with CB receptors19. However, this
has not been substantiated as yet.
In order to get more insight into the structural requirements of the acyl chain of AEA
to selectively interact with the proteins of the cannabinoid system and in particular the
CB1 receptor, we have combined interaction studies,
1H-NMR spectroscopy and
Molecular Dynamic (MD) simulations. The 1Z,4Z-pentadiene systems of the
endocannabinoids were systematically converted into 1-hydroxy-2E,4Z-pentadiene
systems at different positions of the acyl chain by using different lipoxygenases as
biocatalysts. We extended the studies of Hampson et al. and Edgemond et al. to other
oxygenated metabolites to compare all derivatives in one system.25,26 CB1- and CB2-
binding assays were performed as well as assays in which the effects of the oxygenated
metabolites on AEA-inactivation were studied. 1H-NMR was used to study the solvent-
effect on the conformation of the acyl chain. MD-simulations of AEA and congeners with
explicit water molecules were performed to determine the influence of conjugation of the
double bond system on its conformation.
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Materials and Methods
5S-HAEA, 11S-HAEA, 13S-LEA 5,15-diHAEA, 8,15-diHAEA, 15S-HAEA, 15-HO-D-AG
and 15-HO-L-AG were enzymatically synthesized by soybean and barley lipoxygenases as
previously reported and characterized by CD-spectroscopy, 1H-NMR and GC/MS26-31. The
spectra were in accordance with their chemical structures, as previously reported26,27,30,31. Each
lipoxygenase was incubated with LEA, AEA (Cayman Chemicals), 1-D-AG or 1-L-AG  (1 U
enzyme lipoxygenase per 3 µmol substrate) in 100 mM sodium borate buffer (pH 9) for soybean
and 100 mM phosphate buffer (pH7) for barley grain. AEA was incubated with bovine
polymorphonuclear leukocytes in phosphate-buffered saline (pH 7.4) to produce 12S-HAEA.The
products of the plant lipoxygenases were reduced by 3 equivalents sodium borohydride.The HAEAs
were isolated with SPE (Bakerbond, 500 mg), analyzed and purified by reversed-phase and chiral-
phase HPLC as reported27,28,31. [3H]AEA (223 Ci/mmol) and [3H]CP-55,940 (126 Ci/mmol)
were purchased from NEN Life Science Products, Inc.
Membrane  preparation for binding assay
Male Wistar rats (250-280g) were maintained on a 12h light/dark schedule. Food and water
were ad libitum.The experimental protocol and procedures used, met the guidelines of the Ministry
of Health (G.U.No. 40, February 18, 1992) and were approved by the Animal Care Committee
(University of Rome “Tor Vergata”). Rat forebrain and spleen membrane preparations were
obtained using the method of Devane et al.,32 and were stored at a concentration of 1 mg.ml-1
protein in 50 mM Tris.HCl, 2 mM Tris.EDTA, 3 mM MgCl2 buffer, pH 7.4, at -80 °C for no longer
than one week.The protein concentration was determined  using bovine serum albumin (BSA) as
a standard33.
CB-binding assay
A rapid filtration assay was performed with [3H]-labeled CP-55.940, according to Compton et
al.34. Incubations were performed in a final volume of 0.5 ml 50 mM Tris.HCl, 2 mM Tris.EDTA,
3 mM MgCl2, 5 mg ml
-1 BSA buffer, pH 7.4. PMSF (final concentration 50 µM) was added freshly
each time just before the incubations started.The binding was initiated by the addition of 50 µg of
protein of the membrane preparation and stopped after 1h at 30°C. The washed filters were
transferred to vials, which contained 0.5 ml 0.1% Triton X-100 and 3.5 ml Liquid Scintillation
Cocktail (LSC) for nonaqueous solutions (Sigma Chemical Company). The vials were incubated
overnight before counting. Unspecific binding was determined in the presence of 10 µM AEA.
Binding data were elaborated through nonlinear regression analysis, using the Prism 3 program
(GraphPAD Software for Science), and inhibition constants (Ki) were calculated.
AEA-transporter-activity
The uptake of [3H]AEA by intact U937 cells was studied as described previously.35 Incubations
(15 min) were carried out with different concentrations of [3H]AEA, in the range 0-1000 nM, in
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order to determine the kinetic constants, i.e. apparent Michaelis-Menten constant (Km), maximum
velocity (Vmax) and inhibition constant (Ki), by nonlinear regression analysis through the Prism 3
program.35
FAAH-activity
Fatty acid amide hydrolase activity was assayed in U937 cells by measuring the release of
[3H]arachidonic acid from [3H]AEA using RP-HPLC as reported29. Kinetic studies were
performed using different concentrations of [3H]AEA (in the range 0-25 µM), and the kinetic
constants (Km,Vmax and Ki) were calculated by nonlinear regression analysis through the Prism 3
program.7
2D-NMR
1H-NMR spectra of 15-HETE were recorded at 500 MHz with a Bruker DRX-500 (Bijvoet
Center for Biomolecular Research). Spectra were obtained at a probe temperatures 27°C for D2O
(0.2 mmol.l-1; pH 6) and CDCl3 (40 mmol.l
-1) solutions and 4°C for a CD3OD (40 mmol.l
-1)
solution. Phase sensitive (States-TPPI) 2D NOESY, 2D-off-resonance ROESY and 2D TOCSY
were recorded in addition to high-resolution 1D spectra.The 2D TOCSY spectrum was obtained
using an MLEV-17 isotropic mixing sequence of 15 ms at a spin lock field strength corresponding
to 9.2 kHz. 2D NOESY spectra were obtained with an 800 ms mixing time.The 2D off-resonance
ROESY spectrum in D2O solution was recorded with an adiabatic spin-lock pulse of 350 ms at a
field strength corresponding to 6.1 kHz.The spin-lock frequency was alternately placed 3520 Hz
upfield or downfield of the centre of the spectrum, thus obtaining an average spin-lock angle
<ϑ>=60°. Chemical shifts for 1H are expressed in ppm relative to internal TMS (0.0 ppm) for
CDCl3 solutions and relative to internal acetone (2.218 ppm) for D2O solutions.
The chemical shift and scalar coupling values were extracted through direct measurement in the
high-resolution 1D NMR spectra or through simulation of the more complex spectral regions.The
assignment of the 1H-signals in the NMR spectra was obtained through combined analysis of the
multiplet profiles in the 1D-NMR spectra, and cross peaks in the 2D-TOCSY spectrum. The
NOESY and off-resonance ROESY spectrum supplied supporting information to corroborate the
assignments.
Molecular dynamics calculations 
Molecular dynamics simulations were performed using the GROMOS87 program package36
on PC’s running Linux. Each molecule was surrounded by SPC/E37 water molecules in a truncated
octahedron with periodic boundary conditions.All bond lengths were kept fixed using the SHAKE
procedure38. Nonbonded interactions were calculated using the twin-range cutoff procedure with
cutoff radii of 0.9 and 1.2 nm, and a time step of 2 fs was used. Simulations were performed with
loose coupling to a pressure bath at 1 atm and a temperature bath at 300 K39 with time constants
of 0.5 and 0.1 ps, respectively.Atom positions were restrained by applying a harmonic oscillator force
constant of 104 kcal mol-1 Å-2.
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Description of force field adaptions 
A new atom type CS has been created to represent a bare sp3 carbon which is in all aspects
identical to CH1 and CH2, except for the van der Waals parameters that are identical to those of C
or CB.To represent the double bonds, two new atom types, CEH1 and CIH1, have been created.
CEH1 represents the C atoms involved in a double bond, and the external C atoms of a conjugated
double bond. CIH1 represents the internal C atoms of a conjugated double bond. These two new
atom types are equivalent to the CR51 and CR61 atom types except for the parameters listed in
Table S1.
Supporting information:
5R/S-HAEA: Barley lipoxygenase; 1H NMR (CDCl3) δ 6.55 (dd, J=13.6, 10.6 Hz 1H), 6.02 (t
J=10.5 1H), 5.71 (dd, J=13.6 Hz, 1H), 5.39 (m, 5H), 4.16 (m, 1H), 3.72 (t, 2H), 3.42 (q. 2H) 2.97
(m, 2H); 2.81 (m, 2H), 2.22 (t, J=7.8Hz, 2H), 2.11 (m, 2H); 1.72 (q, J=6.2 Hz 2H), 1.34 (m, 6H),
0.89 (t, J=6.2 Hz, 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z 515 [M
+], 500
[M+-CH3], 313 [C16H32OTMS
+], 304 [M+-C15H31], 214 [304-TMSOH], 116 [C2H3OTMS
+], 73
[TMS+]
11S-HAEA: Barley lipoxygenase; 1H NMR (CDCl3) δ 6.52 (dd, J=11.0; 10.1 Hz 1H), 5.98 (t,
J=11.0 Hz 1H), 5.69 (dd, J=15.1; 6.5 Hz 1H), 5.40 (m, 5H), 4.23 (q, 2H); 3.72 (t, J=4.6 Hz, 2H);
3.42 (q J=5.5 Hz; 2H), 2.81 (m, 2H), 2.32 (m, 2H), 2.22 (t, J=7.4 Hz 2H), 2.12 (m, 4H), 1.73 (q,
2H), 1.25-1.38 (m, 6H), 0.88 (t, J=6.9 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS
m/z 515 [M+], 500 [M+-CH3], 388 [M
+-C9H19], 229 [C10H20OTMS
+], 116 [C2H3OTMS
+], 73
[TMS+]
12S-HAEA: Bovine leukocytes; 1H NMR (CDCl3) δ 6.58 (dd, J=14.2 Hz 1H), 5.99 (t, J=10.5
Hz 1H), 5.74 (dd, J=6.2 Hz 1H), 5.40 (m, 5H), 4.25 (q, 1H), 3.72 (t, J=4.6 Hz 2H), 3.42 (q, J=4.6
Hz 2H), 2.95 (m, 2H), 2.33 (m, 2H), 2.21 (t, J=7.5 Hz 2H), 2.10 (m, 4H), 1.74 (q, J=7.3 Hz, 2H),
1.28 (m, 6H), 0.89 (t, J=6.9 Hz 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z 515
[M+], 500 [M+-CH3], 402 [M
+-C8H17
+], 215 [C9H18OTMS
+], 116 [C2H3OTMS
+], 73 [TMS+]
15S-HAEA: Soybean lipoxygenase; 1H NMR (CDCl3) δ 6.55 (dd, J=15.4;12,2 Hz 1H), 6.00 (t,
J=10.7 Hz, 1H), 5.72 (dd J=7.2 Hz 1H), 5.40 (m 5H), 4.12 (q 1H), 3.72 (t, 2H) 3.42 (q, 2H), 2.97
(m, 2H), 2,82 (m, 2H), 2.22 (t, J=7.5 Hz 2H), 2.11 (m 2H), 1.72 (q, J=7.3 Hz, 2H), 1.56 (m, 2H),
1.31 (m, 6H), 0.89 (t, J=6.9 Hz 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z 515
[M+], 500 [M+-CH3], 444 [M
+-C5H11], 173 [C6H11OTMS
+], 116 [C2H3OTMS
+], 73 [TMS+]
5,15-diHAEA: Soybean lipoxygenase; 1H NMR (CDCl3) δ 6.58 (m, 2H), 6.01 (m, 2H), 5.72 (m,
2H), 5.43 (m, 2H), 4.21 (m, 2H), 3.72 (t, J=4.6 Hz 2H), 3.42 (q, J=4.6 Hz 2H), 2.97 (m, 2H), 2.28
(t, J=6.9 Hz 2H), 1.76 (m, 2H), 1.57 (m, 4H), 1.30 (m, 6H), 0.89 (t, 3H); NaBH4 and H2 reduced
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trimethyl silylether GC/MS m/z 603 [M+], 588 [M+-CH3], 532 [ M
+-C5H11], 304 [M
+-C15H31],
214 [304-TMSOH], 116 [C2H3OTMS
+], 73 [TMS+]
8,15-diHAEA: Soybean lipoxygenase; 1H NMR (CDCl3) δ 6.70 (m, 2H), 5.97 (m, 2H) 5.74 (m,
2H), 5.46 (m,2H), 4.27 (m, 1H), 4.18 (m, 1H), 3.72 (t, J=4.6 Hz 2H), 3.42 (q, J=4.6 Hz 2H), 2.32
(m, 2H), 2.19 (t, J=6.9 Hz, 2H), 2.09 (q, 2H), 1.70 (m, 2H), 1.50 (m, 2H), 1.32 (m, 6H), 0.88 (t,
3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z 603 [M
+], 588 [M+-CH3], 532 [M
+-
C5H11], 346 [M
+- C12H24OTMS], 173 [C6H11OTMS
+], 116 [C2H3OTMS
+], 73 [TMS+]
13S-HLEA: 1H NMR (CDCl3) δ 6.49 (dd, J=15.0, 11 Hz, 1H), 5.98 (t, J=10.9 Hz 1H), 5.67 (dd,
J=15.2, 6.8 Hz 1H), 4.16 (q, J=6.5 Hz 1H), 3.72 (t, 2H), 3.42 (q, 2H), 2.17 (m, J=7.4 4H), 1.66-
1.47 (m, 6H), 1.38-1.22 (m, 10H), 0.89 (t, J=6.5 Hz 3H); NaBH4 and H2 reduced trimethyl
silylether GC/MS m/z 487 [M+], 472 [M+-CH3], 416 [M
+-C5H11], 173 [C6H11OTMS
+], 116
[C2H3OTMS
+], 73 [TMS+]
1-L-AG: 1H NMR (CDCl3) δ 5.40 (m, 8H), 4.19 (m, 2H), 3.93 (m, 1H), 3.65 (m, 2H), 2.84 (m,
6H), 2.37 (t, J=7.5 Hz, 2H), 2.09 (m, 4H), 1.72 (m 2H), 1.33 (m, 6H), 0.89 (t, J=6.8 Hz 3H)
1-D-AG: 1H NMR (CDCl3) δ 5.40 (m, 8H), 4.19 (m, 2H), 3.93 (m, 1H), 3.65 (m, 2H), 2.84 (m,
6H), 2.37 (t, J=7.5 Hz, 2H), 2.09 (m, 4H),1.72 (m, 2H), 1.33 (m, 6H), 0.89 (t, J=6.8 Hz 3H)
15-HO-L-AG: Soybean lipoxygenase; 1H NMR (CDCl3) δ 6.53 (dd, J=15.2 Hz 1H), 6.00 (t,
J=11.2 Hz 1H), 5.70 (dd, J=6.5 Hz 1H), 5.40 (m, 5H), 4.19 (m 2H), 3.92 (m 1H), 3.67 (m, 2H),
2.97 (m, 2H), 2.82 (m, 2H), 2.37 (t, J=7.4 Hz 2H), 2.12 (m, 2H), 1.72 (q, J=7.3 Hz 2H), 1.55 (m,
2H), 1.35 (m, 6H), 0.89 (t, J=7.1 Hz 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z
618 [M+], 603  [M+-CH3], 547 [M
+-C5H11], 173[C6H11OTMS
+], 103 [CH2OTMS
+], 73 [TMS+]
15-HO-D-AG: Soybean lipoxygenase; 1H NMR (CDCl3) δ 6.53 (dd, J=15.2 Hz 1H), 6.00 (t,
J=11.1 Hz 1H), 5.70 (dd, J=6.4 Hz 1H), 5.40 (m, 5H), 4.19 (m 2H), 3.92 (m 1H), 3.65 (m, 2H),
2.97 (m, 2H), 2.82 (m, 2H), 2.37 (t, J=7.4 Hz 2H), 2.12 (m, 2H), 1.72 (q, J=7.3 Hz 2H), 1.55 (m,
2H), 1.35 (m, 6H), 0.89 (t, J=6.6 Hz 3H); NaBH4 and H2 reduced trimethyl silylether GC/MS m/z
618 [M+], 603 [M+-CH3], 547 [M
+-C5H11], 173 [C6H11OTMS
+], 103 [CH2OTMS
+], 73 [TMS+]
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Results and Discussion
Interaction with CB1 and CB2 receptors
In accordance with previous observations, AEA inhibited the specific binding of
[3H]CP-55,940 to rat brain membranes, which express CB1 receptors, in a manner typical
of competing ligands with an inhibition constant of 90 nM (Table 1)2. Compounds with
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Displacement constants (Ki) of AEA and their oxygenated metabolites for CB1 and CB2 receptor binding Table 1 
Literature values Literature values
Compound CB1 CB2 CB1 CB2
(nM)a (nM)b (nM) (nM)
AEA 90 ± 20 360 ± 50 71c/107d 94e
5(S)-HAEA > 1000 > 1000 - -
5(R)-HAEA 680 ± 140 710 ± 145 - -
11(S)-HAEA > 1000 > 1000 1102c -
11(R/S)-HAEA > 1000 > 1000 - -
12(S)-HAEA 150 ± 30 500 ± 60 31c/207d 131e
13(S)-HLEA > 1000 600 ± 120 - -
15(S)-HAEA 600 ± 120 > 1000 418c/738d 1000>e
15(R/S)-HAEA 680 ± 140 > 1000 - -
5,15-diHAEA > 1000 > 1000 - -
8,15-diHAEA > 1000 > 1000 - -
aKi values were calculated from the displacement curves of [
3H]CP-55,940 from rat forebrain
membranes.
bKi values were calculated from the displacement curves of [
3H]CP-55,940 from rat spleen
membranes.
cKi values were calculated from the displacement curves of  [
3H]CP-55,940  from rat brain
synaptosomal membranes26
dKi values were calculated from the displacement curves of [
3H]CP-55,940 from rat forebrain membranes25
eKi values were calculated from the displacement curves of [
3H]CP-55,940 from human CB2-receptor
expressed in CHO-cells25
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a Ki > 1 µM were considered inactive, therefore an upper limit of 1 µM was set for
binding potency40. Introduction of a hydroxyl-function and a conjugated diene system in
AEA by various lipoxygenases reduced the capacity of AEA-derivatives to compete for
CB1-binding (Table 1). Only 12S-HAEA retained a binding affinity in the same order of
magnitude as AEA. 15S-HAEA and 5R-HAEA had a ~ 7-fold higher Ki, while 11S-
HAEA, 5S-HAEA, 13S-HLEA were inactive (Table 1). Introduction of a second 1-
hydroxy-2E,4Z-diene system in AEA led to a complete loss of binding affinity as
demonstrated by 5,15-diHAEA and 8,15-diHAEA (Table 1).
AEA also inhibited [3H]CP-55,940 binding to spleen membranes, which express CB2
receptors, with a Ki of 360 nM (Table 1).This is in agreement with previous observations
2.
The CB2 receptor was more critical in accepting oxygenated metabolites of AEA as
ligands than the CB1 receptor. 12S-HAEA and 5R-HAEA were almost as potent as AEA
(Table 1), while 5S-HAEA, 11S-HAEA, 15S-HAEA and the doubly hydroxylated AEAs
(5,15-diHAEA and 8,15-HAEA) were inactive (Table 1). Interestingly, 13S-HLEA had a
binding affinity towards the CB2 receptor with a Ki of 600 nM, whereas it was inactive at
the CB1 receptor.
Interaction with  AEA-transporter and FAAH
Human lymphoma U937 cells have a selective AEA-transporter with a Km and Vmax
of 0.13 µM and 140 pmol/min per mg protein, respectively.6 These cells also have an
active FAAH with a Km and Vmax of 6.5 µM and 520 pmol/min per mg protein,
respectively.6 Introduction of 1-hydroxy-2E,4Z-diene into AEA at any position disrupted
its ability to inhibit the transport of [3H]AEA into U937 cells (Table 2).This indicates that
the HAEAs have a reduced binding affinity for the AEA-transporter. It has been suggested
that at least one cis-double bond is necessary for binding to the AEA-transporter protein,
and four cis-double bonds for translocation into the cell41. Our data are in line with these
observations7,41,42.
FAAH accepted all AEA-derivatives as inhibitors (Table 2), thereby making FAAH the
least selective protein of the endocannabinoid system. Introduction of the 1-hydroxy-
2E,4Z-pentadiene system increased the ability of all AEA-derivatives to competitively
inhibit [3H]AEA-hydrolysis by human U937 cells. 13S-HLEA was the most potent
inhibitor with a Ki of 0.43 µM (23-fold better than AEA), while 12S-HAEA had a 3-
fold higher Ki than AEA. Introduction of a second hydroxyl group did not improve the
inhibition power any further. The rank order was: 13S-HLEA > 11S-HAEA > 15S-
HAEA ≈ 8,15-diHAEA > 5,15-HAEA > 5R-HAEA > 5S-HAEA > 12S-HAEA.The
solubility of HAEAs in aqueous solutions was higher than that of the parent compound,
due to the introduction of the hydroxyl function.This improves the feasibility of the use
of HAEAs as inhibitors of FAAH, compared to saturated congeners.
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Interaction of 2-AG and its congeners with the proteins of the cannabinoid system
2-AG rapidly isomerizes into 1-AG both in vitro and in vivo.The rate of this process is
increased by high temperature and by acidic or basic pH. Two stereoisomers can be
formed, i.e. 1-D-AG and 1-L-AG (Fig. 1). In endocannabinoid analysis, usually 10-40%
of a racemic mixture of 1-AG is found43.To date, most interaction studies of 2-AG with
proteins of the endocannabinoid system have not accounted for isomerisation of 2-AG
into 1-AG during the incubation period. Here, it is shown that 2-AG inhibited potently
the binding of [3H]CP-55,940 to CB1 and CB2 receptors with a Ki of 100 nM (Table 3).
2-AG also inhibited [3H]AEA-transport with a Ki of 3 µM, and was 2-fold more potent
than AEA in inhibiting FAAH (Table 3). However, 1-D-AG and 1-L-AG did not bind to
either CB receptor and did not interfere with AEA-transport (Table 3). Thus, upon
isomerisation 2-AG is inactivated, thereby decreasing effective concentrations of 2-AG.
This uncontrolled isomerisation may account to some extent for the large differences in
71
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Inhibition constants (Ki) of AEA and its oxygenated metabolites for FAAH activity and AEA-transporter activity Table 2 
Compound FAAH Transporter
(µM)a (µM)b
AEA > 10 > 10
5(S)-HAEA 2.52 ± 0.13 > 10
5(R)-HAEA 1.89 ± 0.09 > 10
11(S)-HAEA 1.57 ± 0.03 > 10
11(R/S)-HAEA 1.69 ± 0.03 > 10
12(S)-HAEA 2.90 ± 0.15 > 10
13(S)-HLEA 0.43 ± 0.02 > 10
15(S)-HAEA 0.63 ± 0.03 > 10
15(R/S)-HAEA 0.63 ± 0.03 > 10
5,15-diHAEA 1.26 ± 0.06 > 10
8,15-diHAEA 0.69 ± 0.03 > 10
aAll compounds were competitive inhibitors of FAAH activity in U937 cells. [3H]AEA was used as
substrate, in the 0 -25 µM concentration range.
bAll compounds were competitive inhibitors of AEA-transporter activity in U937 cells. [3H]AEA
was used as substrate, in the 0-1000 nM concentration range.
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Ki-values reported in the literature for 2-AG binding to CB receptors, and for its
inhibition of AEA-transport6.
Interestingly, introduction of the 15-hydroxy-11Z,13E-diene system in 1-L-AG
increased its CB2-binding affinity compared to its parent compound, but this was not the
case for 1-D-AG. Both 15-HO-L-AG and 15-HO-D-AG could inhibit AEA-transport at
low micromolar concentrations, but were worse inhibitors of [3H]AEA-hydrolysis than
the parent compounds (Table 3).
It should be noted that different mammalian lipoxygenases are capable of using AEA
and 2-AG as substrates in in vitro systems25,26,44,45. If this action of lipoxygenases would
be functional in vivo, this might be instrumental to generate in vivo selectivity in the
endocannabinoid system. In this line, it has been shown that 5-lipoxygenase inhibitors
“disclose” a cryptic FAAH activity in human mast cells46. Furthermore, the increased
capability of HAEAs to inhibit FAAH may be a way to enhance endocannabinoid
signaling, i.e an “entourage” effect for AEA similar to that shown for 2-AG47.
Conformation and solvation effects studied with NMR spectroscopy
In order to study the conformational effects induced by different solvents on an acyl
chain, 1D and 2D-NMR spectroscopy experiments were performed with 15-
hydroxyarachidonic acid (15-HETE) in chloroform and water. Double bonds and areas
with conjugated double bonds induce considerable conformational restraints to
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Table 3 Inhibition and displacement constants (Ki) of 2-AG and congeners for FAAH activity, AEA-transporter  
activity and CB1 and CB2 receptor binding
Compound CB1 CB2 FAAH Transporter
(nM)a (nM)b (µM)c (µM)d
2-AG 100 ± 20 100 ± 20 5 ± 0.25 3 ± 0.15
1-L-AG > 1000 > 1000 3 ± 0.15 > 10
1-D-AG > 1000 > 1000 2.5 ± 0.15 10 ± 0.50
15-HO-L-AG > 1000 550 ± 80 6 ± 0.30 9 ± 0.45
15-HO-D-AG > 1000 > 1000 5 ± 0.25 7 ± 0.35  
a All compounds were competitive inhibitors of FAAH activity in U937 cells. [3H]AEA was used as
substrate, in the 0 – 25 µM concentration range.
b All compounds were competitive inhibitors of AEA-transporter activity in U937 cells. [3H]AEA was used
as substrate, in the 0 – 1000 nM concentration range.
c Ki values were calculated from the displacement curves of [
3H]CP-55,940 from rat forebrain membranes.
d Ki values were calculated from the displacement curves of [
3H]CP-55,940 from rat spleen membranes.
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molecules. Therefore, spectral analysis was focused on regions containing signals from
these restrained areas, and especially on the flexible methylene group regions that connect
them.
The NMR-spectra of 15-HETE in D2O and CDCl3 were remarkably similar in terms
of chemical shift values and coupling constants. (Fig. 2a,b and Table S2). The spectral
region containing the signals for H7 and H10, which are regarded as sensitive probes for
conformational differences, did not show any notable differences. In order to get more
insight into the conformational properties of 15-HETE, 2D NMR spectra were recorded
that reveal information about short inter-proton distances (NOESY or off-resonance
ROESY). In D2O solutions the signal-to-noise ratio was poor, despite extended
measuring times, due to the low solubility of 15-HETE. Qualitative comparison of
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NOESY spectra of 15-HETE CDCl3 solution and off-resonance ROESY spectra in D2O
solution revealed that the more intense cross peaks were present in both solutions (data
not shown). In order to obtain high quality 2D-NMR data of 15-HETE in a polar
environment, a NOESY spectrum of 15-HETE was recorded in a CD3OD solution.This
NMR spectrum showed similar spectral properties as had been obtained for CDCl3 or
D2O solutions and also the NOE cross peaks were qualitatively and quantitatively similar
(data not shown). The NOESY spectra did not show any cross peaks that signify long
range (primary structure) interactions.Thus, analysis of the 1D-NMR profiles, chemical
shifts, scalar coupling values and the distance correlation spectra did not reveal notable
differences, which could originate from different conformations of 15-HETE induced by
chloroform, methanol or water.
Special attention was given to the conjugated pentadiene system. An intense cross
peak in the methanol NOESY-spectrum was observed between H12 and H14, whereas the
NOE for the interresidual contact between H12 and H13 was less intense (Fig. 3a). Proton
distances were estimated from cross-peak intensities and were calibrated to distances on
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Figure 3 2D-NMR-spectrum (NOESY) of 15-HETE.
2D-NMR-spectrum (NOESY) of 15-HETE (A). The region of interest (6.8-5.2 ppm) is displayed,
showing that NOE-contacts between H12 and H14 are more intense than H12 and H13.This indicates that the
conformation of the conjugated 1-hydroxy-2Z,4E-pentadiene system is represented by figure 3B than figure 3C.
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the basis of the distance of the vicinal protons H11-H12 (2.20 Å).The distance between
H12-H14 was 2.24 Å, and that between H12-H13 was 2.98 Å, which indicated that the
dihedral angle C11-C12-C13-C14 was almost exclusively 180º (Fig. 3b) rather than 0º (Fig.
3c).Thus, a single conformation of the conjugated pentadiene system was indeed strongly
preferred.
Conformational analysis of (H)AEA 
To develop an endocannabinoid pharmacophore model, an ensemble of active
conformations of AEA has to be identified. The conformation of AEA is mainly
determined by its acyl chain.The unsaturated acyl chain of AEA is known to adopt many
conformations that are energetically almost equivalent and that are not separated by high-
energy barriers. This property originates from those areas, where two double bonds are
separated by one methylene group48.The conformational space of the two dihedral angles
involved shows a large occupied region49. Molecular dynamics studies were performed
with AEA, 5S-, 5R-, 11S-, 12S- and 15S-HAEA, to investigate whether the 1-hydroxy-
2E,4Z-pentadiene system is responsible for inducing conformations different from AEA,
which affect their ability to adopt folded conformations, and thus their bioactivities.
Previous molecular modeling studies have been performed in vacuo, or with solvent
treated as a dielectric continuum22-24,50. It has been shown that the choice of the solvent
influenced the shape of AEA, which was basically extended in chloroform or in vacuo,
while it was more compact in water50. It has been suggested that a compact shape reduces
the exposure of hydrophobic portions19. However, our NMR-data indicate that the
choice of solvent does not notably influence the average conformation of the acyl chain
of 15-HETE.We have performed MD simulations with explicit water molecules instead
of chloroform to mimic physiological conditions.
Analysis of all dihedral angles of the MD trajectories of AEA and the HAEA
compounds showed a number of common features.The dihedral angle of bonds between
two methylene groups was predominantly 180°, but also many short visits to -60° and 60°
were observed.The dihedral angle of bonds between a hydroxymethylene carbon and a
sp2 carbon of a conjugated double bond was chiefly -140°, but showed a number of
transitions to 60°.The dihedral angle of bonds between a hydroxymethylene carbon and
a sp2 carbon of a (non-conjugated) double bond was mainly 170°, but visited 60° many
times. The dihedral angles of bonds inside a 1Z,4Z-pentadiene system involving a
methylene group and a sp2 carbon could be any of -60°, -120°, 180°, 120°, 60° and all
values in between, with some preference for -120° and 120°. The many transitions
observed for all these dihedral angles indicate low energy barriers and facilitate adequate
sampling of the conformational space.
Idealized conformations of AEA and HAEAs are displayed in Fig. 4, with all dihedral
angles set to the most populated orientations according to the MD trajectories. It is shown
that the 1Z,4Z-pentadiene systems induce bent-shaped conformations. When both
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Figure 4 Idealized conformations of oxygenated anandamides
Idealized conformations of compounds (a) AEA, (b) 15S-HAEA, (c) 12S-HEAE, (d) 11S-HEAE, (e) 5R-
HEAE, and (f) 5S-HEAE.The dihedral angles for the free rotational bonds in the 1Z,4Z-pentadiene systems
could take any value from 60° going via 180° to -60°, and were set to 180° .
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dihedral angles for the free rotational bonds in the 1Z,4Z-pentadiene systems, denoted ϕ1
and ϕ2, are set to 180°, a bent shape for AEA is observed. In addition, when ϕ1, ϕ2 have
opposite signs, e.g. 120°, -120°, again a bent shape emerges. Only, when both dihedrals
have the same signs, the shape of the molecule is more stretched. As opposite signs and
equal signs occur with equal abundance, and dihedral angles around 180° also result in
bent shapes, more than half of the low-energy conformations have shapes that are bent.
This is in contrast to saturated acyl chains, where a dihedral angle of 180° is favored
leading to an extended shape.This makes strongly bent shapes energetically unfavorable
for saturated aliphatic chains (see also Rich49).Therefore, it seems that the easy adaptation
of folded conformations of poly-unsaturated acyl chains originates in the inclination of
1Z,4Z-pentadiene systems to form bent shapes, and is not so much a result of the
flexibility of the chains as previously suggested19.
Introduction of a conjugated double bond in AEA, by creating a 1-hydroxy-2E,4Z-
pentadiene system, transfers a non-rotatable bond with a dihedral angle of 0° to a new
non-rotatable bond with a dihedral angle of 180° (1Z to 2E).Therefore, it changes the
global shape of the chain. It also makes the chain rigid as it essentially fixates the middle
bond in the conjugated system to 180°, which results in 6 carbon atoms lying in one
plane. Conjugation of the pentadiene system (such as depicted in the specific
conformation of AEA in Fig. 4a) results in more extended chains for 12S-HAEA (Fig. 4c)
and 11S-HAEA (Fig. 4d), while in  5R-HAEA (Fig 4e) and  5S-HAEA (Fig. 4f) the chains
are not more extended but the direction of the loops are influenced.
Structural comparison of pharmacophores  of (H)AEAs with CP-55,940
To investigate whether the introduction of the 1-hydroxy-2E,4Z-pentadiene system
in AEA influenced the  orientation  and distances of  pharmacophoric groups in the
HAEAs, the pharmacophores of the reference compound CP-55,940 were compared
with pharmacophores in the (H)AEA series (Fig. 5). The pharmacophoric groups were
identified based on the model of Tong et al 24.This model was capable of discriminating
between structurally related compounds exhibiting different pharmacological potencies
for the CB1 receptor, i.e. AEA and prostaglandinethanolamide. Furthermore, it could be
used in a 3D-QSAR-study to predict the Ki-value of AEA. The following
pharmacophoric units in CP-55,940, (i) the phenolic hydroxyl oxygen, (ii) the cyclohexyl
hydroxyl oxygen, and (iii) the first carbon on the alkyl side chain (C’1), correspond to (i)
the oxygen of the carbonyl, (ii) the ethanol oxygen, and (iii) the first carbon of the pentyl
tail (C16) in the (H)AEA series. In the model of Tong et al. the pyran oxygen of THC (or
HHC) was not included as pharmacophoric unit, as was done in the model of Thomas et
al.22, since it is not considered essential for the interaction.The model of Tong was chosen,
because in our studies synthetic [3H]CP-55,940 (Fig.1), which also lacks the pyran
oxygen, was used to determine displacement constants of HAEAs at both CB1 and CB2
receptors. Furthermore, the cyclohexyl OH in the cannabinoids and the corresponding
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terminal OH of AEA both enhance binding, but their absence (as in THC and alkyl
arachidonate derivatives) does not eliminate activity24.
First, the conformation of CP-55,940 was analyzed to find the orientation of the
hexyl ring in relation to the phenyl ring, and the orientation of the alkyl side chain.
NOESY data  for CP-47,497 (in chloroform) have shown that the orientation of the two
rings around the C6-C7 bond, determined by the dihedral angle C5-C6-C7-C8 (see Fig.
5 for numbering), is -60° rather than 120°51. In this orientation, the OH of the cyclohexyl
ring is at the same side of the phenolic ring, as is the case for HHC-DMH. This is in
agreement with the proposal that the dihedral angle Ohexyl-C9-C1-Ophenyl (which is -90°
for CP-55,940) must be negative, in order to get the most active conformation52. The
NMR data51 have also indicated that the 1’,1’-dimethylheptyl side chain can occur in four
different orientations in relation to the phenyl ring, with almost equal probability.To get
the positions of the pharmacophores, a MD simulation of CP-55,940 was performed with
the orientation of the rings following that of CP-47,497.
The CP-55,940 acyl chain has no single preferred orientation, and it is not yet known
how it is oriented when it binds to the receptor.This hampers an easy comparison with
the orientation of the tail of the acyl chain of the (H)AEA series. To facilitate the
comparison of the orientation of the pentyl chain between different compounds, the
orientation of the pentyl chain was expressed in polar coordinates, by using the
orientation of vector C1’-C2’ relative to the Ophenyl-C1-C1’ plane for CP-55,940 and C16-
C17 relative to the Ocarbonyl-C1-C16 plane for the (H)AEA series. (For CP-55,940: ϕ =
dihedral angle Ophenyl-C1-C1’-C2’ and θ = angle C1-C1’-C2’, and for the (H)AEA series
ϕ = dihedral angle Ocarbonyl-C1-C16-C17 and θ = angle C1-C16-C17).
The following four atoms were used to analyze the atom positions of the
pharmacophores: phenolic oxygen, cylohexyl oxygen, C1 and C1’ for CP-55,940, and the
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carboxyl oxygen, the oxygen of the ethanol, C1 and C16 for the (H)AEAs, respectively.
Average distances between the pharmacophores in CP-55,940 are: phenolic and cylohexyl
oxygen = 0.63 nm (d1), cyclohexyl oxygen and C1’ = 0.91 nm (d3), phenolic oxygen
and C1’ = 0.49 nm (d2).The distance between the oxygen of the carboxyl and the oxygen
of the ethanol in the (H)AEA series (d2), is somewhat smaller (0.55 nm).The distances
d2 and d3 in the (H)AEA series demonstrate a large degree of variation, as shown in Fig.
6. In the same figure, the region of distances in CP-55,940 is indicated by an ellipse that
is marked by an arrow.This CP-55,940 region falls within the much broader region of the
(H)AEA series for all members, except for 5R-HAEA.
From the MD simulations of the (H)AEA series, all frames were selected that had
appropriate Ohydroxyl-C16 (d3) and Ocarbonyl-C16 (d2) and C1-C16 (d4) distances (Fig. 7)
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Scatter plots of distances d3 and d2 in HAEAs and CP.55.940 during MD simulations. Figure 6
Scatter plots of distances d3 and d2 obtained during simulation of compounds (a) AEA, (b) 15S-HAEA,
(c) 12S-HEAE, (d) 11S-HEAE, (e) 5R-HEAE, and (f) 5S-HEAE.The corresponding region of CP-55,940 is
inside the ellipse and indicated by the arrow. Frames were selected with a time step of 1 ps.
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and from these frames, the orientation of vector C16-C17 was determined.The results of
the CP-55,940 run are indicated in Fig. 7 by the region between the curved lines.The
MD simulations of 11S-HAEA and 5R-HAEA did contain only a few frames with
matching distances.As 5R-HAEA and 5S-HAEA are enantiomers, the MD runs of these
compounds must furnish the same results in distances after adequate conformational
sampling.This is clearly not the case after 5 ns. MD simulations show the presence of the
required conformations in most of the simulations, therefore it can be concluded that the
80
Chapter 3
-180 -120 -60 0 60 120 180
0
60
120
180
-180 -120 -60 0 60 120 180
0
60
120
180
-180 -120 -60 0 60 120 180
0
60
120
180
-180 -120 -60 0 60 120 180
0
60
120
180
-180 -120 -60 0 60 120 180
0
60
120
180
-180 -120 -60 0 60 120 180
0
60
120
180
a b
c d
e f
θ
θ
θ
φ φ
Figure 7 Scatter plots of the orientation of vector C16-C17 in HAEAs during MD simulations.
Scatter plots of the orientation of vector C16-C17, expressed in polar coordinates, during the 5 ns MD
simulation of compounds (a) AEA, (b) 15S-HAEA, (c) 12S-HEAE, (d) 11S-HEAE, (e) 5R-HEAE, and (f) 5S-
HEAE, for frames that had distances d2 < 0.55 nm, d3 < 0.95 nm and d4 < 0.55 nm. Frames were selected
with a time step of 0.1 ps.The corresponding results of the CP-55,940 simulation are indicated by the region
between the curved lines. For CP-55,940: ϕ = dihedral angle Ophenyl-C1-C1’-C2’ and θ = angle C1-C1’-C2’,
and for the (H)AEAs ϕ = dihedral angle Ocarbonyl-C1-C16-C17 and θ = angle C1-C16-C17.
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required conformations have sufficiently low energy to make their existence feasible.The
results of the simulations of AEA and 12S-HAEA display a great similarity. For both
simulations, many conformations emerge inside the CP-55,940 region enclosed by 60°
> ϕ > 180°.This region is scarcely populated for 5R-HAEA and 5S-HAEA, and not at
all for 15S-HAEA and 11S-HAEA. It is tempting to suggest a preference for analogous
orientations of the pentyl tail for AEA and 12S-HAEA, which have a similar affinity for
the CB1 receptor, while the low affinity and inactive ligands do not show a preference for
this pentyl tail orientation.
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Scatter plots of the orientation of vector C16-C17 in HAEAs during the restrained MD simulations. Figure 8
Scatter plots of the orientation of vector C16-C17, expressed in polar coordinates, during the 5 ns restrained
MD simulation of compounds (a) AEA, (b) 15S-HAEA, (c) 12S-HEAE, (d) 11S-HEAE, (e) 5R-HEAE, and
(f) 5S-HEAE. Frames were selected with a time step of 1 ps. The corresponding results of the CP-55,940
simulation are indicated by the region between the curved lines.
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Structural alignment of  CP-55,940 and restrained (H)AEAs
The MD simulations of the (H)AEA series do not provide enough suitable
configurations for analysis, therefore, the positions of the pharmacophores in the (H)AEA
series were aligned with those of the pharmacophores in CP-55,940. For that purpose,
MD simulations were performed with positionally restrained atoms representing the
pharmacophores according to the model of Tong et al.24. Stereospecificity is important, as
indicated by differences in activity of the enantiomers 5R-HAEA and 5S-HAEA.To take
this stereospecificity into account, a minimum of four atom positions has to be restrained.
Selected atoms were the oxygen in the ethanol, the C16 atom of the aliphatic chain, and
the carbon and oxygen in the carboxyl. Both carboxyl carbon and oxygen positions were
chosen, in order to make sure that the availability of the oxygen for binding to CB1 is not
diminished by possible shielding by the position of the carbon. The results of the MD
simulations for the orientation of the pentyl tail for AEA and all HAEAs are given in
Fig.8. As expected, this orientation (represented by the vector C16-C17), in the (H)AEA
series is less restricted than that of the corresponding vector C1’-C2’ in the acyl chain of
CP-55,940. However, the overlapping regions of CP-55,940 and the (H)AEA series do
not reveal great differences between the various (H)AEAs investigated.The differences in
binding can not be explained by these results.
The most populated overlapping region of CP-55,940 and AEA in Fig. 8 was with
ϕ ≈ 50° and θ ≈ 100°. An illustrative configuration is selected from that region and is
presented in Fig. 9. It demonstrates the flexible hairpin-shaped loop C2 to C15 of AEA,
that does not correspond to any part of CP-55,940, and that accommodates the
differences in the various (H)AEA compounds. Configurations from the restrained MD
simulations of the (H)AEA compounds with a C16-C17 vector orientation of ϕ, θ = 50°,
100° were selected and studied for differences in the orientation and shape of this loop.
It turns out that restrained MD simulations yield conformations of the (H)AEAs that
are very much the same, as demonstrated  by 11S-HAEA and 12S-HAEA.This becomes
evident from the orientation of the C16-C17 vector in Figs 8  and  10.The shape of the
C2 to C15 loop differs slightly in the various HAEAs, due to the different positions of the
hydroxyl and conjugated double bonds, that define a ‘6-atoms-in-a-plane’ stiff part. Note
that the loop formed by the carbons C2 to C15 adopted various conformations during the
simulations. Nevertheless, the conformational space of the orientation of the loop C2 to
C15, relative to the orientation of the C16-C17 tail vector, is essentially identical for both
compounds during the simulations (data not shown).
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Conclusions
Towards the design of selective molecular probes for interaction with the proteins of the cannabinoid
system
This study has shown that restricting the flexibility of AEA and 2-AG and introducing
hydroxyl functions in their acyl chains brings selectivity and attenuates their binding
potency towards the proteins of the endocannabinoid system. For example, 15S-HAEA
selectively bound to the CB1 receptor, whereas 13S-HLEA and 15-HO-LAG were the
only eicosanoid ligands that selectively bound to the CB2 receptor to date. 11S-HAEA
did not bind to CB1 or CB2 receptors, but was a very good inhibitor of FAAH (Ki= 0.57
µM). By contrast, 12S-HAEA bound both CB receptors with an affinity similar to that of
AEA, but it was a poor inhibitor of FAAH. Nevertheless, all HAEAs displayed an increased
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Stereoview of snapshots CP-55,940 and AEA. Figure 9
Stereoview of snapshots CP-55,940 (upper panel) and AEA (lower panel) with a vector C16-C17 orientation
of ϕ, θ = 50°, 100°, depicted with dotted Van der Waals surfaces of the pharmacophores to highlight
corresponding positions.
BOC van der Stelt3  06-02-2002  11:07  Pagina 83
potency to inhibit FAAH, whereas their ability to interact with the AEA-transporter was
disrupted (Ki> 10 µM).This makes it possible to discern the physiological contribution
of FAAH and AEA-transporter in the clearance of endocannabinoids.Thus, the HAEAs
can serve as structural templates to generate selectivity in the endocannabinoid system and
may possibly be used as targets for drug development.
The NMR experiments indicated that chloroform and water did not induce different
conformations in the acyl chain of 15-HETE. Consequently, there were no indications
that 15-HETE would adopt a more compact overall conformation in aqueous solutions.
For the first time, MD simulations of AEA and derivatives were performed that included
explicit water molecules. Conformation analysis revealed that poly-unsaturated fatty acids
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Figure 10 Stereoview of snapshots of 12S-HAEA and 11S-HAEA.
Stereoview of snapshots of 12S-HAEA (upper panel) and 11S-HAEA (lower panel) with vector
C16-C17 orientation of ϕ, θ = 56°, 105°.
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such as AEA assume more folded conformations than saturated fatty acids, because of an
inclination of the 1Z,4Z-pentadiene subsystems to form bent shapes. Furthermore, our
data indicated that the ability to adopt a tightly folded conformation is not the only
essential feature of the acyl chain, which enables AEA to bind to the CB1 receptor. In the
free MD simulations all HAEA derivatives, both active and inactive at the CB1 and CB2
receptors, could adopt a folded conformation in which the pharmacophores in AEA
matched those of CP-55,940. Close inspection of the free and restrained MD simulations
of the HAEA series indicated that the differences must be located in the conformational
details of the loop (C2 to C15), e.g. the position and orientation of the hydroxyl group.
Furthermore, evaluation of the binding data indicated that a sp2 carbon is required at
position C11 in AEA-derivatives for binding to the CB1 receptor. The free MD-
simulations may suggest that the pentyl tail orientations of the high-affinity ligands AEA
and 12S-HAEA are different from that of the low-affinity and inactive ligands. Distinct
differences in terms of tail and loop orientations between high-affinity CB1 receptor
ligands and inactive compounds could not be detected in the restrained MD simulations.
Our data also indicated that the binding of HAEAs to the CB2 receptor is more sensitive
towards steric hinder along the acyl chain. However, more conclusive statements about the
nature of the interactions of the CB receptors with their ligands await purification and
crystallization of the proteins with their ligands.
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Proton D2O CDCl3
3J D2O CDCl3
H-2a,b 2.182 2.347 2,3 7.8 7.0
H-3a,b 1.613 1.691 3,4 6.6 6.8
H-4a,b 2.106 2.135 4,5 7.8 7.8
H-5 5.48 5.41 5,6 n.d. n.d.
H-6 5.48 5.41 6,7 6.3 6.0
H-7a,b 2.869 2.834 7,8 6.3 6.0
H-8 5.48 5.41 8,9 n.d. n.d.
H-9 5.48 5.41 9,10a 6.3 6.0
9,10b 7.4 7.5
H-10a 2.959 2.950 10a,10b -15.7 -16.5
H-10b 3.037 3.030 10a,11 7.9 7.8
H-11 5.54 5.41 10b,11 8.0 8.0
H-12 6.074 6.000 11,12 10.6 10.5
H-13 6.600 6.595 12,13 11.1 11.1
H-14 5.739 5.717 13,14 15.3 15.3
H-15 4.202 4.258 14,15 7.2 6.0
H-16a,b 1.548 1.553 15,16 6.8 6.3
H-17a,b 1.283 1.393 16,17 n.d. n.d.
H-18a,b 1.283 1.298 17,18 n.d. n.d.
H-19a,b 1.283 1.298 18,19 n.d. n.d.
H-20a,b,c 0.854 0.887 19,20 6.3 6.7
Chemical shifts are relative to acetone = 2.218 ppm in D2O and to TMS = 0.000 ppm in CDCl3.
500 MHz 1H chemical shifts and coupling constants of 15-HETE in D2O and CDCl3. Table S1.
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Bond stretching Force constants Equilibrium Identical to
term (kcal mol-1 Å -2) values (Å)
CEH1-CE/IH1
a 1000.0 1.33 b
CEH1-CHnc 850.0 1.50 b
CIH1-CIH1 850.0 1.45 b
Bond angle term Force constants Equilibrium Identical to
(kcal mol-1 rad-2) values (°)
CE/IH1
a-CIH1-CIH1 100.0 § 125.0 b
CIH1-CEH1-CHnc 100.0 125.0 b
CEH1-CH2-CEH1 110.0 111.0 CB-CH2-CH2
CEH1-CHnc-CH2 110.0 111.0 CB-CH2-CH2
CEH1-CH1-OA 110.0 109.5 CH1-CH1-OA
Dihedral term Force constants Phase angle Multi- Identical to
(kcal mol-1) (°) plicity
Xd-CEH1-CE/IH1
a-X 10.0 180.0 2 X-CR61-CB-X
X-CIH1-CIH1-X 3.0 180.0 2 e
X-CEH1-CHnc-X 0.1 0.0 6 X-C-CHnc-X
aCE/IH1 = CEH1 as well as CIH1  
bThe average value obtained from the diene systems of 35 linear structures
selected from the Crystallographic Structure Database. cCHn = CH1 as well as CH2.
dX = any atom type  eDr. L.M.J. Kroon-Batenburg, personal communication.
Table S2. Detailed force field parameter modifications.
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Abstract
Excitotoxicity is a paradigm used to explain the biochemical events in
both acute neuronal damage and in slowly progressive, neurodegenerative
diseases. Here, we show in a longitudinal Magnetic Resonance Imaging
(MRI)-study that ∆9-tetrahydrocannabinol (∆9-THC), the main active
compound in marijuana, reduces neuronal injury in neonatal rats injected
intracerebrally with the Na+/K+-ATPase inhibitor ouabain to elicit
excitotoxicity. In the acute phase ∆9-THC reduced the volume of
cytotoxic edema by 22%. After 7 days, 36% less neuronal damage was
observed in treated rats compared with control animals. Coadministration
of the CB1 cannabinoid receptor antagonist SR141716 prevented the
neuroprotective actions of ∆9-THC, indicating that ∆9-THC afforded
protection to neurons via the CB1-receptor. In ∆
9-THC-treated rats the
volume of astrogliotic tissue was 36% smaller. The CB1 receptor
antagonist did not block this effect. These results provide evidence that
the cannabinoid system can serve to protect the brain against neuro-
degeneration.
Introduction
The endogenous cannabinoid system comprises two cannabinoid receptors, designated
CB1 and CB2, which have been cloned and characterized
1.Two main endogenous ligands
based on fatty acids, i.e. anandamide and 2-arachidonoylglycerol (2-AG) have been
identified1.The CB1 receptor is mainly found in the central nervous system, whereas the
CB2 receptor is almost exclusively expressed by cells of the immune system
2. The
discovery of the endogenous cannabinoid system initiated intense research into the
therapeutic potential of cannabinoids in a variety of neurological and neurodegenerative
disorders, such as gliomas, cerebral ischemia, and multiple sclerosis3-6.
(Endo)cannabinoids have also been tested in models of excitotoxicity, which is a
concept of neuronal cell death caused by overactivation of excitatory amino acid
receptors.The excitotoxicity hypothesis is used to explain the common biochemical basis
behind many acute and chronic neurodegenerative disorders such as stroke, traumatic
brain injury, amyotrophic lateral sclerosis, Parkinson’s, Huntington’s, and Alzheimer’s
diseases7,8. N-acylethanolamines, including anandamide, and their precursors and 2-AG
accumulate, when tissues and cells are subjected to excitotoxic stress3-6,9-12. Whether this
increase in endocannabinoids is neuroprotective and if so via which mechanism is still
under debate13-19.
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The therapeutic effects of cannabinoids in in vivo models of cerebral ischemia are also
not consistent. Chronic ∆9-THC administration has been shown to reduce the impact of
an ischemic insult evoked by a reduced blood pressure and 12 min bilateral carotid artery
occlusion.The involvement of the CB1 receptor was not studied
5. However, no protective
effect could be found for WIN55.212, a synthetic CB receptor agonist, in rats when the
middle cerebral artery was occluded for 2 h. Surprisingly, the CB1 receptor antagonist
SR141716 was protective (C.J. Hillard, personal communication). Remarkably, WIN
55.212-2 afforded protection to hippocampal and cortical neurons in CB1-dependent
manner in rats with a permanent middle cerebral artery occlusion or global ischemia3.The
reason for this discrepancy is not known at the moment, but (endo)cannabinoid-induced
vasorelaxation20 may have a different impact on the pathway of neuronal demise in each
of these stroke models.
In light of the ambiguous results from both in vitro models of excitotoxicity and in vivo
models of cerebral ischemia, we investigated the neuroprotective properties of ∆9-THC in
an in vivo model of secondary excitotoxicity. Neurodegeneration was elicited by inhibition
of the Na+/K+-ATPase. Diffusion-weighted magnetic resonance imaging (MRI), T2-
weighted MRI and histology, were used to study the effects of ∆9-THC in both the acute
and late phases after the induction of excitotoxicity.
Animals, Materials and Methods
Animal model
Neonatal Wistar rats (U:Wu/Cpb; 7- to 8-day-old) were anesthetized with ether and
immobilized in a stereotaxic frame. A small burr hole was drilled in the cranium over the left
hemisphere, 2.5 mm lateral of bregma.A 1 µl syringe was lowered into the left striatum to a depth
of 4.0 mm 21. Ouabain (0.5 µl 1mM; n=30, Zwijndrecht,The Netherlands) or vehicle (0.5 µl 40
mM Tris-HCl buffer, pH 7.4; n=2) was injected at a rate of 0.125 µl/min with a microdrive.After
injection the needle was left in situ for 2 min to avoid leakage of injection fluid from the needle
tract.Animals were then positioned in the magnet and anesthesia was continued with a mixture of
halothane (0.4-1%) in N2O/O2. Body temperature was maintained at 37°C using a water-filled
heating pad and an infrared heating lamp. Animals were treated with ∆9-THC (Sigma Aldrich,
n=12), THC + SR141716 (Sanofi Recherche, n=5, Montpellier, France), SR141716 (n=6) (all
drugs at 1 mg/kg in 1 ml/kg bodyweight 18:1:1 v/v Phosphate Buffered Saline
(PBS)/Tween80/Ethanol) 30 min prior to toxin injection.There was no difference in body weight
and growth rate between any of the groups.The vehicle injection i.p. did not affect lesion size. The
University’s Animal Experimental Committee approved all protocols.
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MRI-experiments
MRI was performed on a 4.7T Varian horizontal bore spectrometer. Excitation and signal
detection were accomplished by means of a Helmholtz volume coil (9 cm ∅) and an inductively
coupled surface coil (2 cm ∅), respectively. A single-scan diffusion-trace MRI-sequence (four b-
values:100-1300 s/mm2, repetition time (TR) 3s, time of echo (TE) 100 ms) was used to generate
quantified images of tissue water trace apparent diffusion coefficient (ADC). Diffusion trace- and
T2-weighted-imaging (TE=18, 40, 62 and 84 ms; TR=2s, nt=2) were performed in all animals,
starting at t=15 min after injection on day 0 and were repeated one week later.
Both the T2-weighted and the diffusion-weighted datasets consisted of seven consecutive, 1.5
mm thick slices, with 0 mm slice gap.To minimize interference at the slice boundaries, slices were
acquired in alternating order (1,3,5,7,2,4,6), thus maximizing the time between excitation of two
neighbouring slices. For the diffusion-weighted imaging we used a double spin-echo pulse sequence
with four pairs of bipolar gradients with specific predetermined signs in each of the three
orthogonal directions22. The combination of gradient directions leads to cancellation of all off-
diagonal tensor elements, effectively measuring the trace of the diffusion tensor. This provides
unambiguous and rotationally invariant ADC values in one experiment, circumventing the need for
three separate experiments. For each b-value, two scans were averaged. The total scan time for
acquisition of seven slices, with four b-values and two averages, was 17 minutes.
As expected, at the early time point no changes in T2-weighted MRI were detected. Animals
not scanned at day 0, were kept under halothane anesthesia for equal durations as the scanned
animals to prevent anesthesia-induced bias.
Data analysis
Mono-exponential fitting using the Interactive Data Language software package generated
ADC and T2 maps. Parametric images were analyzed in anatomic regions of interest using Image
Browser (Varian). Pixels in the ipsilateral hemisphere were considered pathological when their
ADC- or T2-value differed more than twice the SD from the mean value in the contralateral
hemisphere. The ventricles were segmented out in the average ADC and T2 measurements. The
lesion volume per slice was calculated by multiplying the lesion area (= number of pathological
pixels × field-of-view in cm2 / number of points acquired per image) by the slice thickness.The
total lesion volume was obtained by summation of the lesion volumes for all slices.The absence of
a slice gap makes interpolation of lesion areas between slices unnecessary, reducing systematic errors
to within-slice ‘averaging’ of signal intensity.
Statistical analysis was performed with SPSS 9.0. Differences between groups were analyzed
using Student’s t-test; reported p-values correspond to two-tailed significance.
Histology
After the last MRI-measurements animals, needed for histology were transcardially perfused
with 4% paraformaldehyde in 0.1 M PBS. Dissected brains were post fixed overnight by immersion
in the same fixative, cryoprotected in 10% sucrose in PBS for 24 hours, followed by 25% sucrose in
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PBS for 72 hours and quickly frozen in liquid nitrogen-cooled isopentane.We cut 10 µm coronal
sections and stained for glial fibrillary acidic protein (GFAP), Nissl-substance or hematoxylin/eosin
with standard procedures. Position of the histological slices was matched to the position of MRI-
images by known position relative to bregma, after which a gross correlation was done.
Results
Loss of cellular ion homeostasis was initiated by unilateral intrastriatal injection of 0.5
µl of the Na+/K+-ATPase inhibitor ouabain (1 mM) into 7- to 8-day-old Wistar rats 23-26.
Twelve animals received an additional injection i.p. with ∆9-THC (1 mg/kg) and five
animals received both ∆9-THC and the CB1 antagonist SR141716 (1 mg/kg ) 30 min
prior to ouabain-injection.
ADC maps of brain tissue water, calculated from diffusion-weighted MR images
acquired 15 min after ouabain injection, showed hypo intense regions with reduced ADC
values (~0.67 I 10-3 mm2 s-1) in the ipsilateral hemisphere in all animals (Fig. 1). Normal
ADC values (~1.11 I 10-3 mm2 s-1) were measured in the contralateral hemisphere of the
ouabain-injected rats (Fig. 1) and in the brain of the control animals, which received only
vehicle (0.5 µl Tris-HCl; 40 mM, pH 7.4).The reduction in ADC values in the ipsilateral
hemispheres after ouabain-injection is considered to reflect neuronal swelling, i.e.
cytotoxic edema, because of a relocation of part of the extracellular water into depolarized
cells 21,27. In this acute phase, the volume of brain tissue with cytotoxic edema was 22%
smaller in the ∆9-THC-group (p<0.05) (Figs. 1 and 2). Coinjection of the CB1 receptor
antagonist SR141716 completely abolished the ∆9-THC-induced effect (Figs. 1 and 2).
The same brain regions, including the caudate putamen, cortex and hippocampus, were
affected in all animals (Fig. 1).
After seven days, sharply delineated hyperintense regions were observed in the ADC
maps (data not shown), indicative of the formation of vasogenic edema as well as tissue
loss and ventricle dilatation.The volume of infarcted tissue as calculated from ADC maps,
was 36% smaller in ∆9-THC-treated rats (p<0.01) (Fig. 2). SR141716 abolished the
protective effect (p<0.005) (Fig. 2).A 10% increase in infarct volume was observed in the
CB1-antagonist-treated rats compared to non-treated rats (Fig. 2).This trend did not reach
statistical significance. Neuroprotection was observed in brain regions known to express
CB1 receptors, such as the hippocampus, caudate putamen, and cortex
28. Western blot
analysis confirmed the presence of CB1-like receptors, but as expected, not of CB2-like
receptors, in 7- and 14-day-old rat brains (data not shown). The effects of ∆9-THC
treatment on neuronal damage after seven days was also assessed using T2-weighted
imaging and verified with a histological procedure. T2 maps demonstrated both hyper-
and hypointensities (Fig. 3). Both types of T2 abnormalities indicate pathological changes.
Hyperintense areas correspond to vasogenic edema, tissue loss, and ventricle dilatation,
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whereas hypointensities correlate to astrogliosis, i.e. phenotypic changes (hypertrophy)
and proliferation of astroglial cells in response to neuronal injury (Fig. 4)27,29. Lesion
volumes, based on the combination of hyper- and hypointense abnormalities on T2 maps,
were reduced by 36% (p<0.005) in ∆9-THC-treated rats compared with the control
group (Figs. 2 and 3). Infarct size based on T2-hyperintense abnormalities was reduced by
35% in the ∆9-THC-treated group (p<0.05) compared to the control animals (Figs. 2 and
3). This effect could be blocked by the CB1 antagonist (p<0.05) (Figs. 2 and 3).
Conventional histology (Nissl- and hematoxylin/eosin staining) showed the same lesion
pattern on brain sections and confirmed the assessment made by ADC and T2map analysis
(data not shown).
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Figure 1 Three adjacent coronal ADC maps of neonatal rat brain 15 min after ouabain injection: effect of THC-pretreatment
a) no treatment, b) THC-treatment, c) THC + SR141716 treatment. Hypointensities correlate to cytotoxic
edema.
a
b
c
BOC van der Stelt4  05-02-2002  17:53  Pagina 96
The hypointense regions on the T2 maps corresponded to regions exhibiting increased
staining for GFAP staining, which is typical of astrogliosis, on brain sections of ouabain-
treated rats (Fig. 4). No indications were found for hemorrhage. Astrogliotic tissue
constituted 40% of the lesion on T2-maps and usually surrounded the edematous tissue
and the dilatated ventricles (Fig. 3).The volume of astrogliotic tissue in ∆9-THC-treated
rats was reduced by 37% compared with nontreated rats (p<0.05). Importantly, this effect
was not blocked by the CB1 receptor antagonist (Fig. 2).
Discussion
In the brain at least 40% of the energy produced by mitochondrial respiration is
required by the Na+/K+-ATPase to maintain ion gradients across the cell membranes.
Energy levels in the brain can be compromised by a lack of glucose and oxygen or by
defects in the respiratory chain such as occurring in stroke and Parkinson’s disease,
respectively. Na+/K+-ATPase function is inhibited during energy failure.This may lead to
a prolonged depolarization of the neuron, excessive release, and reversal of the uptake of
excitatory amino acids, i.e. the induction of excitotoxicity7,8. Ouabain inhibits Na+/K+-
ATPases and is a very potent neurotoxin that leads to pancellular necrosis and infarction23.
It is used to study the involvement of Na+/K+-ATPase in central nervous system
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pathology23-26,30. Ouabain rapidly perturbs ion homeostasis, induces cell swelling and
glutamate dependent damage of cells, which can be prevented, at least in part, by blockade
of the NMDA receptor23-26,30.
The diffusion-weighted MRI data acquired 15 min after the injection of ouabain
showed that activation of the CB1 receptor by ∆
9-THC attenuates in vivo cell swelling in
an early phase after the induction of excitotoxicity. Activation of the CB1 receptor on
presynaptic-neuron terminals can lead to inhibition of the Ca2+ influx via N-, and P/Q-
type voltage-sensitive calcium channels, thereby preventing the release of glutamate and
subsequent depolarization of other neurons17,31. Furthermore, cannabinoids can induce
hyperpolarization via the CB1-mediated activation of inward rectifying and A-type K
+-
channels32. Hyperpolarization raises the threshold to depolarization, which therefore may
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Figure 3 Three adjacent coronal T2-maps of neonatal rat brain 7 days after ouabain injection: effect of THC-pretreatment.
a) no treatment, b) THC treatment, c) THC + SR141716 treatment. Hyperintensities correlate to ventricle
dilatation, vasogenic edema and tissue loss, whereas hypo-intensities correlate to astrogliosis.
a
b
c
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contribute to the observed reduction in the development of cytotoxic edema.
ADC and T2 data acquired after seven days, demonstrated that ∆
9-THC or its CB1-
active metabolite 11-HO-∆9-THC reduced neuronal damage by 36%. Various
mechanisms could underlie the observed effects:
(i) ∆9-THC-induced hypothermia2. In our experimental setup, the body temperature
of the rats was externally controlled by an infrared lamp and a water-heated pad, making
the contribution of cannabinoid-induced hypothermia to the protective effects unlikely.
(ii) Anti-oxidative properties of ∆9-THC16.Anti-oxidant activity most likely does not
play a major role in our model, because a) the neuroprotective effects were blocked by the
CB1 antagonist and b) the dose of ∆
9-THC (1 mg/kg) is low compared to the high dose
of anti-oxidant (50-100 mg/kg) required for effective protection in other studies33
(iii) Down-regulation of brain-resident mast cells by activation of a CB2-like receptor
14,15. This process is also unlikely to be effective in our model, because a) the
neuroprotective effects were blocked by SR141716, b) ∆9-THC has been shown to have
a low efficacy on the stimulation of the CB2 receptor
2 and c) a CB2 like receptor could
not be detected.
(iv) Closing of N- and P/Q-type calcium channels via a CB1-receptor-mediated
mechanism17,34. Reduced influx of calcium decreases directly the activation of destructive
pathways, e.g. it prevents the activation of neuronal NO-synthase35 and it reduces
glutamatergic transmission, i.e induction of excitotoxicity17,36,37. This CB1-mediated
mechanism is likely to dominate the observed neuroprotective effects in the late phase in
our model.
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GFAP-staining of a brain section of a ouabain-injected rat. Figure 4
Markedly increased staining was observed in the thalamus, external capsule and cortex of the injected
hemisphere, whereas normal staining was seen in the contralateral hemisphere.
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Neuroprotection by ∆9-THC was observed in the hippocampus, striatum and cortex.
Western blots verified the presence of CB1 receptors in neonatal rat brain. Previously,
radioligand binding studies have demonstrated that CB receptors were expressed in the
cerebral cortex, striatum, hippocampus, cerebellum and brain stem at postnatal day 5 28,38.
The presence of mRNA transcripts for the CB1 receptor was also observed in some
forebrain areas, such as the subventricular zone of the striatum, nucleus accumbens and
neocortex.The abundance of the mRNA transcripts was high at gestational day 21 but
tended to wane to postnatal day 5 and disappeared at day 3038. Thus, these data support
a CB1-mediated neuroprotection.
The gliotic response to neuronal injury after ouabain-injection has been reported in
adult rats25.We also observed astrogliosis surrounding vasogenic edema in our model. ∆9-
THC-treatment reduced the volume of brain tissue with astrogliosis.Although astrocytes
express CB1-like receptors sensitive to SR141716
28, administration of the SR141716 did
not block the reduction in astrogliotic tissue.Therefore, this process does not seem to be
mediated by a CB1-like receptor. Noteworthy, dexanabinol, a non-psychotropic
cannabinoid, inhibits tumor necrosis factor-α (TNF-α) release from astrocytes39. It is
thought that TNF-α sets the stage for inflammatory reactions including glial cell
activation and proliferation29. ∆9-THC is known to inhibit the release of TNF-α from
immune cells40.Thus, ∆9-THC or one of its metabolites might also inhibit the release of
TNF-α from astrocytes (or immune cells) and reduce astrogliosis. Furthermore, non-
psychotropic cannabinoid metabolites inhibit prostaglandin synthesis41. Cyclooxygenase-
2 activation has been shown to induce astrogliosis42. Thus, it is also possible that non-
psychotropic metabolites of ∆9-THC reduce astrogliosis via this mechanism. Further
research is required to investigate the mechanism of ∆9-THC-induced reduction of
astrogliosis.
Our data may suggest that endogenous cannabinoids could be released upon neuronal
injury and protect neurons in the periphery of the infarct: on the ADC-maps we observed
a trend towards a larger infarct (+10%) in antagonist-treated rats compared with non-
treated rats (Figs. 2 and 3). It should be noted that tissue was considered to be pathological
only in case ADC or T2 values differed more than twice the SD of the mean value in the
contralateral hemisphere.The periphery of the infarct with smaller changes in ADC or T2
is not incorporated in this way, but may nevertheless have benefited from endogenous
release of cannabinoids. Interestingly, the cortex was not severely damaged in the non-
treated animals, whereas in the SR141716-injected animals this area was infarcted (Figs.
3a and 3c). It has been shown that glutamate-induced neurotoxicity leads to the formation
of anandamide and its precursor N-acylphosphatidylethanolamine9,10. However,
SR141716 is an inverse agonist. It is possible that SR141716 blocks constitutively active
CB1-receptors
2. Yet, Mechoulam and co-workers have found that the endogenous
cannabinoid 2-AG is upregulated in the first hours after closed head injury in mice, and
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that administration of 2-AG reduces edema formation via the CB1-receptor, which
strongly corroborates our findings (R. Mechoulam, personal communication).
In summary, we have shown that in an in vivo model of neurodegeneration  ∆9-THC
reduces neuronal damage via a CB1 receptor-mediated mechanism.This holds in both the
acute and late phase after induction of excitotoxicity. ∆9-THC inhibits astrogliosis via a
non-CB1-receptor-controlled mechanism. The results strengthen the concept that the
endogenous cannabinoid system may serve to establish a defense system for the brain.This
system may be functional in several neurodegenerative diseases in which excitotoxicity is
thought to play a role, such as amyotrophic lateral sclerosis, Huntington’s, and Parkinson’s
diseases, and also in acute neuronal damage as found in stroke and traumatic brain injury.
It is conceivable that the endogenous cannabinoid system can be exploited for therapeutic
interventions in these types of primarily incurable diseases.
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Abstract
The endocannabinoid anandamide [N-arachidonoylethanolamine; (AEA)] is
thought to function as an endogenous protective factor of the brain against
acute neuronal damage. However, this has never been tested in an in vivo model
of acute brain injury. Here, we show in a longitudinal pharmacological
magnetic resonance imaging (MRI) study that exogenously administered AEA
dose-dependently reduced neuronal damage in neonatal rats injected
intracerebrally with the Na+/K+-ATPase inhibitor ouabain. At 15 min after
injury, AEA (10 mg/kg) administrated 30 min before ouabain injection,
reduced the volume of cytotoxic edema by 43 ± 15 % in a manner insensitive
to the cannabinoid CB1 receptor antagonist SR141716A. At seven days after
ouabain treatment, 64 ± 24% less neuronal damage was observed in AEA-
treated (10 mg/kg) rats compared with control animals. Coadministration of
SR141716A prevented the neuroprotective actions of AEA at this end point. In
addition, (i) no increase in AEA and 2-arachidonoylglycerol levels was detected
at 2, 8 or 24 h after ouabain injection; (ii) application of SR141716A alone did
not increase the lesion volume at days 0 and 7; and (iii) the AEA-uptake
inhibitor, VDM11, did not affect the lesion volume. These data indicate that
there was no endogenous endocannabinoid tone controlling acute neuronal
damage induced by ouabain. Although our data seem to question a possible
role of the endogenous cannabinoid system in establishing a brain defense
system in our model, AEA may be used as a structural template to develop
neuroprotective agents.
Introduction
The central nervous system is highly vulnerable to ischemia. Neuronal death caused
by ischemia is executed via a complex array of processes in which excitotoxicity plays a
major role. In excitotoxicity, cell death is triggered by the overstimulation of excitatory
amino acid receptors.This leads to cytotoxic levels of calcium and to subsequent activation
of destructive pathways, involving among others caspases, calpains, and the generation of
reactive oxygen species1,2.
Compounds that interfere with excitotoxicity may be used as neuroprotective
therapeutic agents. Interestingly, the brain has various endogenous protection factors at its
disposal, (e.g. adenosine, melatonin, and estrogens)3,4. Several reports have also revealed a
connection between the endogenous lipid anandamide [N-arachidonoylethanolamine;
(AEA)] and neurodegenerative diseases5,6.
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AEA mimics in part the actions of ∆9-tetrahydrocannabinol (THC), the psychoactive
compound in marijuana.Together with 2-arachidonoylglycerol (2-AG),AEA represents a
class of lipids, termed endocannabinoids, because of their ability to activate the CB1 and
CB2 cannabinoid receptors. AEA is rapidly translocated into the cell via a transporter
protein, and is then immediately inactivated by a fatty acid amide hydrolase (FAAH)7,8.
Several lines of evidence indicate that AEA can serve to protect the brain against
neuronal injury9,10: (i) AEA and its precursor N-arachidonoylphosphatidylethanolamine
are normally found in low concentrations in the brain, but their levels increase in a
calcium-dependent manner postmortem and with severe neuronal injury10-14; (ii)
exogenous AEA protects cerebral neurons from in vitro ischemia15; (iii) CB1-mediated
closing of N-, and P/Q-type calcium channels protects neurons against in vitro secondary
excitotoxicity16,17; (iv) we have demonstrated recently that THC can reduce neuronal
damage via the CB1 receptor in an in vivo model of excitotoxicity (See Chapter 4); (v)
WIN55.212, a synthetic cannabinoid, protected rat brain against focal and global
ischemia18; (vi) CB1 expression is enhanced in the cortical mantle zone in rats after
ischemia19.As yet, in vivo neuroprotection by AEA has never been reported.
To date no effective drugs are available to treat brain injury following transient (global)
or permanent focal cerebral ischemia. Insights into how the brain defends itself may lead
to novel strategies to develop new therapeutic agents. Therefore, it was our goal to test
whether the endogenous cannabinoid system affords the brain protection in an in vivo
model of neuronal injury. In this study we combined longitudinal pharmacological
magnetic resonance imaging (MRI) and isotope dilution gas chromatography / mass
spectrometry (GC/MS) techniques. Our data indicate that there is no endogenous
endocannabinoid tone controlling the acute neuronal damage induced by ouabain, a
Na+/K+-ATPase-inhibitor, although exogenous AEA can effectively reduce toxin-
induced injury in the neonatal rat brain.
Animals, Materials and Methods
Animal model
See chapter 4.
Pharmacological  Treatments
Animals used for the MRI study were treated i.p. with AEA (1 or 10 mg/kg, n= 5 and 6,
respectively, Biomol, Heerhugowaard, The Netherlands), AEA + SR141716A (10 and 3 mg/kg,
n=4, Sanofi Recherche, Montpellier, France), SR141716A alone (3 mg/kg, n=5), the selective AEA
membrane transporter inhibitor,VDM11 (10 mg/kg, n=5), synthesized as described previously52, or
vehicle alone (n=12) (all drugs in 1 ml/kg body weight 18:1:1 v/v phosphate buffered saline
(PBS)/Tween80/Ethanol) 30 min before toxin injection.There was no difference in body weight
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and growth rate between any of the groups. Utrecht University’s Animal Experimentation
Committee approved all protocols.
MRI-experiments, data analysis and histology
See Chapter 4.
Protein analysis
Mouse melanoma cells (B16-G4F) were transiently transfected with 6-10 µg recombinant
cDNA (pcDNA3-vector) encoding the CB2 receptor (kind gift of Dr. R. Delwel, Institute of
Hematology, Erasmus University, Rotterdam, the Netherlands). Rat tissue (brain and spleen) and
cells were homogenized and sonicated (3 × 10 s) in buffer containing 50 mM Tris-HCl, 1 mM
EDTA and 3 mM MgCl2 (pH 7.4). Membrane fractions were prepared by centrifugation at 5000 ?
g for 5 min. Samples were stored at –20 °C until further use.
Samples containing 30 mg of protein were separated by 10% SDS-PAGE (reducing) and
transferred to a nitrocellulose membrane. Membranes were blocked overnight in 1% gelatin in PBS-
0.1% Tween (CB1, FAAH) or in PBS-0.1% Tween containing 5% nonfat milk powder (CB2).
Membranes were rinsed twice and washed once for 15 min and four times 5 min with 20 ml PBS-
0.1% Tween.The membranes were incubated with polyclonal primary antibodies for 3 h (1: 1000,
CB1, Cayman Chemicals), 2 h (1: 1000, CB2, Cayman Chemicals) and 1.5 h (1:5000, FAAH, a kind
gift from Dr. M. Maccarrone, University of Rome “Tor  Vergata”, Rome, Italy) and washed. A
donkey anti-rabbit antibody conjugated to horseradish peroxidase (1:5000, Biorad) was used as a
secondary antibody (1h incubation). Membranes were washed and developed with Western-blotting
detection reagents (ECL,Amersham Pharmacia Biotech) according to the manufacturer’s manual.
Lipid extraction
Neonatal rats (postnatal day 7 (P7) and P8) i.c. injected with ouabain or vehicle were killed by
decapitation at 0, 2, 8 and 24 h after induction of excitotoxicity (n= 6 for each time point). Ipsilateral
and contralateral hemisphere were rapidly removed and separately homogenized in 5 ml ice-cold
Tris buffer (50 mM, pH 7.4). Lipids were extracted according to the method of Bligh and Dyer
(1957)53. One nmol of d8-AEA and d8-2-AG (Cayman Chemicals) were added as internal standards.
The organic phases were dried under nitrogen, and purified by normal phase-HPLC performed as
described previously20. Mono-AGs and AEA standards were eluted after 18-23 min and 27-28 min,
respectively.The mono-AGs fraction contained the 1- (3)- and 2-stereoisomers.
To limit postmortem accumulation of endocannabinoids, the time between decapitation and
homogenization in cold organic solvents was kept as short and constant as possible (< 5 min) and
the tissues were kept on ice.
GC/MS analysis
HPLC fractions were dried under a flow of nitrogen and derivatized with 15 µl N-methyl-
trimethylsilyl-trifluoroacetamide containing 1% trimethylchlorosilane for 2 h at room temperature,
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thus yielding the trimethylsilyl derivatives of AEA and 2-AG. The two derivatized fractions were
analyzed by GC/MS performed as described previously20,21.The derivatives of both deuterated and
non-deuterated AEA, 2-AG and 1-(3)AG standards were eluted after 18, 19 and 19.5 min,
respectively. MS-detection was run in the selected ion-monitoring mode to improve sensitivity.
Selected ions for AEA were at m/z 427 and 419 corresponding to the molecular ions for d8-AEA
and nondeuterated AEA, and m/z 412 and 404, corresponding to the loss of a methyl group in both
compounds. Selected ions for 2-AG were at m/z 530 and 522, corresponding to the molecular ions
of d8-2-AG and nondeuterated 2-AG and m/z 515 and 507, corresponding to the loss of a methyl
group in both compounds.The endocannabinoids were identified on the basis of the same retention
time as the deuterated internal standards of the corresponding MS signals with the appropriate
relative abundance. The amounts of AEA and 2-AG were calculated from the peak area ratios
between the signals at m/z 404 and 412, and m/z 507 and 515, respectively. A linear correlation
between these area ratios and the amounts of standards was observed in separate studies. In the case
of 2-AG, the amount of the 1-(3) isomer, which is almost exclusively formed during tissue workup
and lipid purification22 were added to the amount of the 2-isomer.
Results
The presence of CB1 and CB2 receptors and FAAH in neonatal rat brain was verified
by Western blotting; endocannabinoid levels were determined by isotope dilution
GC/MS.Western blot analysis demonstrated the presence of the CB1 receptor in 7- and
14-day-old rat brain, whereas the CB2 receptor could not be detected (Fig. 1). FAAH was
also detected in 7-day-old rats (Fig. 1). Neonatal rat brains (P7) contained 32.5 ± 6.5
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Western blot of CB1 and CB2 cannabinoid receptors and FAAH in neonatal rat (P7 and 14) and adult brain. Figure 1
The CB2 receptor was absent in rat brain, but was detected in spleen and CB2-transfected cell line.
CB1 CB2 FAAH
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pmol/g AEA and 1.17 ± 0.22 nmol/g 2-AG, which is in the same order of magnitude as
reported previously23.
In our model, excitotoxicity was triggered by the unilateral intrastriatal injection of 0.5
µl ouabain (1 mM) in 7- to 8-day-old rats. Ouabain, a cardiac glycoside, inhibits Na+/K+-
ATPases and induces cellular swelling, eventually leading to pancellular necrosis and
infarction24-28. The acute cellular swelling is conveniently monitored by diffusion-
weighted MRI. ADC-maps of brain tissue water, calculated from diffusion-weighted MR
images acquired 15 min after ouabain-injection, showed hypointense regions with
reduced ADC values (~0.65 ± 10-3 mm2s-1) in the ipsilateral hemisphere in all animals
(Fig. 2). Normal ADC values (~1.11 ± 10-3 mm2s-1) were measured in the contralateral
hemisphere of the ouabain-injected rats (Fig. 2) and in the brains of the control animals,
which received only vehicle (0.5 µl Tris.HCl; 40 mM, pH 7.4).The reduction in ADC
values in the ipsilateral hemisphere after ouabain-injection is considered to reflect
neuronal swelling, i.e. cytotoxic edema, because of a relocation of part of the extracellular
water into depolarized cells29,30.The same brain regions, including the caudate putamen,
cortex and hippocampus, were affected in all animals (Fig. 2). In this acute phase, AEA
reduced the volume of brain tissue with cytotoxic edema dose-dependently.The volume
of tissue at risk to go into infarction was reduced by 43 ± 15% (p<0.05) at 10 mg/kg AEA
(Fig. 2 and 3A). This effect was observed at the borders of the affected tissue, namely
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Figure 2 Coronal ADC maps of neonatal rat brains 15 min after ouabain injection: effect of AEA-pretreatment.
Hypointensities correlate to cytotoxic edema.Treatments:A) vehicle, B) AEA (1 mg/kg), C) AEA (10 mg/kg),
D) AEA + SR141716A (10 and 3 mg/kg, respectively), E) SR141716A (3 mg/kg) and F) VDM11 (10 mg/kg).
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cortex and striatum. Coinjection of the CB1 receptor antagonist SR141716A with AEA
did not reverse AEA action (Fig. 2 and 3A). Application of SR141716A or VDM11 (an
endocannabinoid uptake inhibitor), alone did not change lesion volume at day 0,
compared with vehicle-treated animals (Fig. 2 and 3A).
After seven days the effect of AEA treatment on neuronal damage was assessed using
T2-weighted imaging and verified by standard histology. Normal T2 values (T2= 73 ± 1
ms) were observed in contralateral hemispheres and in the brains of control animals (Fig.
4). The T2 maps of ouabain-injected animals demonstrated both hyperintensities and
hypointensities (Fig. 4).
Both types of T2 abnormalities indicate pathological changes. Hyperintense areas
correspond to vasogenic edema, tissue loss, and ventricle dilation, whereas hypointensities
can correlate to astrogliosis, i.e. phenotypic changes (hypertrophy) and proliferation of
astroglial cells in response to neuronal injury (Fig. 4)29,31. Infarct size based on T2
hyperintense abnormalities was dose-dependently reduced in the AEA-treated group
compared with the control animals (Fig. 3B and 4). The infarct volume was 64±24%
(p<0.05) smaller at 10 mg/kg AEA, than in the vehicle-treated animals. Protection was
primarily observed in the caudate putamen, cortex and hippocampus. This effect was
blocked by the CB1 antagonist (p<0.05) (Fig. 3B and 4).The infarct was ~2.5 fold larger
than that in vehicle-treated animals (p<0.05), and primarily involved the hippocampus
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Mean lesion volumes (± SE) of ouabain-injected rats: effect of ligands of the cannabinoid system. Figure 3
Mean lesion volumes (± SE) of ouabain-injected rats on day 0 (A) and 7 (B) based on ADC and T2 maps
(hyperintensities), respectively.Asterisk denotes a p<0.05 compared to vehicle-treated rats.The numbers at the
bottom indicate the dose of compound (mg/kg). See Materials and Methods for lesion volume calculation.
-
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and caudate putamen.Application of SR141716A and VDM11 alone did not affect lesion
size. Conventional histology (Nissl- and hematoxylin/eosin-staining) showed a similar
lesion pattern on brain sections and confirmed the assessment made by T2 map analysis
(data not shown).
The hypointense regions on the T2 maps corresponded to regions exhibiting increased
staining for GFAP on brain sections of ouabain-treated rats, which is typical of astrogliosis
(Fig. 5B-D; See also chapter 4). No indications for hemorrhage were found. Astrogliotic
tissue constituted ~44% of the lesion on T2 maps of nontreated animals and usually
surrounded the edematous tissue and the dilated ventricles (Fig. 5B). The volume of
astrogliotic tissue in AEA-treated rats was not affected compared to nontreated rats
(p>0.05), which is in accordance with our previous observation that THC reduces
astrogliosis via a CB1 and CB2 independent mode of action in our model (chapter 4; our
unpublished results).This reinforces the notion that also classical cannabinoids have other
modes of action, in addition to their interaction with the CB1 and CB2 receptors
32.
Finally, rat brain endocannabinoid levels were measured 2, 8 and 24 h after ouabain or
vehicle injection. No rises in concentrations of AEA and 2-AG were observed after
inducing acute neuronal damage in the ipsilateral hemisphere (Fig. 6). There were no
significant differences in endocannabinoid levels between ipsilateral and contralateral
hemispheres and between vehicle and ouabain-injected animals (data not shown).
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Figure 4 Coronal T2 maps of neonatal rat brains seven days after ouabain injection: effect of AEA-pretreatment.
Hyperintensities correlate to vasogenenic edema, tissue loss, and ventricle dilatation.Treatment:A) vehicle, B)
AEA (1 mg/kg), C) AEA (10 mg/kg), D) AEA + SR141716A (10 and 3 mg/kg, respectively), E) SR141716A
(3 mg/kg) and F) VDM11 (10 mg/kg).
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Astrogliosis in neonatal rat brain 7 days after ouabain injection. Figure 5
Transversal T2 map (A) of an ouabain-injected animal showing that vasogenic edema is surrounded
by astrogliosis (hypointense area) (B). Nissl-staining (C) and GFAP(D)-staining of a brain section of
an ouabain-injected rat demonstrate a sharp line  between affected and healthy tissue.
Endocannabinoid levels in rat brain 2, 8 and 24 h after ouabain injection. Figure 6
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Discusson and conclusions
The (patho)physiological role of the endogenous cannabinoid system is beginning to
be unraveled33,34. It has been postulated that the endocannabinoid system may serve to
establish a defense system for the brain during neurotoxicity and ischemia10,19; see also
chapter 4). Yet the therapeutic effects of classical and synthetic cannabinoids were
contradictory in models in which transient (20-120 min) or permanent cerebral ischemia
was induced18,35 (C.J. Hillard, personal communication). Because the cannabinoid system
has complex (cerebro)vascular effects36,37, this might explain the difference in therapeutic
outcome in the various models of stroke.
We investigated the presumed neuroprotective properties of the most studied
endocannabinoid,AEA, in an in vivo model of secondary excitotoxicity, in which neuronal
injury was induced by unilateral intrastriatal injection of the Na+/K+-ATPase-inhibitor
ouabain without direct cerebrovascular intervention. Ouabain rapidly perturbs ion
homeostasis, induces cellular swelling and glutamate-dependent damage of cells, which
can be prevented in part by blockade of the NMDA-receptor24-28.
Diffusion-weighted MRI data acquired 15 min after the injection of ouabain showed
that exogenous AEA dose-dependently reduces in vivo cellular swelling in the early phase
after the induction of excitotoxicity. We have shown previously that THC was able to
reduce in vivo cellular swelling in a CB1-mediated manner in the same model (see chapter
4). The AEA-induced reduction in cellular swelling was not attenuated by the CB1-
antagonist SR141716A. Because there are no CB2 receptors detected in the brain, the
early in vivo neuroprotective action of AEA does not seem to be mediated via the CB1 or
CB2 receptors.
The failure of SR141716A to block the reduction in cytotoxic edema by AEA in the
early phase does not seem to be a matter of dose and pharmacokinetics.The antagonist (3
mg/kg) did block the late effects (after 7 days) of AEA (10 mg/kg). Furthermore, a lower
dose of SR141716A (1 mg/kg) was more than sufficient to block the neuroprotective
actions of THC (1 mg/kg) at days 0 and 7 (see chapter 4). It is noteworthy that THC is a
more potent agonist of the CB1-receptor than AEA. In addition, SR141716A is effective
in blocking the behavioral effects of THC in the mouse “tetrad” with AD50s of ~0.1
mg/kg, whereas some of the actions of AEA were insensitive to SR141716A38. Moreover,
some of the behavioral actions of AEA in mouse were still observed in the CB1 knock-
out mice38,39. Others15 have shown that neuroprotection of AEA in in vitro experiments
was also independent of CB1 and CB2 receptors.
Recent data demonstrate that AEA is capable of interacting with other molecular
targets, such as 5-hydroxytryptamine receptors, N-methyl-D-aspartate receptors, vanilloid
receptors, L-type calcium channels, Shaker related K+-channels,TASK-1 channels, a non-
CB1 G-protein coupled AEA receptor in astrocytes  and a non-CB1 non-CB2 G-protein
coupled receptor for AEA and WIN55,212-2 in mouse brain40,41, some of which may
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contribute to a reduction in cellular swelling. For example, the inhibition of gap junctions
and intracellular calcium signaling in striatal astrocytes by the non-CB1 G-protein-
coupled AEA-receptor42 or the inhibition of L-type calcium channels43 may prevent
glutamate exocytosis and the spreading of excitotoxicity.We cannot rule out the possibility
that metabolites of AEA may account for some of the observed effects.Additional studies
are necessary to understand the molecular mechanism of AEA-induced reduction of
cytotoxic edema.
T2-weighted MRI data recorded one week after ouabain injection showed that
exogenous AEA reduced neuronal damage by 64 ± 24% (p<0.05). Compared with the
early phase, AEA-induced neuroprotection was blocked by the CB1 receptor antagonist
after 7 days.This can be explained by the different stages in the cascade of events induced
by excitotoxicity. Calcium entry is held responsible for delayed neurodegenerative events,
which can occur even if the initial cellular swelling is reversed or prevented 2,44.We have
suggested previously that THC protected rat brains in the late phase via the CB1-mediated
closing of N-, and P/Q-type calcium channels and inhibition of glutamatergic
transmission in the same model (45; see chapter 4). It is reasonable to assume that this CB1-
mediated process of closing voltage-sensitive calcium channels also contributes to the
observed neuroprotection of AEA after seven days. As noted before for THC, AEA-
induced neuroprotection was observed in brain regions such as cortex, striatum and
hippocampus (See chapter 4).
Strikingly, the combination of AEA and the antagonist produced an infarct that was
2.5 times larger than seen for the control group. This observation is not likely to be
explained by (i) blockade of the effect of endogenously released cannabinoids; (ii) inverse
agonism of SR141716A or (iii) toxic effects of SR141716A. In fact, treatment of rats with
SR141716A at 1 and 3 mg/kg or with SR141716A+THC (1 mg/kg) did not increase
infarct size significantly (See chapter 4). In addition, endocannabinoid levels do not appear
to increase after ouabain injection.
Hampson et al. have shown that AEA can enhance calcium influx presumably via
direct activation of NMDA-receptors.46 This enhancement could only be observed when
CB1 receptors were blocked by SR141716A. This might explain the extra deleterious
effect of the combination AEA and SR141716A. Interestingly, the site and size of the
infarcted region in these animals was similar to those observed in animals that received a
unilateral intrastriatal injection with NMDA (unpublished results).
Several lines of evidence gained in this study indicate that there is no endogenous
cannabinoid tone controlling the acute neuronal damage induced by ouabain: (i) No
increases in AEA and 2-AG levels were detected at 2, 8 or 24 h after ouabain injection;
(ii) Application of SR141716A alone (3 mg/kg) did not increase the lesion volume at day
0 nor at day 7.This implies that activation of CB1 receptors by constitutive levels of AEA,
2-AG or any other novel CB1 ligand, such as noladin ether
47, does not tonically protect
the brain; (iii) The AEA uptake inhibitor,VDM11, did not reduce neuronal swelling at day
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0, nor did it reduce the infarct volume after seven days. This also argues against a CB1
receptor-independent tonic protective role of endogenous AEA and 2-AG.Thus, in our
in vivo model of acute neuronal damage the data do not support the previously proposed
role of the endogenous cannabinoid system in neuroprotection.
However, it cannot be excluded that technical issues have prevented the detection of
a tonic protection by endocannabinoids. The lesion was considered pathological when
ADC or T2 values differed more than twice the SD of the mean value in the contra-lateral
hemisphere.Thus, the periphery of the infarct with smaller changes in ADC or T2 was not
taken into account, but may have benefited from a possible endogenous release of
cannabinoids. In addition, endocannabinoid levels were measured in total hemispheres,
and a possible local up-regulation of AEA and 2-AG could have been missed. However,
this last possibility appears unlikely if one considers the massive accumulation of
endocannabinoids observed in other models of neuronal injury14,48.
In addition, Hansen et al. (2001) have demonstrated that the increase in  N-acyl-
phosphatidylethanolamines varies in different in vivo models of neuronal damage and is
dependent on the type of cell death.14 High levels of these lipids, which act as biosynthetic
precursors for AEA and its congeners, were found in NMDA-injected neonatal rats.
However, only moderate and low increases were observed in a closed head injury model
and in an apoptotic model, respectively.Although our model does not represent a model
of apoptotic cell death, ouabain-induced injury was not severe enough to elicit
endocannabinoid formation.
In this respect it is interesting to note that Wilson and Nicoll, 2001 have suggested that
release of relevant levels of endocannabinoids probably only occurs in response to
particularly intense stimuli.49 Thus, endogenous AEA may only be released after the
intense stimulus, and, hence, too late to exert a protective action, whereas exogenous AEA
may inhibit the ouabain-induced glutamatergic transmission, thereby preventing the
spreading and reducing the effect of the toxic stimulus.This explanation is consistent with
recent studies in which endogenous cannabinoids were shown to mediate retrograde
signaling from postsynaptic neurons to presynaptic terminals in hippocampal and
cerebellar synapses49-51.
In summary, we were able to accumulate data that strongly suggest that there is no
endogenous endocannabinoid tone controlling the acute neuronal damage induced by
ouabain. In contrast, our data, together with previous reports, indicate that exogenous
AEA can protect the neonatal rat brain via a variety of mechanisms.Although our findings
do question the role of the endogenous cannabinoid system in establishing a tonic brain
defense system in our model, AEA may be used as a structural template to develop new
neuroprotective agents.
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High and Healthy: neuroprotection by cannabinoids
The endocannabinoid system is a valuable target for drug discovery. The
endocannabinoid system seems to be involved in the regulation of several physiological
functions such as embryo implantation and development, motor coordination, learning
and memory, pain, appetite and blood pressure1-4. Selective molecular probes targeted to
one of the proteins of the endocannabinoid system may yield useful therapeutics for a
variety of disorders such as liver cirrhosis, multiple sclerosis and obesity5-8. Furthermore,
(endo)cannabinoid-based drugs may potentially be useful to reduce the effects of
neurodegeneration.
The central nervous system is highly vulnerable to ischemia induced by a stroke or
traumatic brain injury. In western societies stroke is the third cause of mortality and the
first in disability9. At the moment no effective drugs are available to improve outcome
after neuronal injury. Neuronal death caused by ischemia is executed via a complex array
of processes in which excitotoxicity plays a major role. In excitotoxicity, cell death is
triggered by the overstimulation of excitatory amino acid receptors, such as NMDA and
AMPA receptors, by high concentrations of glutamate. This overstimulation leads to
cytotoxic levels of calcium and subsequent activation of destructive enzymatic pathways
and the generation of reactive oxygen species.9,10 In conjunction with providing a
theoretical concept underlying acute neuronal damage, the excitotoxicity hypothesis is
also used to explain the biochemical basis of many chronic and slowly neurodegenerative
disorders such as amyotrophic lateral sclerosis, Parkinson’s, Huntington’s, and Alzheimer’s
diseases9,10.
In vitro neuroprotection by cannabinoids 
CB-dependent protection
Various in vitro and in vivo models are used to test neuroprotective agents and to study
the molecular mechanisms of neuronal cell death10,11. Depending on the model, classical
and synthetic cannabinoids have been shown to exert neuroprotection via different
mechanisms. For example, (i) cerebellar granule neurons were rescued from glutamate
toxicity by administration of WIN55.212-2, ∆8-THC, 11-OH-THC and
palmitoylethanolamide 15 min after glutamate exposure (Table 1; no 1)12.The mechanism
of protection is unknown, but it was suggested that palmitoylethanolamide interfered with
downstream consequences of an excitotoxic stimulus upon binding to CB2-like receptors.
However, the involvement of such a CB2-like receptor was not demonstrated. (ii) In
another study it was shown that WIN55.212-2 and CP55.940 protected hippocampal
neurons in vitro via the CB1 receptor against secondary excitotoxicity, which was induced
by reduction of Mg2+-levels (Table 1, no 2)13. Presynaptic CB1-mediated inhibition of
Ca2+-spiking and glutamate release were assumed to be responsible for the
neuroprotective effects13. This is in line with the observation that the cannabinoids could
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not rescue the cells from direct glutamate exposure (Table 1, no 2).13 (iii) In contrast,THC
could protect cultured mouse spinal neurons against direct kainate toxicity in a CB1-
dependent manner (Table 1, no 3)14. It should be noted that in studies 13 and 14 the
distribution of the CB1 receptor was different. In spinal neurons the CB1 receptor was
located on cell bodies14, whereas a CB1-like receptor was thought be located at
presynaptic sites in hippocampal neurons13,15. It is noteworthy that AEA could reduce
NMDA-induced calcium influx via CB1-mediated closing of voltage sensitive calcium
channels in rat brain slices16. A CB1-mediated closing of voltage sensitive calcium
channels may also be responsible for the observed neuroprotection in spinal neurons. (iv)
In addition, it was shown that CP-55,940 could protect cortical neurons against glutamate
exposure at low concentrations in a CB1-dependent manner via closing of N- and P/Q-
type calcium channels (Table 1, no 6)17. It was shown that the protective effects of CP-
55,940 in vitro could only be observed when the cAMP levels were elevated.
CB-independent neuroprotection
In other studies cannabinoids were shown to protect neurons independently of CB
receptors. For example, (v) WIN55212-2 protected cerebral cortical neurons from in vitro
hypoxia and glucose deprivation in a CB1- and CB2-independent manner (Table 1, no
4)18. (vi) Exogenous AEA and 2-AG protected cultured cerebral neurons in the same
model also in a CB-independent manner (Table 1, no 7)19. The mechanism of
neuroprotection of the synthetic and endocannabinoids was not investigated in these
studies. (vii) In another study cannabidiol and THC protected via their anti-oxidative
properties rat cortical neurons exposed for a short time to glutamate,AMPA and kainate
receptor ligands (Table 1, no 5)20. The neuroprotection was unaffected by CB receptor
antagonists. THC and cannabidiol were anti-oxidants as was demonstrated by cyclic
voltammetry. Furthermore, THC and cannabidiol prevented H2O2-induced damage in
neuronal cultures20. Interestingly, it has been reported that 2-AG surpressed the formation
of reactive oxygen species and tumor necrosis factor-α (TNF-α), a neurotoxic
inflammatory mediator, by murine macrophages in vitro following stimulation with
lipopolysaccharide (LPS)21.
Thus, the mechanism of neuroprotection by cannabinoids differs in the various in vitro
models and could involve a) activation of CB2-like receptors, b) CB1-mediated inhibition
of glutamatergic transmission via closing of N-, and P/Q-type calcium channels, c)
reduction of calcium influx and subsequent inhibition of deleterious cascades, d) anti-
oxidant activity, and e) inhibition of TNF-α formation.
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In vivo neuroprotection of classical and synthetic cannabinoids
Stroke models
To date, the neuroprotective effects of cannabinoids have only been addressed in a few
in vivo models of neuronal injury. However, the results show a large degree of variation.
(i) Chronic ∆9-THC administration has been shown to reduce the impact of an ischemic
insult evoked by a reduced blood pressure and 12 min bilateral carotid artery occlusion
(Table 1, no 12)22.THC at was injected i.p. either a low (0.1 mg/kg) or high (10 mg/kg)
dose every 12 h for 7 days prior to ischemia.Three weeks after neuronal injury rat brains
were analyzed via a histological procedure. No protection was observed in the
hippocampus at either dose, whereas animals treated with the high dose showed
significantly less neocortical injury.The striatum was protected in all THC-treated animals.
The involvement of the CB1 receptor was not studied. (ii) In contrast, no protective effect
could be found for the CB receptor agonist WIN55.212-2 in rats when the middle
cerebral artery was occluded for 2 h. Surprisingly, CB1 receptor antagonists were
protective, which may suggest that endogenously released endocannabinoid are toxic.a
The CB1 antagonists SR141716A and LY320135 reduced the size of the infarct and
improved neurological outcome. (iii) Yet, in another study WIN55.212-2 afforded dose-
dependent protection to hippocampal and cortical neurons in a CB1-dependent manner
in rats with a permanent middle cerebral artery occlusion or global ischemia (Table 1, no
10 and 11)18.WIN55.212-2 (1 mg/kg, i.p.) could reduce the infarct volume in rat brains
when administered up to 30 min after permanent focal ischemia (Table 1, no 11)18. (iv)
Finally, in gerbils subjected to transient global ischemia CP-55,940 (4 mg/kg i.p.) reduced
the ischemia-induced hyperlocomotion and improved electroencephalographic (EEG)
spectral power after 24h (Table 1, no 14)23. These CP-55,940-induced effects were still
observed after 7 days. Coadministration of SR141716A completely blocked the effect of
CP-55,940, which indicated  that the CB1 receptor was involved.
It should be noted that in each of these stroke models different perturbations in
cerebral blood pressure and flow were induced, which may explain the varying results. It
has recently been shown that endocannabinoids generated in monocytes and platelets
contributed to hypotension in acute myocardial infarction24. It might be possible that
(endo)cannabinoid-induced vasorelaxation is affecting the extent and pathway of neuronal
demise in a different manner in each of the stroke models.Therefore, we have tested the
neuroprotective effects of THC in a model of acute neuronal damage without directly
affecting blood pressure and flow to the brain (Chapter 4).
Excitotoxicity model
In our in vivo model acute neuronal damage was elicited in neonatal rats by inhibiting
the Na+/K+-ATPase, thereby producing secondary excitotoxicity (Table 1, no 13;Chapter
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4).THC (1 mg/kg, i.p.) could reduce the volume of cytotoxic edema in a CB1-dependent
manner already 15 min after blockade of the Na+/K+-ATPase.After seven days the infarct
volume in THC-treated rats was ~40% smaller compared with control animals.The effect
was abolished by coadministration of SR14716A.We have suggested that a CB1-mediated
reduction in calcium influx and a reduced glutamate release were responsible for the
neuroprotection in the hippocampus, striatum and cortex.This suggestion was based on
several studies, which had shown that both synthetic and classic cannabinoids as well as
AEA could inhibit presynaptic glutamatergic transmission via CB1-mediated closing of
voltage sensitive calcium channels in different areas of rat brain such as striatum,
hippocampus25-27, substantia nigra pars reticulata28, as well as in prefrontal cortex
pyrimidal neurons29(see also Chapter 1).
Endogenously released endocannabinoids: to be protective?
It has been postulated that the release of endocannabinoids during neuronal injury
might be an endogenous protective response. If this is the case, inhibitors of
endocannabinoid clearance may provide useful therapeutics for neurodegenerative
diseases.The lines of evidence are the following:
(1) 2-AG, AEA and its precursor N-arachidonoylphosphatidylethanolamine are
normally found in low concentrations in the brain, but their levels increase in a calcium-
dependent manner postmortem and upon (severe) neuronal injury30-34. AEA levels were
increased in cultured primary neocortical neurons treated with NMDA or glutamate35.
High levels of NAPEs were found in neonatal rat brains after receiving a striatal injection
of NMDA (25 nmol)36. In the last model, total NAE levels were increased 46-fold in
cerebral cortex after 24 h and AEA concentrations were elevated by a factor of 13.34 In
addition, a large increase in 2-AG was found in a closed head injury model in mice37 and
in rats treated with picrotoxinin38.
(2) CB1 expression is enhanced in the cortical mantle zone in rats after 20 min
occlusion of the middle cerebral arteries39.Western blotting and immunohistochemistry
showed that the increased CB1 expression began by 2 h and persisted for 72 h or more
after ischemia. CB1 transcripts and [
3H]CP55.940 binding capacity were also elevated in
the border regions of the cortex in mice subjected to mild concussive head trauma34.
(3) The neuroprotective effects of classical, synthetic and endogenous cannabinoids
have been reported (see above). However, only one in vitro study described a
neuroprotective effect of endocannabinoids (Table 1, no 7)19 and in vivo studies were still
lacking. Recently, it has been shown that 2-AG may have a protective role at least in part
via the CB1 receptor after closed head injury to mouse brain (Table 1, no 15).
37
Synthetical 2-AG administered to mice after closed head injury reduced brain edema,
improved clinical recovery, reduced infarct volume and reduced hippocampal cell death
compared to controls. The reduction in brain edema by 2-AG was dose-dependently
attenuated by SR141716A.
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Table 1: Neuroprotection by (endo)cannabinoids in different in vitro and in vivo models of neuronal injury.
No Compound Dose Time of  of Type Model and toxin used
application
relative to injury
1 WIN55.212-2 24.5 µM1 15 min post In vitro glutamate
∆8-THC 2.8 µM1 toxin
11-OH-THC 0.88 µM1
PEA 54.6 µM1
2 WIN55.212-2 100 nM2 coapplication In vitro reduced [Mg2+]  
CP55940 100 nM2
WIN55.212-2 100 nM2 glutamate
3 ∆9-THC  0.5 µM2 coapplication In vitro kainate
4 WIN55.212-2 30 nM2 coapplication In vitro  hypoxia and glucose
THC 10 µM 2 deprivation
5 ∆9-THC 3.7 µM1 coapplication In vitro glutamate
CBD 30 µM2 AMPA-ligand
kainate-ligand
6 CP55940 10 nM2 coapplication In vitro glutamate 
7 AEA 100 nM2 coapplication In vitro hypoxia and glucose
2-AG 1000 nM2 In vitro deprivation
8 AEA 100 µM1 15 min post glutamate
toxin
9 AEA 10 µM2 pre and post In vitro glutamate 
PEA 10 µM2 toxin
10 WIN55.212-2 0.1-1 mg/kg2, 40 min pre injury In vivo global ischemia; four   
i.p. vessel occlusion
11 WIN55.212-2  1mg/kg2, i.p. 30 min post In vivo focal ischemia, MCA-
injury occlussion 
12 ∆9-THC 0.1-10 mg/kg2, 7-day pre injury In vivo ischemic reperfusion
i.p reduced blood pressure    
bicarotid occlusion
13 ∆9-THC 1 mg/kg2, i.p. 30 min pre injury In vivo ouabain-induced 
excitotoxicity
14 CP55940 4 mg/kg2, i.p., 5 min post injury In vivo global ischemia;
bicarotid occlusion 
15 2-AG 0.1-10 mg/kg2, 15 min post In vivo traumatic brain injury
i.v, injury
16 AEA 1-10 mg/kg2, 30 min pre injury In vivo  ouabain-induced
i.p. excitotoxicity
1) ED50 values. 2) highest (effective) concentration tested.
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Dose of toxin Species Neuron type Protection? Time of CB Ref.
and duration of assessment dependent?
toxin application after injury
500 µM, rat cerebellar yes 24 h CB2-like 12
5 min granule
18-24 h rat hippocampal yes 0 h CB1 13
30 µM, 18-24 h no
100 µM, mouse spinal yes 24 h CB1 14
24 h
8 h, rat cortical yes 16 h CB1 and CB2 18
no independent
250 µM, 10 min rat cortical yes 18-20 h Anti-oxidant 20
1.5 µM, 20 h
10 µM, 20 h
200 µM, rat cortical yes 18-20h  CB1 17
15 min
8 h rat cortical yes 16 h CB1 and CB2 19
independent   
500 µM, rat cerebellar  no 24 h  12
5 min granule
100 µM, chicken  telencephalon no 24 h  40
1 or 24 h
15 min rat  hippocampal yes  3 d CB1 18
permanent rat cortical reduction in 24 h CB1 18 
infarct volume
12 min rat striatal, yes 3 wk N.D. 22
cortical
0.5 nmol rat hippocampal, reduction in 15 min and CB1 Ch4
intrastriatal striatal, cortical infarct volume 7 d
10 min gerbil - improvement 1, 3 and 7 d CB1 23
of locomotion 
and EEG
mouse hippocampal reduction in 1 and 7 d In part CB1 37
infarct volume
0.5 nmol rat hippocampal, reduction in 15 min and In part CB1 Ch5
intrastriatal striatal, cortical infarct volume 7 d
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At the same time, we have shown in a longitudinal MRI-study that exogenously
applied AEA reduced dose-dependently neuronal damage in neonatal rats injected i.c.
with the Na+/K+-ATPase inhibitor ouabain (Table 1, no 16; Chapter 5). Fifteen minutes
after injury, AEA (10 mg/kg)-administration, 30 min before ouabain injection, reduced
the volume of cytoxic edema in a manner insensitive to the CB1 receptor antagonist.
Seven days after ouabain treatment, the lesion volume was 64% smaller in AEA-treated
rats. After this period of time, neuroprotective actions of AEA were abolished by
SR141716A.
Endogenously released endocannabinoids: or not to be protective?
However, several other observations question the role of the endocannabinoid system
as a general endogenous protection system.
(1) It has been demonstrated that the increase in NAPE and AEA varies in different in
vivo models of neuronal damage and is dependent on the type of cell death.36 As stated
above, high levels of these lipids were found in NMDA-injected neonatal rats, but only
moderate and low increases were observed in a closed head injury model and in an
apoptotic model, respectively. No increase in 2-AG levels was found after traumatic brain
injury or NMDA-injection in rats.34 In our secondary excitotoxicity model in which
neurodegeneration was elicited by ouabain, AEA and 2-AG concentrations were not
elevated (Chapter 5).
(2) Some in vitro studies do not support a neuroprotective action of endocannabinoids.
(i) AEA did not protect cerebellar granule neurons in a post-glutamate paradigm, whereas
THC and palmitoylethanolamide protected these neurons (Table 1, no 8)12. (ii) AEA was
also ineffective against prolonged glutamate exposure of chicken telencephalon neurons
(Table 1, no 9)40. (iii) Hippocampal neurons exposed to THC died in a CB1-dependent
manner, probably due to an activated arachidonic acid pathway41.
(3) Observations in four different in vivo models indicate that endogenously released
or constitutive endocannabinoids do not protect the brain against acute neuronal injury.
(i) In a mice traumatic brain injury model application of SR141716A (20 mg/kg) did not
increase the volume of edematous tissue and the application of entourage compounds did
not reduce the volume of edematous tissue.37 (ii) No increase in infarct volume upon
application of SR141716 was found in global and (iii) focal ischemia models (MCA-
occlusion)18. (iv) In our secondary excitotoxicity model compared to control animals,
application of AEA-uptake inhibitor,VDM11, or SR141716A alone did not affect lesion
volumes at day 0 nor at day 7. (Chapters 4 and 5).
(4) In an ischemic reperfusion model, application of SR141716A was neuroprotec-
tivea. In this study neuronal damage was assessed after 24 h, whereas in most of the other
in vivo studies neuronal injury was quantified after 3 days or more (Table 1, no 10-16).
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Some possible explanations:
Why can exogenously applied (endo)cannabinoids prevent neuronal loss, while
endogenously released endocannabinoids do not seem to be able to reduce neuronal
damage? Several explanations can be put forward, which can act independently or in
concert with each other.
(1) As described above, the neurodegenerative insult may not always lead to an
upregulation of endocannabinoid biosynthesis. It seems to be dependent on the species
and on the type of injury. For example, traumatic brain injury in mice resulted in a
substantial increase in 2-AG levels37, whereas in neonatal rats no increase was found36.
Intrastriatal injection of  NMDA in neonatal rats led to an increase in AEA36, but not with
an ouabain injection (Chapter 5). Recently, it has been shown that the simultaneous
application of glutamate and carbachol (an acetylcholine receptor agonist), but not of
either agent alone, caused a marked increase in AEA biosynthesis in cortical neurons42.
Thus,membrane depolarization was necessary for the biosynthesis, but was insufficient per
se to initiate AEA biosynthesis. At the moment the biosynthetic pathways of
endocannabinoids have been characterized, but their regulation is largely unknown.
Isolation or cloning of the proteins responsible for endocannabinoid formation may help
to understand the regulation of endocannabinoid biosynthesis in response to neuronal
injury.
(2) The distribution and localization of the CB1 receptor is also of importance.The
CB1 receptor is highly expressed in several areas of the central nervous system at
presynaptic and postsynaptic sites as well as on cell bodies. As noted before in in vitro
models, presynaptic CB1 receptors can block secondary excitotoxicity by inhibiting
glutamate release. However, these presynaptic CB1 receptors are ineffective against a direct
glutamate-induced elevation of postsynaptic calcium concentrations25,26, such as
occurring in glutamate toxicity models.43
It is noteworthy that endocannabinoids have been shown to act as retrograde
messengers in the hippocampus and cerebellum.44-47 They are released from the
postsynaptic membrane and have to diffuse back to the presynaptic CB1 receptors. Upon
activation of these receptors the release of GABA or glutamate is inhibited. If during the
in vivo toxic stimulus glutamate has been released in large quantities (or exogenously
applied), then endogenously released endocannabinoids might be too late to exert a
protective action.The damage has already been inflicted. In this way the endocannabinoid
system may not be able to function as an endogenous protection system. Conversely,
pretreatment with exogenous (endo)cannabinoids may inhibit the toxic stimulus-induced
glutamate exocytosis in advance, thereby preventing the spreading and reducing the effect
of the toxic stimulus.
(3) The ability of endocannabinoids to influence downstream effects of increased
calcium concentrations are also dependent on the cell type, strength, duration, and
stimulus type. In most studies cannabinoids have been shown to reduce intracellular
129
High and Healthy: neuroprotection by cannabinoids
BOC van der Stelt6  06-02-2002  09:39  Pagina 129
calcium concentrations via CB1-mediated closing of voltage sensitive calcium channels,
but several studies have indicated that cannabinoids may also increase calcium
concentrations.48 For example, CB1 and CB2 receptor activation by AEA and 2-AG in
N18TG2 neuroblastoma and NG108-15 neuroblastoma-glioma hybrid cells has been
shown to induce a rapid transient increase in intracellular free calcium via its release from
IP3-sensitive calcium stores.
49,50 It has been shown that synthetic cannabinoids can
enhance peak amplitude of NMDA-elicited signals via calcium release of intracellular
stores in cerebellar granule neurons by a CB1-dependent mechanism
51. Moreover, AEA
was shown to directly modulate NMDA receptors in the presence of SR141716, thereby
potentiating calcium currents16.
(4) Another possibility is that the inflicted damage in the in vivo models of acute
neuronal injury is too severe. It has been shown that severe excitotoxic injury leads to a
loss of CB1 receptor expression
36. If so, endogenously released endocannabinoids may
only be effective in the border zone of the damaged brain area or in mild to moderate
brain injury in which the expression of the CB1 receptor is not lost
18,36,39 (Chapter 4 and
5).Thus, the extent of the neurodegenerative process may be a major determinant of the
ability of endocannabinoids to exert neuroprotection.
Conversely, it is interesting to speculate that if the endocannabinoid system is
dysfunctioning, (e.g., endocannabinoid biosynthesis is inhibited, CB1 receptor is inactive
or its expression is lost), then glutamate homeostasis is lost and excitotoxicity may be
initiated. For example, in a genetic model of Huntington’s disease CB1 mRNA was
decreased prior to the development of either Huntington’s disease phenotype or
neurodegeneration52. Also a loss of CB receptor binding capacity was evident before
degeneration of the nerve terminals was seen. It is tempting to suggest that the early
downregulation of CB receptors induces excitotoxicity and subsequent
neurodegeneration. Furthermore, it has been speculated that the CB1 knock-out mice,
which die suddenly without any obvious sign of disease, might succumb to neurological
problems such as seizures53.
(5) The lack of CB1 receptor antagonists to demonstrate endogenous neuroprotective
actions of endocannaboids, may result from neuroprotective actions of AEA and 2-AG via
other molecular targets than CB1 receptors. For example, palmitoylethanolamide reduced
glutamate toxicity via a CB1-independent manner.
12 This observation has not been
extended yet to an in vivo model, but palmitoylethanolamide was a potent anticonvulsant
in electroshock and chemically-induced seizures in mice54. Furthermore,AEA and 2-AG
have been shown to reduce neuronal damage both in vitro and in vivo, partially via a CB-
independent pathway. It is unclear which molecular targets may be responsible for these
effects. Recent data demonstrate that AEA is capable of interacting with many other
proteins, such as 5-hydroxytryptamine receptors, vanilloid receptors, L-type calcium
channels, Shaker related K+-channels, TASK-1 channels, a non-CB1 G-protein coupled
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AEA-receptor in astrocytes and a non-CB1 non-CB2 G-protein coupled receptor for
AEA and WIN55,212-2 in mouse brain.44 The inhibition of gap junctions and
intracellular calcium signaling in striatal astrocytes by the non-CB1 G-protein-coupled
AEA-receptor or the inhibition of L-type calcium channels might help to prevent
glutamate exocytosis and the spreading of excitotoxicity.55,56 Recently, a new CB-type
receptor was suggested to be responsible for WIN55,212-2-induced reduction in
glutamatergic transmission in the hippocampus of CB1 knock-out mice
15. Thus,
endocannabinoids may provide neuroprotection through other molecular targets.
However, it should be noted that the AEA-uptake inhibitor VDM11 (Chapter 5) and
entourage compounds of 2-AG did not affect lesion volumes33, which argues against an
endogenous endocannabinoid tone controlling acute neuronal damage via any
extracellular molecular target.
Perspectives
Recent developments, such as the generation of CB1 and CB2 knock-out mice and
synthesis of selective antagonists of the CB1 and CB2 receptors, have provided insight into
the (patho)physiological roles of the endocannabinoid system. However, some important
fundamental aspects of the endogenous cannabinoind system remain to be discovered. For
example, the proteins responsible for the biosynthesis of endocannabinoids and their
transport into cells have not been identified yet.The regulation of the biosynthetic and
inactivation pathways of AEA and 2-AG is also largely unknown. It is likely that novel CB
receptor subtypes as well as novel endogenous ligands will be found.The understanding
of the complex interplay of the endocannabinoid system with other neurotransmitters in
the CNS and their function as retrograde messengers will greatly enhance our knowledge
about the physiological roles of the endocannabinoid system. This may provide useful
information to exploit the cannabinoid system for therapeutic intervention in various
diseases, ranging from liver cirrhosis, multiple sclerosis, pain, obesity to schizophrenia.
Crystal or NMR structures of the proteins of the cannabinoid system may help to
elucidate the nature of the ligand-protein interaction, thereby facilitating the design of
selective and potent molecular probes for each of these proteins.
The studies reported in this thesis indicate that agonists of CB1 receptors might also
be useful to enhance the neurological outcome after acute brain damage. It is interesting
to note that THC and CP-55,940 are partial agonists which can reduce excitotoxicity
without completely blocking glutamatergic transmission. Complete inhibition of
glutamatergic neurotransmission may lead to serious complications such as
hallucinations57. Nevertheless, many questions have to be answered, before a CB1 agonist
can be used as a neuroprotective agent, such as a) which type of human brain injury can
be treated?  b) to what extent do cannabinoids improve functional and neurological
outcome after brain damage? c) What is the therapeutic time-window? d) Does the
cannabinoid-induced vasorelaxation and psychotropic side effects pose a problem? At the
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moment it is not clear whether CB2 agonists, which do not cause psychotropic effects, are
also able to reduce neuronal damage in vivo, but other anti-inflammatory drugs have been
proven to reduce neuronal injury and improve functional recovery. It is noteworthy that
dexanabinol (HU-211), a non-psychotropic cannabinoid which do not bind to CB
receptors, has been shown to be a powerful neuroprotective agent. Its neuroprotection is
thought to be mediated via direct antagonism of the NMDA receptor, anti-oxidative
properties and blockade of TNF-α production58.The fact that dexanabinol has recently
entered phase III clinical trials against brain trauma, substantiates the hope that
cannabinoid-based drugs will be useful as therapeutic agents for acute brain damage. If the
extent of neuronal damage is not too large, inhibitors of endocannabinoid clearance may
prove to be suitable leads for drug development, because they have probably limited side
effects compared with CB1 agonists and NMDA receptor antagonists.
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Summary
Endocannabinoids: the Body’s own Marijuana
Marijuana and its constituents: the classical cannabinoids
Marijuana is the most widely used illegal drug throughout the world and has aroused
great controversies. In the Netherlands, public debate centres upon the possible
legalization of marijuana for recreational and therapeutic uses. Nowadays, marijuana is
used by multiple sclerosis patients to alleviate tremors and by aids-patients as well as
cancer-patients with chemotherapy to stimulate appetite and to relieve nausea. However,
in 1996, the health council of the Netherlands came to the conclusion, based on a
literature survey, that the scientific evidence to justify the medical use of marijuana was
insufficient.The council believes that physicians cannot accept responsibility for a product
of unknown composition that has not been subjected to a quality control.The council was
unable to comment on the use of any other preparation of the hemp plant, and its active
ingredient ∆9-tetrahydrocannabinol (THC), or other components, since there were no
published (clinical) reports. The recent and rapidly evolving developments in the field of
cannabinoid research may give rise to a new assessment of these issues.
Marijuana (cannabis, bangh, hashish) is an extract from the plant cannabis sativa and
contains at least 400 chemical components of which 60 belong to the cannabinoid-class.
Marijuana and its main psychoactive compound THC have been used for centuries. It
took until 1964 before THC was isolated and characterized.The structure elucidation of
THC led to the design of a series of analogs. By 1986, over 300 cannabinoid derivatives
were synthesized and used to determine the structural prerequisites, necessary for
cannabinoids to exert their typical psychotropic properties.
Proteins are responsible for the action of cannabinoids
The mechanism of action of THC has also been subject of discussion.At first it
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was thought that cannabinoids perturbed the membrane due to their lipophilic nature,
thereby producing cellular effects. However, the requirement of one enantiomer and
stringent structural features of THC to produce pharmacological responses raised the
question whether cannabinoids could act via membrane proteins.The development of the
potent bicyclic cannabinoid CP-55.940, which could be radio-labelled, allowed Devane
and coworkers to demonstrate selective and specific binding sites in the brain in 1988.The
identification and cloning of a protein responsible for this binding followed within two
years. This protein was termed cannabinoid (CB1) receptor. The existence of another
subtype cannabinoid receptor  (CB2) was demonstrated in 1993. CB1 receptors have been
detected both in the central nervous system and in certain peripheral tissues.The central
distribution pattern of CB1 receptor is heterogeneous and was found in high levels in
several brain regions. The activation of CB1 receptors in these brain areas is thought to
mediate typical cannabinoid effects, such as impairment of motor behaviour (cerebellum,
basal ganglia), memory (hippocampus) and cognition (cerebral cortex). The CB2 receptor
is found in cells of the immune system.
The cannabinoid receptors have the structural characteristics of G-protein coupled
receptors. Both CB1 and CB2 receptors inhibit cAMP formation via Gi-proteins and
activate mitogen activated protein kinases. In addition, CB1 receptors activate ion channels
such as A-type and inwardly rectifying potassium channels and inhibit voltage sensitive N-
type and P/Q-type calcium channels.
The body’s own marijuana: endocannabinoids
The presence of cannabinoid receptors in mammalians suggested the existence of
endogenous compounds in brain, which could bind and activate these proteins. In 1992,
Mechoulam et al isolated the first endogenous compound for these receptors from porcine
brain. This component proved to be an amide of ethanolamine and arachidonate. The
compound was named anandamide. Ananda is Sanskrit for internal bliss. Anandamide
[5Z,8Z,11Z,14Z-eicosatetraenoyl-N-(2-hydroxyethyl)-amine] was able to mimic many
biochemical, pharmacological and behavioural properties of the classical cannabinoids. In
contrast to most other neurotransmitters, anandamide is not stored in vesicles, but is
released from cells upon demand by stimulus-dependent cleavage of membrane
phospholipid precursors. Already in the early 80’s Schmid et al had characterized a
biosynthetic pathway for N-acylethanolamines. According to this scheme N-
acylethanolamines, including anandamide, are formed through sequential N-acylation and
phosphodiesterase activities. A membrane-bound calcium-dependent transacylase
catalyzes the transfer of fatty acids from the first position of various lipids to the
ethanolamine of phosphatidylethanolamine, which yields the precursor NAPE. The
formation of NAPE seems to be rate limiting.
Enzymatic hydrolysis of NAPE by a phosphodiesterase of the phospholipase D-type,
which seems to be an unregulated enzyme, generates the N-acylethanolamines. So far, no
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fatty acid selectivity for either the biosynthesis or hydrolysis of NAPE could be
demonstrated. Any selectivity in anandamide generation must therefore rely on other
mechanisms. Another problem with this scheme concerns the very low amounts of
arachidonic acid that are found at the first position of phospholipids. It is almost
exclusively in the second position of brain phospholipids. It is noteworthy that the N-
acyltransferase and the phospolipase D have not been purified or cloned yet.
Three years after the discovery of anandamide, 2-arachidonoylglycerol (2-AG) was
found as a second endogenous ligand for the cannabinoid receptors.Anandamide and 2-
AG are termed endocannabinoids. Very recently a third endogenous compound, 2-
arachidonoyl glyceryl ether, was isolated from porcine brain, which could activate CB1
receptors.
How the body terminates the action of endocannabinoids
In order to function as a neurotransmitter the concentrations of the endocannabinoids
have to be regulated in a strict manner.We have shown that after release, anandamide can
be eliminated by a two-step mechanism in human brain and immune cells (Chapter 2). It
consists of anandamide transport into cells followed by enzymatic hydrolysis. Both human
neuronal and immune cells rapidly take up extracellular anandamide through a
mechanism that meets four key criteria of carrier-mediated transport: fast rate,
temperature dependent, saturability, and substrate selectivity. Importantly and in contrast
with transport systems for classical neurotransmitters, anandamide uptake is neither
dependent on external Na+ nor affected by metabolic inhibitors. This suggests that the
uptake is a process of carrier-facilitated diffusion.Anandamide-uptake was not affected by
fatty acids, neutral lipids, neurotransmitters, biogenic amines, prostaglandins and
leukotrienes.To date, the protein responsible for anandamide-uptake has not been purified
or cloned, but its activity has been demonstrated in several human cells and in rat brain
slices.
Once inside the cell, anandamide is inactivated by hydrolysis of its amide bond to
arachidonic acid and ethanolamine.A similar activity was already identified by Schmid and
co-workers in rat liver in 1984.After the discovery of anandamide, biochemical evidence
suggested that the same enzyme activity could degrade anandamide. In 1996, the enzyme
responsible for the degradation of anandamide was purified and cloned from rat liver and
termed fatty acid amide hydrolase (FAAH). FAAH is an intracellular membrane-bound 64
kDA protein with a conserved amidase sequence. We have shown that FAAH is also
present and active in human brain (Chapter 2). Interestingly, FAAH-activity and
expression were downregulated in  meningioma tumors. FAAH has been shown to
degrade a broad spectrum of fatty acid amides and esters.Among them were oleamide (a
novel sleep inducing factor), palmitoylethanolamide and 2-arachidonoylglycerol.The CB
receptors, endocannabinoids and the proteins of the inactivation process constitute the
endogenous cannabinoid system.
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Anandamide is not only inactivated via FAAH, but it is also converted by other
enzymes such as lipoxygenases. Various oxidative metabolites of anandamide were
synthesized via a lipoxygenase reaction and their cannabinoid properties were
characterized (Chapter 3).The oxidative metabolites were shown to competively inhibit
FAAH. Furthermore, depending on the position of the hydroxyl group in the metabolites,
they were able to selectively bind to the CB1 or CB2 receptor.The metabolites did not
interfere with anandamide uptake into the cell.These results indicate that small changes
in the chemical structure of anandamide can lead to the generation of novel compounds
which can specifically interact with each of the proteins of the endogenous cannabinoid
system (Chapter 3). With computer simulations we have tried to identify the essential
structural elements of anandamide, which are necessary for the interaction with the CB1
receptor (Chapter 3).
How endocannabinoids influence the communication between nerve cells
The feeling of getting ‘high’ is experienced when CB1 receptors are activated in
various brain areas. When these receptors are activated, they alter the communication
between the nerve cells in the brain. Glutamate is the main excitatory neurotransmitter in
the brain which carries the signal from one nerve cell to the other.THC and anandamide
reduce the release of glutamate from the nerve ending of the cell and thereby prevent the
activation of the second nerve cell and slow down communication. The relation of the
cannabinoid system to various neurotransmitter systems is of importance to understand its
action on the central and peripheral nervous system.The cannabinoid system is involved
via presynaptic and postsynaptic CB1 receptors in regulation of the release, uptake and
actions of various other neurotransmitters such as GABA and dopamine.
The relation of endocannabinoid to brain diseases
Glutamate is not only important for normal communication between nerve
cells. It also plays a role in several brain diseases such as Parkinson’s disease, amyotrophic
lateral sclerosis and in acute brain damage.When concentrations of glutamate are rising
above a certain level, then nerve cells cannot cope with the sustained activation anymore.
The nerve cells will eventually die. Since cannabinoids can reduce glutamate release from
nerve ending, we speculated that cannabinoids could protect nerve cells against acute
brain injury.We tested this hypothesis in the following way (Chapters 4, 5  and 6).
Seven days old rats were directly injected in the brain with a toxin which causes nerve
cells to die. This process of dying was followed by magnetic resonance imaging. We
followed this process for one week. One group of rats received a solution with THC or
anandamide 30 min prior to the toxin.Another group received THC or anandamide plus
a compound which blocked the action of the cannabinoids at the CB1 receptor. One
group of rats was used as a control.
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We observed that the animals which had received THC or anandamide had an infarct
which was ~ 40 or 64% smaller than the non-treated animals after seven days, respectively
(Chapters 4 and 5).Thus, both classical and endogenous cannabinoids can protect rat brain
against acute brain damage.The animals which received cannabinoids plus a blocker had
an infarct which was as large as in the control animals.This indicated that the protective
effects of the cannabinoids were mediated via the CB1 receptor.We could not observe a
protection by endogenous endocannabinoids.
Future ‘high’ lights
The discovery of the endocannabinoids and the way they work in the brain have
opened a new road to study the effects of marijuana. In addition, it has become possible
to investigate its participation in normal body function and in disease. It is thought that
the cannabinoid system is involved in the regulation of a variety of physiological processes
such as pain, appetite, memory, blood pressure and motor coordination. In several diseases
such as liver cirrhosis, Parkinson’s disease, multiple sclerosis, schizophrenia and glaucoma
components of the cannabinoid system are involved. Possibly, selective and potent
compounds targeted towards proteins of the cannabinoid system can be used to design
new drugs for such diseases. This will circumvent the need of a marijuana extract as a
medicine, thereby avoiding marijuana’s complex, unknown and varying composition and
possibly its psychotropic side effects. For example, the development of compounds, which
selectively activate the CB2 receptor, which is not present in brain, may lead to therapeutic
agents which prevent the patient from becoming “high”. Our results indicate that
compounds, which activate the CB1 receptor might be used to reduce acute neuronal
damage. However, much research effort is necessary before we will witness the
introduction of the first cannabinoid-based drug.
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Nederlandse samenvatting
Marihuana en haar ingrediënten: de cannabinoïden
Marihuana is het meest gebruikte illegale genotmiddel ter wereld en heeft aanleiding
gegeven tot vele controverses. In Nederland richt de discussie zich op het legaliseren van
het gebruik voor zowel medische als recreatieve toepassingen. Tegenwoordig wordt
marihuana  gebruikt door multiple sclerose patiënten om ongecontroleerde trillingen te
onderdrukken en door aids-patiënten alsmede door mensen die een chemotherapie
ondergaan om de eetlust op te wekken. Wetenschappelijke onderzoek om de claims te
ondersteunen is summier. In 1996 adviseerde de Gezondheidsraad minister Borst van
Volksgezondheid dan ook om marihuana niet als medicijn te registreren. De afwezigheid
van een goede kwaliteitscontrole van een product met onbekende en variërende
samenstelling maakt het onverantwoord voor artsen om het als medicijn voor te schrijven.
Over afgeleide actieve componenten deed de gezondheidsraad geen uitspraak omdat daar
te weinig over bekend was. De Nederlandse regering heeft in het najaar van 2001 dit
advies naast zich neergelegd en besloten in navolging van Canada, dat marihuana
gelegaliseerd wordt voor medicinale toepassingen. In dit proefschrift wordt de huidige
stand van het wetenschappelijk onderzoek beschreven en wordt een aantal nieuwe
aspecten van ∆9-tetrahydrocannabinol (THC), de meest actieve stof in marihuana, en de
lichaamseigen stoffen met een marihuana-achtige werking onderzocht. Er is speciale
aandacht voor de mogelijk positieve effecten van cannabinoïden op acute hersenschade.
Marihuana is een product van de plant cannabis sativa en bevat op zijn minst 400
verschillende componenten, waarvan 60 stoffen tot de klasse van cannabinoïden behoren.
Hoewel marihuana al eeuwen wordt gebruikt, werd in 1964 pas voor het eerst de actieve
stof THC geïsoleerd en gekarakteriseerd. De structuuropheldering van THC leidde tot
het ontwerp van een serie van verbindingen met vergelijkbare activiteit. In 1986 waren
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meer dan 300 verbindingen gemaakt. Deze stoffen werden gebruikt om er achter te
komen welk deel van de structuur van THC verantwoordelijk was voor het “high”
worden.
Eiwitten zijn verantwoordelijk voor de werking van de cannabinoïden
Het werkingsmechanisme van THC was het middelpunt van een heftige discussie. In
eerste instantie werd gedacht dat cannabinoïden via een a-specifieke interactie de
vloeibaarheid van de celmembraan van hersencellen veranderden, waardoor het “high”-
zijn werd veroorzaakt. Aangezien niet alle cannabinoïden dit effect vertoonden en een
kleine verandering in THC de werking uitschakelde, vroeg men zich af of de effecten niet
via bepaalde eiwitten tot stand werden gebracht. Dit bleek inderdaad het geval te zijn. In
1988 werd met behulp van een radioactieve cannabinoïd specifieke bindingsplaatsen in de
hersenen van ratten aangetoond. Het eiwit dat verantwoordelijk was voor de specifieke
binding van THC werd in 1990 gevonden. Dit eiwit werd de cannabinoïd (CB1) receptor
genoemd. Drie jaar later werd het bestaan een tweede eiwit aangetoond: de CB2 receptor.
De twee eiwitten komen op verschillende plaatsen in het lichaam voor. De CB1 receptor
wordt vooral gevonden in de hersenen en de CB2 receptor in cellen van het immuun
systeem. De CB1 receptor komt ondermeer voor in hersengebieden die verantwoordelijk
zijn voor beweging  (cerebellum, basale ganglia), het geheugen (hippocampus) en cognitie
(cerebrale cortex).Als THC aan de CB1 receptoren bindt, dan wordt het eiwit geactiveerd
en de signaal overdracht in de cel gedempt. De productie van het signaalmolecuul cyclisch
AMP wordt in de cel geremd en calcium ionen kunnen niet meer de cel instromen.
Lichaamseigen marihuana: de endocannabinoïden
De aanwezigheid van CB1 receptoren in de hersenen van muizen, ratten en ook
mensen suggereerde het bestaan van een stof, die van nature zou voorkomen in de
hersenen en die de CB1 receptor zou kunnen activeren. Deze stof werd voor het eerst
gevonden in varkenshersenen in 1992. Het bleek een vetzuuramide te zijn, dat was
samengesteld uit arachidonzuur en ethanolamine. Deze lichaamseigen stof wordt
anandamide genoemd naar het Sanskrit voor “gelukzalig”. Anandamide bootst vele
biochemische, farmacologische en gedragseffecten van THC na. Moleculen die van nature
in de hersenen voorkomen en de CB1 receptor kunnen activeren, worden
endocannabinoïden genoemd. Na de ontdekking van anandamide werden nog meer van
deze stoffen gevonden. Anandamide is echter nog steeds één van de belangrijkste
vertegenwoordigers van de klasse van endocannabinoïden. Anandamide wordt
vrijgemaakt uit de celmembraan van zenuwcellen, nadat de cellen geactiveerd zijn. Al in
het begin van de jaren tachtig werd ontdekt hoe dit proces voor andere vergelijkbare
moleculen in zijn werk ging. De eiwitten verantwoordelijk voor de biosynthese van
anandamide zijn echter nog niet gevonden.
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Beëindiging van de werking van anandamide
Als anandamide zijn werk gedaan heeft op de CB1 receptor, dan wordt
anandamide afgebroken. Wij hebben laten zien dat menselijke cellen van zowel het
immuun systeem als de hersenen anandamide kunnen elimineren via een proces dat uit
twee stappen bestaat. In hoofdstuk twee wordt dit in detail beschreven.Anandamide werd
in eerste instantie de cel in getransporteerd en daarna afgebroken door een eiwit dat
vetzuuramidehydrolase wordt genoemd. Anandamide werd opgenomen door een proces
dat voldoet aan de vier criteria van ‘drager’-gemedieerd transport: snel, temperatuur
afhankelijk, verzadigbaar and structuur afhankelijk. In tegenstelling tot transportsystemen
voor klassieke signaalmoleculen in de hersenen was de opname van anandamide niet
afhankelijk van een natrium ion gradiënt en het kostte geen energie. Het transport van
anandamide werd niet beïnvloed door een variëteit aan andere vergelijkbare moleculen.
Tot op heden is het eiwit dat verantwoordelijk lijkt te zijn voor het transport van
anandamide nog niet gevonden.
Als anandamide eenmaal in een hersencel is, dan wordt de binding tussen het
ethanolamine en het arachidonzuur verbroken. Een vergelijkbare activiteit was al eens
aangetoond in de lever van ratten voor andere vetzuuramide moleculen in 1984. Na de
vondst van anandamide in varkenshersenen werd gesuggereerd dat één eiwit
verantwoordelijk was voor de afbraak van deze vetzuuramide moleculen. Dit eiwit werd
in 1996 in rattenlever gevonden en vetzuuramidehydrolase genoemd. Wij hebben in
hoofdstuk twee aangetoond dat dit eiwit ook voorkomt en actief is in humane hersenen.
Vetzuuramidehydrolase kan een zeer uiteenlopend spectrum van vetzuuramide moleculen
afbreken, waaronder ook een stofje dat slaap veroorzaakt. De CB receptoren, de
endocannabinoïden en de eiwitten van het inactivatie-proces vormen met elkaar het
endogene cannabis systeem.
Het blijkt echter dat anandamide niet alleen wordt aangepakt door het
vetzuuramidehydrolase. Er zijn ook eiwitten die de structuur van anandamide een klein
beetje kunnen veranderen. Eén van deze klasse van eiwitten zijn de lipoxygenases. Deze
eiwitten bouwen een zuurstof molecuul op verschillende plaatsen in anandamide. Wij
hebben in hoofdstuk drie aangetoond dat deze varianten van anandamide ook aan de CB1
en CB2 receptor kunnen binden, maar minder goed dan anandamide zelf. De sterkte van
de binding was afhankelijk van de plaats van de nieuwe zuurstof-atoom in de structuur
van anandamide. Deze nieuwe anandamide varianten waren in staat om het
vetzuuramidehydrolase zeer goed te remmen in zijn taak om ananamide af te breken, maar
verhinderden niet de opname van anandamide in de cel. De resultaten gaven ook aan dat
kleine veranderingen in de structuur van anandamide kunnen leiden tot nieuwe stoffen
met specifieke interacties met de  CB1 of met de CB2 receptor.We hebben in hoofdstuk
drie ook geprobeerd met computer simulaties te achterhalen welke structuurelementen
van anandamide verantwoordelijk waren voor de specifieke interacties.
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Endocannabinoïden en communicatie tussen hersencellen
Het gevoel ‘high’ te zijn wordt ervaren wanneer de CB1 receptor wordt geactiveerd in
verschillende hersengebieden.Wanneer deze receptoren geactiveerd zijn, veranderen zij de
communicatie tussen zenuwcellen in de hersenen. Glutamaat is een van de belangrijkste
neurotransmitters in de hersenen, die het signaal van de ene zenuwceluiteinde overbrengt
naar het begin van een andere zenuwcel.THC en anandamide verminderen de vrijgifte
van glutamaat uit de zenuwceluiteinden. Daarmee voorkomen zij dat de volgende
zenuwcel wordt geactiveerd en veranderen zij de communicatie tussen de zenuwcellen.
De relatie met acute hersenziekten
Glutamaat is niet alleen belangrijk voor normale communicatie tussen zenuwcellen.
Het speelt ook een rol bij verschillende hersenziekten, zoals de ziekte van Parkinson en
amyotrofe lateraal sclerose (ALS) en in acute hersenschade. Als de concentraties van
glutamaat boven een bepaalde waarde stijgen, dan kunnen de zenuwcellen niet meer
omgaan met de langdurige activatie. De zenuwcellen gaan uiteindelijk dood. Aangezien
cannabinoïden de vrijgifte van glutamaat beperken, speculeerden wij dat THC en
anandamide wel eens zenuwcellen zouden kunnen beschermen tegen acute hersenschade.
We hebben deze hypothese in hoofdstukken vier en vijf op de volgende manier getest.
Zeven dagen oude ratten kregen een injectie in de hersenen met een toxine,
waardoor de hersencellen afstierven. Dit proces werd een week gevolgd met behulp van
magnetische resonantie beeldvormende (MRI) technieken. Een groep ratten kreeg dertig
minuten voor de toxine injectie een oplossing met THC of anandamide.Een andere groep
ontving THC of anandamide plus een stof die de werking van de CB1 receptor
blokkeerde en een laatste groep ratten werd gebruikt als controle groep.
Na zeven dagen zagen we dat de groep ratten die THC of anandamide hadden
gekregen een kleiner infarct hadden ontwikkeld dan de controle dieren. De dieren die
ook behandeld waren met de blokker, vertoonden een infarct dat net zo groot (of zelfs
groter) was als bij de controle dieren. Dit wijst erop dat de beschermende effecten van
zowel THC als anandamide via de CB1 receptor tot stand kwamen.
Toekomst perspectieven
De ontdekking van de endocannabinoïden en hoe zij werken in de hersenen hebben
geleid tot een nieuwe manier van denken over de werking van marihuana. Het is mogelijk
geworden om de medische claims die aan marihuana worden toegeschreven op een
fundamenteel moleculair niveau te onderzoeken. Er wordt gedacht dat het endogene
cannabis systeem een regulerende werking heeft bij verschillende fysiologische processen,
zoals pijn, eetlust, geheugen, bloeddruk en beweging. Het lijkt erop dat het cannabis
systeem betrokken is bij het ontstaan van verschillende ziekten, zoals lever cirrose, multiple
sclerose, schizofrenie en glaucoom. Mogelijkerwijs kunnen selectieve en potente stoffen
die een interactie aangaan met de eiwitten van het endogene cannabis systeem worden
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gebruikt om medicijnen te ontwikkelen voor deze ziekten. Dit zal het gebruik van
marihuana als medicijn overbodig maken. Hiermee worden de nadelen van marihuana,
zoals haar complexe en voor een groot deel onbekende samenstelling en psychotrope
bijwerking omzeild. Het ontwikkelen van stoffen die alleen de CB2 receptor kunnen
activeren, zal bijvoorbeeld kunnen leiden tot medicijnen die de patiënt niet ‘high’ maken,
omdat de CB2 receptor niet voorkomt in de hersenen. Onze resultaten geven aan dat
moleculen die de CB1 receptor activeren mogelijkerwijs gebruikt kunnen worden om
acute hersenschade te verminderen. Stoffen die de afbraak van anandamide verhinderen
spelen in dit opzicht ook een belangrijke rol, omdat zij op een indirecte wijze de CB1
receptor kunnen activeren. Dit zal waarschijnlijk niet leiden tot een algehele activatie van
het cannabis systeem en dus een verminderde beleving van het ‘high’ zijn.
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Marihuana gedogen als medicijn?
Mario van der Stelt en Wouter Veldhuis
-Opinie artikel in het Utrechts Nieuwsblad, 20 juli 2001 –
Marihuana is het meest gebruikte illegale genotmiddel ter wereld en het middelpunt
van een verhit debat tussen voor- en tegenstanders van legalisering van deze softdrug. Met
enige regelmaat verschijnt in de kolommen van de krant weer een artikel over de
vermeende positieve of slechte eigenschappen. Marihuana zou schadelijk zijn voor de
hersenen, omdat het een delicaat evenwicht zou verstoren. Marihuana zou jongeren
aanzetten tot het overstappen naar harddrugs en Nederwiet zou zelf een harddrug zijn
vanwege het hoge percentage THC, de belangrijkste psychoactieve stof in marihuana.
Deze claims zijn echter niet gebaseerd op wetenschappelijk onderzoek en nooit bewezen.
Ze missen derhalve elke basis om als argument te dienen in de politieke besluitvorming
omtrent legalisering van marihuana als softdrug.
Aan de andere kant heb je de fervente voorstanders die elke strohalm aangrijpen om
hun pleidooi kracht bij te zetten voor legalisering van drugs in zijn algemeenheid en
marihuana in het bijzonder. De medicinale aspecten van marihuana dienen als kruiwagen
om de drug zelf te legaliseren. Het is de vraag  echter of marihuana geschikt is als medicijn
voor verschillende kwalen. Marihuana bestaat uit meer dan 60 verschillende THC-achtige
stoffen waarvan de werking voor het merendeel onbekend is. Hoewel marihuana
tegenwoordig wordt gebruikt door multiple sclerose patiënten om ongecontroleerde
trillingen te onderdrukken en door aids-patiënten alsmede door mensen die een
chemotherapie ondergaan om de eetlust op te wekken, is de wetenschappelijke
onderbouwing om de claims te ondersteunen summier.Wetenschappelijk onderzoek met
goede controles ontbreekt nog. In 1996 adviseerde de Gezondheidsraad minister Borst
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van Volksgezondheid dan ook om marihuana niet als medicijn te registreren. De
afwezigheid van een goede kwaliteitscontrole van een product met onbekende en
variërende samenstelling maakt het onverantwoord voor artsen om het als medicijn voor
te schrijven. Over afgeleide actieve componenten deed de gezondheidsraad geen uitspraak
omdat daar te weinig over bekend was.
De laatste tien jaar is door wetenschappelijk onderzoek van marihuana en met name
naar zijn actieve componenten zoals THC, de werking beter bekend geworden.
Onderzoek naar zuivere componenten uit marihuana en afgeleide producten biedt nu de
mogelijkheid om de medicinale claims te onderzoeken en eventueel afgeleide medicijnen
te ontwikkelen. Uit onderzoek uitgevoerd met behulp van muizen in het Verenigd
Koninkrijk blijkt dat er inderdaad een wetenschappelijk basis bestaat voor de positieve
effecten van marihuana in ms-patiënten. Waarschijnlijk wordt het zelfs mogelijk om de
psychotrope bijwerkingen te omzeilen en toch baat te hebben bij een behandeling met
een afgeleid product. Dit geldt ook voor onderzoek uitgevoerd in Spanje waaruit bleek
dat een bepaald type hersentumor bestreden kon worden door de ratten te behandelen
met zuivere THC.
Ons onderzoek toont nu aan dat preventieve behandeling met THC de hersenschade
beperkt in een proefdiermodel voor herseninfarcten. Dit is een eerste stap op weg naar
een mogelijke toepassing als medicijn voor bepaalde neurodegeneratieve hersenziekten.
De suggestie die gewekt is dat het roken van een joint bij mensen de gevolgen van een
herseninfarct beperkt, ligt voor de hand, maar mag niet worden afgeleid uit ons
onderzoek. Roken vergroot zelfs de kans op hart- en vaatziekten. Wel maakt onze
benadering het mogelijk producten te ontwikkelen die niet het “high”-zijn veroorzaken,
maar wel de medicinale werking hebben. De discussie over het behandelen van mensen
door het roken van een joint zal dan gelukkig overbodig zijn en tot het verleden behoren.
Tot die tijd is het onverstandig om marihuana te gedogen als medicijn. Patiënten die baat
vinden bij het gebruik van marihuana zijn zelf verantwoordelijk voor de risico’s. De
discussie of marihuana gelegaliseerd moet worden als softdrug is een politiek vraagstuk en
zal losgekoppeld moeten worden van de medicinale aspecten.
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houding in grote mate. Ook al liep het onderzoek in het begin soms iets minder, je wist
me altijd weer met een goed gevoel verder te laten gaan. Hans, ik heb veel van je geleerd.
Ik vond de discussies over de manuscripten erg stimulerend.
Na een congres in Montpellier had ik een idee. Ik wilde aantonen dat marihuana
hersenschade kon beperken. Prof. Klaas Nicolay (Experimentele In Vivo NMR) is de
persoon geweest die het mogelijk heeft gemaakt om de hypothese te testen. Klaas, zonder
jouw steun en gastvrijheid was dit proefschrift niet in deze vorm tot stand gekomen. Mijn
waardering is groot. Prof. Dop Bär (Experimentele Neurologie) wil ik ook graag op deze
plaats bedanken voor de goede samenwerking en de interesse voor mijn onderzoek.
Wouter en Guus, zonder jullie was er niets terecht gekomen van de experimenten.
Wouter, onze samenwerking steeg uit boven het professionele. Samen kunnen we elk
probleem oplossen! Ik vond de weekenden die we op het lab doorbrachten (en de
avonden in de kroeg) erg leuk. Ik ben blij dat we goede vrienden zijn geworden. Dank je
wel, dat je mijn paranimf wilt zijn.Guus, jouw expertise op het gebied van vetzuuroxidatie
is ongeëvenaard. Je was altijd bereid op korte termijn wat stofjes te maken. Zonder jou
zou de organisatie van het lab totaal in het honderd lopen! De biertjes na het werk in JP
samen met Paul zal ik missen. Albert en Bas, jullie brachten mij weer terug bij de
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kind to help me with my research. First of all, I would like to thank prof. Raphael
Mechoulam (Hebrew University, Jerusalem, Israel). Dear Raphael, your visit to our
laboratory was very inspiring.Thank you for the many pieces of advice and the help you
have given me. I hope we will be able to continue our e-mail correspondence for a very
long time! I am also very grateful to prof.Vincenzo di Marzo (Endocannabinoid Research
Group, Naples, Italy). Our collaboration was very fruitful and efficient. I hope that our
new project will be even more successful as our previous one. Furthermore, I would like
to thank dr. Mauro Maccarrone and prof.Allesandro Finazzi-Agrò  (University of Rome,
‘Tor Vergata’, Italy) for their hospitality and nice collaboration. My visit to your lab was
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the beginning of a successful story and has led to a valuable contribution to this thesis.
Best regards to the  “Club del Café”.
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BOC, en dat zijn er heel wat geweest, bedanken. Met name,Anne Marie, Merel en Mieke,
dank voor het verzenden van de vele pakketjes. Gelukkig zijn ze nooit onderzocht door
de douane. Ze bevatten namelijk cannabis-achtige stoffen. Irene van Delden wil ik graag
bedanken voor de prettige samenwerking in verschillende commissies. Jan, Aloys en
Ingrid van de audio-visuele dienst wil ik graag bedanken voor het maken van alle mooie
posters en de lay-out van dit proefschrift.
In dit dankwoord mogen mijn biologie- en scheikundeleraren van het Altena College
niet ontbreken. Met name Wim van Laar en Harm de Vries hebben door hun enthousiaste
manier van lesgeven ervoor gezorgd, dat ik scheikunde ben gaan studeren en dat mijn
interesse in de chemie van de hersenen  werd aangewakkerd. Dank jullie wel.
Graag wil ik ook op deze plaats mijn (oud)huisgenoten van Huize Rembrandt
bedanken voor de gezellig tijd in huis. Langzaamaan is het ‘wilde-diergeneeskunde-
studenten-huis’ getransformeerd tot een ‘rustig-bèta-AiO-huis’. Sjors, je bent altijd een
grote steun geweest als dat nodig was. Ik hoop dat we elkaar nog veel zullen zien, ook al
ga jij samen met Rosa naar Spanje. Dank je, dat je mijn paranimf wilt zijn.
Verder wil ik Maurice,Teus-Jan en Koert bedanken voor ondermeer het plezier van
de vele avonden dat we één bepaalde kroeg ‘onveilig’ hebben gemaakt. Hopelijk zullen er
nog meer volgen met de andere leden van de ’maffia’. Sicco, dank je voor de mooie
stelling. Karin, dank voor de vele gezellige avonden! Ook wil ik graag mijn andere
vrienden en vriendinnen bedanken.
Dan hebben we ook nog de mensen van D66, die mij van het werk gehouden hebben.
Dank voor de ontspanning; jullie hebben laten zien dat politiek ook leuk kan zijn! Als je
wilt, dan is er daadwerkelijk wat te bereiken, zelfs op lokaal niveau. Ingrid, jij verdient
natuurlijk speciale aandacht. Volgens mij vormen we een goed team om de Wondere
Wereld van de Bèta’s over te brengen aan anderen. Dank voor alle steun!
Als laatste wil ik Hilde & André en mijn ouders bedanken voor alle onvoorwaardelijke
steun. Ik ben erg trots op jullie, dankzij jullie sta ik hier nu! 
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